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Background: Many glaucoma referrals from the community to hospital eye services are unnecessary.
Imaging technologies can potentially be useful to triage this population.
Objectives: To assess the diagnostic performance and cost-effectiveness of imaging technologies as triage
tests for identifying people with glaucoma.
Design: Within-patient comparative diagnostic accuracy study. Markov economic model comparing the
cost-effectiveness of a triage test with usual care.
Setting: Secondary care.
Participants: Adults referred from the community to hospital eye services for possible glaucoma.
Interventions: Heidelberg Retinal Tomography (HRT), including two diagnostic algorithms, glaucoma
probability score (HRT-GPS) and Moorfields regression analysis (HRT-MRA); scanning laser polarimetry
[glaucoma diagnostics (GDx)]; and optical coherence tomography (OCT). The reference standard was
clinical examination by a consultant ophthalmologist with glaucoma expertise including visual field testing
and intraocular pressure (IOP) measurement.
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Main outcome measures: (1) Diagnostic performance of imaging, using data from the eye with most
severe disease. (2) Composite triage test performance (imaging test, IOP measurement and visual acuity
measurement), using data from both eyes, in correctly identifying clinical management decisions, that is
‘discharge’ or ‘do not discharge’. Outcome measures were sensitivity, specificity and incremental cost per
quality-adjusted life-year (QALY).
Results: Data from 943 of 955 participants were included in the analysis. The average age was 60.5 years
(standard deviation 13.8 years) and 51.1% were females. Glaucoma was diagnosed by the clinician in
at least one eye in 16.8% of participants; 37.9% of participants were discharged after the first visit.
Regarding diagnosing glaucoma, HRT-MRA had the highest sensitivity [87.0%, 95% confidence interval
(CI) 80.2% to 92.1%] but the lowest specificity (63.9%, 95% CI 60.2% to 67.4%) and GDx had the
lowest sensitivity (35.1%, 95% CI 27.0% to 43.8%) but the highest specificity (97.2%, 95% CI 95.6% to
98.3%). HRT-GPS had sensitivity of 81.5% (95% CI 73.9% to 87.6%) and specificity of 67.7% (95% CI
64.2% to 71.2%) and OCT had sensitivity of 76.9% (95% CI 69.2% to 83.4%) and specificity of 78.5%
(95% CI 75.4% to 81.4%). Regarding triage accuracy, triage using HRT-GPS had the highest sensitivity
(86.0%, 95% CI 82.8% to 88.7%) but the lowest specificity (39.1%, 95% CI 34.0% to 44.5%), GDx had
the lowest sensitivity (64.7%, 95% CI 60.7% to 68.7%) but the highest specificity (53.6%, 95% CI
48.2% to 58.9%). Introducing a composite triage station into the referral pathway to identify appropriate
referrals was cost-effective. All triage strategies resulted in a cost reduction compared with standard care
(consultant-led diagnosis) but with an associated reduction in effectiveness. GDx was the least costly and
least effective strategy. OCT and HRT-GPS were not cost-effective. Compared with GDx, the cost per QALY
gained for HRT-MRA is £22,904. The cost per QALY gained with current practice is £156,985 compared
with HRT-MRA. Large savings could be made by implementing HRT-MRA but some benefit to patients will
be forgone. The results were sensitive to the triage costs.
Conclusions: Automated imaging can be effective to aid glaucoma diagnosis among individuals referred
from the community to hospital eye services. A model of care using a triage composite test appears to be
cost-effective.
Future work: There are uncertainties about glaucoma progression under routine care and the cost of
providing health care. The acceptability of implementing a triage test needs to be explored.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
G laucoma is a lifelong eye disease. Treatment is usually effective to slow the progression of glaucoma.About 4000 people are registered with sight impairment each year because of glaucoma. Many
healthy subjects are unnecessarily referred from the community to hospital eye services to rule
out glaucoma.
New imaging tests that investigate the back of the eye can aid in the diagnosis of glaucoma and are safe
and easy to perform. These technologies measure with high accuracy the tissues in the back of the eye
that are typically thinned in glaucoma. This study was designed to evaluate the performance of four
imaging tests at identifying, among patients referred to hospital, those who have glaucoma or are at risk
and those who do not have any eye disease. We compared the imaging test results with an experienced
eye doctor’s diagnosis. We also evaluated how well a possible care pathway would perform using imaging
results combined with measurements of the eye pressure and vision, to identify whether or not the
individual needed to see an eye doctor.
In total, 955 individuals were recruited. The best-performing test correctly diagnosed glaucoma in 87 out
of every 100 patients tested. If imaging tests with an eye pressure test and a visual acuity test were used to
screen out people without eye disease, there would be substantial savings to the health service, but not all
patients with disease would be picked up. A relatively small proportion of patients with glaucoma and at
risk of glaucoma would be missed (approximately one in seven).
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Scientific summary
Background
Glaucoma describes a group of chronic age-related eye diseases in which there is progressive damage of
the optic disc and characteristic visual field loss. Glaucoma is a significant public health problem, as it is the
second leading cause of blindness in the UK.
Glaucoma care constitutes a major proportion of the workload of the hospital eye service. In England there
are over 1 million glaucoma-related outpatient visits to the acute sector annually. Considerable NHS
resources are required to assess referrals to hospital eye services for possible glaucoma, which are typically
initiated by community optometrists. However, fewer than one-quarter of referrals are found to have
glaucoma, and nearly half of the referred individuals are discharged after their first visit. If referrals could be
triaged in a clinically effective and cost-effective manner, resources could be better utilised for other needs.
Glaucoma is diagnosed by clinicians detecting structural changes of the optic nerve head, also known as
the optic disc, and corresponding visual field defects. New imaging techniques for assessment of the
structural changes have emerged: scanning laser ophthalmoscopy, commercially available as the
Heidelberg Retinal Tomograph [HRT; including two diagnostic algorithms, Moorfields regression analysis
(HRT-MRA; Heidelberg Engineering, Heidelberg, Germany) and glaucoma probability score (HRT-GPS;
Heidelberg Engineering, Heidelberg, Germany)] and scanning laser polarimetry, commercially available as
glaucoma diagnostics (GDx; Carl Zeiss Meditec, Dublin, CA, USA) and spectral domain optical coherence
tomography (SD-OCT; Heidelberg Engineering, Heildelberg, Germany), with several commercial
devices available.
Imaging technologies are being introduced into glaucoma services but their role in the diagnostic pathway
is unclear. Imaging tests are user-friendly and safe, provide automated classifications and potentially could
reduce the need for an examination by a clinician.
Aim
To assess the relative performance and cost-effectiveness of diagnostic imaging technologies as triage tests
in secondary care for identifying people with glaucoma.
Objectives
Primary objective
To compare the diagnostic performance (in terms of sensitivity and specificity) in a cohort of patients
referred to hospital eye services with possible glaucoma, of:
l four imaging tests [HRT-MRA, HRT-GPS, GDx and optical coherence tomography (OCT)] for diagnosis
of glaucoma
l a composite triage test [combining imaging tests, visual acuity (VA) and intraocular pressure (IOP)
measurements] in correctly identifying patients to be discharged from secondary care.
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Secondary objectives
l To explore alternative thresholds for determining abnormal tests.
l To evaluate the diagnostic performance of combinations of imaging tests.
l To evaluate the performance of the tests across the spectrum of glaucoma (mild, moderate
and severe).
l To evaluate the cost-effectiveness of incorporating imaging in a triage test in hospital eye services
compared with current practice of diagnostic examination by a clinician.
l To evaluate patient preferences related to different imaging technologies.
Methods
We designed a pragmatic within-patient comparative diagnostic and triage evaluation of imaging
techniques for glaucoma. Participants were adult patients referred from community optometrists or general
practitioners with any possible glaucoma-related findings. Five UK NHS centres participated: three
academic centres and two district general hospitals.
Participants received all imaging tests: HRT-GPS, HRT-MRA, GDx and OCT. Possible tests results were
within normal limits, borderline or outside normal limits.
The HRT uses confocal laser scanning to allow quantitative structural measurement of the optic disc
anatomy. There are two main classification tools to relate measurements to normative data: (1) HRT-MRA,
which requires user definition of the optic disc boundary, and (2) HRT-GPS, which is fully automated.
The GDx scanning laser polarimeter measures the retinal nerve fibre layer (RNFL) thickness surrounding the
optic disc utilising the birefringent properties of the RNFL. The software provides a discriminating classifier
termed the nerve fibre indicator, which is fully automated.
Spectral domain OCT is an optical imaging technique providing high-resolution, cross-sectional imaging of
the retina analogous to B-scan ultrasonography but using light instead of sound. The Spectralis® optical
coherence tomograph (Heidelberg Engineering, Heidelberg, Germany) was used in this study.
The reference standard was a full clinical examination, including visual field testing, by a consultant
ophthalmologist with glaucoma expertise to determine (1) a diagnosis of glaucoma (mild, moderate or
severe) according to well-defined criteria (diagnosis analysis) and (2) whether or not the patient would be
discharged or should be monitored/treated within hospital eye services (triage analysis).
Statistical analysis
Sample size calculations were based on standard diagnostic accuracy study methods. A 5% significance
level based on a two-sided test was used, which required a study of 897 individuals to have 90% power
to detect an accuracy difference of 9% for the primary outcome of glaucoma diagnosis. Including a 6%
indeterminacy rate increased the sample size to 954.
Two diagnostic performance analyses were undertaken: a diagnosis and a triage analysis. For the diagnosis
analysis (classification of glaucoma), one eye per patient was used: the eye with more severe disease
except for in one sensitivity analysis. The test ‘abnormal’ definition was an imaging test result of ‘outside
normal limits’, with ‘borderline’ cases classified as ‘normal’. This was compared with a reference standard
diagnosis of ‘glaucoma’.
For the triage analysis, a composite test (including three components: imaging, IOP measurement and VA)
was compared with a reference standard of clinical decision ‘do not discharge’. The test categorised a patient
as needing evaluation by a clinician if any elements of the composite triage test were themselves ‘abnormal’
in either eye: imaging classification ‘outside normal limits’ or IOP> 21mmHg or VA of 6/12 or poorer.
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Primary diagnostic performance outcomes were the sensitivity and specificity of tests. Secondary diagnostic
performance outcomes were likelihood ratio and diagnostic odds ratio (DOR). The proportions of
indeterminate test results, low-quality imaging and need for pupil dilatation were measured and patient
preference for the tests was ranked. The test performance was assessed with respect to the glaucoma
spectrum (mild, moderate and severe), when including glaucoma suspects in the reference standard
diagnosis, and when including ‘borderline’ results as abnormal. The diagnostic performance of
combinations of tests was also evaluated.
Economic analysis
A current practice pathway model was developed whereby patients referred to hospital eye services were
seen by a nurse for VA assessment, a technician for visual field measurement and by a clinician.
In an alternative triage care pathway model, individuals were seen by a nurse for VA examination and
IOP measurement and a technician for imaging assessment. The triage test results classified patients as
needing referral for clinician diagnosis or as discharged. Those referred were seen by a technician for visual
field measurement and examined by a clinician.
The cost-effectiveness of four triage pathways, each using IOP, VA and one of the four imaging
technologies (which varied by their diagnostic ability and capital cost), and their subsequent care
management pathways was assessed using a multistate Markov model compared with current practice.
The cohort started in one of six health states: normal; at risk of glaucoma; mild glaucoma; moderate
glaucoma; severe glaucoma; or sight-impaired. The sensitivity and specificity of each triage strategy
determined if diagnosis was correct and, depending on this, the health state that patients would move
to and the associated progression of any underlying glaucoma.
Modelled care pathways were developed in consultation with the study team and the independent
steering committee and used our previous models in this area and reviewed guidelines, study data and
expert opinion.
Consequences were considered in terms of monetary costs (of testing and subsequent management of the
patient’s condition) to the NHS and in terms of the effects on quality of life (by assigning utility weights).
Combining these data with the probabilities of events occurring over time enabled costs, patient outcomes
and quality-adjusted life-years (QALYs) to be estimated for a hypothetical cohort of patients undergoing
each modelled strategy.
Model results were analysed as incremental cost per QALY and incorporated (1) costs (of testing) and triage
diagnostic outcomes, (2) costs (of testing and subsequent management) and (3) QALYs. The base-case
analysis used a cohort of 40-year-old males using prevalence data from the Glaucoma Automated Tests
Evaluation (GATE) study and for a 50-year time horizon. Cycle length was 1 year. The results were presented
in incremental cost-effectiveness ratios (ICERs).
Several deterministic sensitivity analyses were explored, which varied: the annual probability of discharged
patients having a sight test; the cost of triage tests; the start age of the cohort; the performance of the
diagnosing clinician; the diagnostic performance of imaging technologies; the prevalence of glaucoma in
the referred population; and utility weights for those ‘at risk of glaucoma’. The possibility of a hypothetical
pathway, in which patients diagnosed as ‘at risk of glaucoma’ were discharged from the service, was
explored to investigate the impact in terms of costs and QALYs.
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Results
Between April 2011 and July 2013, 2088 participants were identified as potentially eligible: 2013 were
invited to take part. Of those invited, 966 (48%) agreed to take part. Following consent, 11 participants
were found to be ineligible and did not participate and 12 were excluded as they did not receive all
four imaging tests. Therefore, 943 participants were available for the comparisons of tests.
The average age of participants was 60.5 years [standard deviation (SD) 13.8 years] and 51.1% were
female. Non-participants had similar age and sex balance. Most participants (89.2%) were of ‘white British’
ethnicity. The average IOP at referral was 20mmHg. The most common diagnosis was ‘no glaucoma-related
findings’ (31.7% of participants). Comorbidities were uncommon, except for cataract, which was reported
in 8.3% of right eyes and 7.4% of left eyes. Glaucoma was diagnosed in at least one eye in 16.8% of the
GATE cohort and 6.5% had glaucoma in both eyes at referral. Overall, 37.9% of GATE participants were
discharged after the first visit.
Performance of the imaging tests in diagnosing glaucoma differed. HRT-MRA had the highest sensitivity
[87.0%, 95% confidence interval (CI) 80.2% to 92.1%] but the lowest specificity (63.9%, 95% CI 60.2%
to 67.4%), GDx had the lowest sensitivity (35.1%, 95% CI 27.0% to 43.8%) but the highest specificity
(97.2%, 95% CI 95.6% to 98.3%) and the other two tests provided intermediate results (HRT-GPS
sensitivity 81.5%, 95% CI 73.9% to 87.6% and specificity 67.7%, 95% CI 64.2% to 71.2%;
OCT sensitivity 76.9%, 95% CI 69.2% to 83.4% and specificity 78.5%, 95% CI 75.4% to 81.4%).
Likelihood ratios showed evidence of being able to both rule in and rule out the presence of glaucoma for
all four imaging tests (95% CIs did not contain 1.0). DORs ranged from 9.24 for HRT-GPS to 18.48
for GDx.
When including borderline imaging results as an abnormal test, the sensitivity increased but with a
corresponding decrease in specificity. In this sensitivity analysis, HRT-MRA had the highest sensitivity
(94.9%, 95% CI 89.8% to 97.9%) but the second lowest specificity (43.9%, 95% CI 40.2% to 47.6%),
GDx had the lowest sensitivity (60.4%, 95% CI 51.6% to 68.8%) but the highest specificity (82.8%,
95% CI 79.8% to 85.5%) and the other two tests provided intermediate results.
The impact of combining two imaging tests was improved detection of glaucoma but the effect was
marginal and smaller than the loss of specificity.
When considering participants with severe glaucoma, according to our definition of disease stage,
OCT had the highest sensitivity (95.2%, 95% CI 76.2% to 99.9%) and the second highest specificity
(70.9%, 95% CI 67.7% to 73.9%), GDx had the lowest sensitivity (78.9%, 95% CI 54.4% to 93.9%)
but the highest specificity (93.7%, 95% CI 91.8% to 95.2%) and the other two tests provided
intermediate results.
The performance of triage tests (a composite assessment comprising imaging test, IOP and VA assessments)
in correctly identifying patients to be discharged from secondary care showed that triage including HRT-GPS
had the highest sensitivity (86.0%, 95% CI 82.8% to 88.7%) but the lowest specificity (39.1%, 95% CI
34.0% to 44.3%) and GDx had the lowest sensitivity (64.7%, 95% CI 60.7% to 68.7%) but the highest
specificity (53.6%, 95% CI 48.2% to 58.9%), the other two tests providing intermediate results [HRT-MRA
values were very similar to the HRT-GPS results in sensitivity (86.0%, 95% CI 82.8% to 88.7%) and
specificity (53.6%, 95% CI 48.2% to 58.9%) and OCT had lower sensitivity (75.4%, 95% CI 71.6% to
78.9%) but higher specificity (41.0%, 95% CI 35.8% to 46.3%) values than HRT-GPS and HRT-MRA].
Likelihood ratios (and 95% CI) showed evidence of all four triage tests being able to rule in and out the
presence of abnormalities for all four triage tests (CIs did not contain 1.0). DORs ranged from 2.1 for GDx
to 3.9 for HRT-GPS.
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Participant preference for type of imaging test was collected for 890 participants (94%). Almost half of
responders (48.2%) had no preference. Of those participants who expressed a preference, OCT was
ranked as most preferred (27.6%), followed by GDx (11.9%) and HRT (5.1%). Average time taken to
perform the test varied from 5.2 minutes (SD 3.0 minutes) for OCT to 7.6 minutes (SD 5.0 minutes)
for HRT.
Economic analysis results
All triage strategies were more cost-effective than current practice but resulted in reduced health because
of missing cases (i.e. fewer expected QALYs). The base-case results suggest that, of the triage pathways
modelled, a triage including IOP, VA and HRT-MRA is the most cost-effective strategy. Triage including
GDx was shown to be the least costly and least effective. Triage including OCT and HRT-GPS were not
cost-effective. Compared with GDx, the cost per QALY gained for HRT-MRA was £22,904. The cost per
QALY gained with current practice was £156,985 compared with HRT-MRA. Large savings could be made
by implementing HRT-MRA but some benefit to patients would be forgone.
These results should be interpreted with some caution, particularly in terms of differences among triage
strategies, since the diagnostic accuracy of all tests (except GDx) and their unit costs are very similar.
The incremental cost-effectiveness of the triage strategies compared with current practice is very sensitive
to the costs included in the model. Indeed, current practice becomes cost-effective when the total cost
of a triage test increases to £30 and above. A key assumption used in the model was that clinicians are
100% accurate in their diagnostic ability. Relaxing this assumption increased further the ICER (favouring
triage strategies).
Conclusions
Implications for health care
Imaging technologies can be effective to aid the diagnosis of glaucoma. An alternative pathway for
patients referred from community to hospital eye services with possible glaucoma, using a triage test that
includes imaging, IOP and VA, appears to be cost-effective compared with current practice. Our findings
are based on a relatively inexpensive composite triage test (< £30). The most cost-effective strategy would
include HRT-MRA imaging. However, triaging would be associated with a loss of health, and the
acceptability of this option among users and clinicians has not been evaluated.
Recommendations for research
l Determine the acceptability to patients and health-care providers of implementing an efficient triage
glaucoma diagnostic triage system but with reduced health.
l Obtain data on glaucoma disease progression, specifically including patients classified as having
glaucoma suspects and ocular hypertension, associated utility, and cost of providing health care.
l Investigate varying the results of the imaging tests beyond the standard options, since the
recommended classification may not be the one best suited to the population from which
GATE recruited.
l Examine the effectiveness of implementation of a composite triage test.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
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Chapter 1 Introduction
G laucoma describes a group of eye diseases in which there is progressive damage of the optic nerve. It ischaracterised by a specific pattern of optic nerve head and visual field loss leading to impaired vision and
sometimes blindness if inadequately treated. Primary glaucoma can be classified as open-angle glaucoma
(OAG) or angle-closure glaucoma, the former being the more common.1 Glaucoma is a significant public
health problem, second only to macular degeneration as the most common cause of blindness in the UK,2–4
and is the leading cause of irreversible blindness worldwide.5 The impact on patients is considerable, with the
risks of moderate visual field loss (which affects the ability to drive) and long-term blindness reported as the
most important consequences.6 Late detection is a major risk factor for glaucoma blindness.7 However, if
glaucoma is identified in the early stages, treatment is effective at reducing the progress of the disease.8
A a number of factors increase the risk of developing glaucoma, including elevated intraocular pressure
(IOP), older age, ethnic background and family history of glaucoma. Of these, the level of IOP is the most
important risk factor and is the only one which is treatable. Ocular hypertension (OHT), generally defined
as an IOP of ≥ 21mmHg [2 standard deviations (SDs) above the mean], used to be considered as a part
of the definition of glaucoma, but population studies have consistently found that many people with
glaucoma have an IOP below this level.9–13 However, the risk of developing glaucoma, and of worsening of
existing disease, increases with increasing IOP.14–16 This is supported by the fact that those presenting with
advanced glaucoma at diagnosis are more likely to have higher IOP.12,17
The estimated prevalence of glaucoma in the UK is over 1% of the population over 40 years of age.18–21
Approximately 4000 new cases of severe sight impairment due to glaucoma are registered every year in
the UK. Many more glaucoma patients have sight impairment not severe enough to be registered but with
significant impact on their quality of life (e.g. loss of driving licence). In England and Wales, in 2007, there
were over 5 million outpatient attendances at hospital eye services (around 10% of all annual outpatient
attendances) in the NHS. Of these, approximately 1,400,000 were new patients (costing over £140M).
As the population ages, these numbers are likely to increase.22
Estimates based on official population projections and epidemiological prevalence surveys have predicted
that the number of glaucoma cases in England and Wales will increase by one-third by 2021 and continue
to increase at a similar pace until 2031.23
Management of patients with glaucoma and those at risk of suffering from glaucoma constitutes a major
part of the workload of any secondary care eye services. In two independent surveys, between 8%24 and
13%25 of all new referrals to secondary eye care were a result of glaucoma, and 25% of all follow-up
attendances were glaucoma related. In England alone there are over 1 million glaucoma-related outpatient
visits in the NHS hospital eye services annually (approximately 1% of all outpatient activity).26 Currently,
referrals for glaucoma suspect are usually initiated by a community optometrist and are assessed in
hospital eye services by clinicians. However, the reported referral accuracy of glaucoma by optometrists is
suboptimal. Fewer than one-quarter of people referred actually have glaucoma, and nearly half of referred
individuals are discharged after the first visit.27 Thus, many referrals are unnecessary and overburden the
already busy hospital eye services. It also causes distress and worry to the patient that could be avoided.
Interventions such as glaucoma training28 or agreed guidelines29 may not always have an effect in the rates
of false-positive referrals by community optometrists.
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Diagnosing glaucoma
Glaucoma is diagnosed primarily by detecting glaucomatous optic neuropathy (i.e. characteristic changes
of the optic nerve head – the optic disc) and a compatible visual field defect. According to current National
Institute for Health and Care Excellence (NICE) guidelines,26 a definitive glaucoma diagnosis is based on the
expertise of a clinician who subjectively interprets the appearance of the optic disc and the results of
visual field testing. In addition to diagnosing glaucoma, the clinical examination will include a visual acuity
(VA) test (to measure central vision), anterior chamber angle examination (to determine the mechanism of
glaucoma, e.g. open-angle or angle-closure), and IOP measurement (which is a risk factor for glaucoma
and also for disease progression).
Accurate clinical diagnosis of glaucoma is limited by subjectivity, reliance on the examiner’s experience and
a wide variation of optic disc structure in the population. Imaging techniques for assessment of the
structural changes at the optic nerve head and retinal nerve fibre layer (RNFL) have emerged and are in
routine use in the NHS: Heidelberg Retinal Tomography (HRT)-III, scanning laser polarimetry [glaucoma
diagnostics (GDx; Carl Zeiss Meditec, Dublin CA, USA)] and spectral domain optical coherence tomography
(SD-OCT; Heidelberg Engineering, Heidelberg, Germany). These techniques can be easily performed by
trained technicians and provide an automatic glaucoma classification index. Some clinicians now routinely
incorporate the information from such imaging technologies to help make a diagnosis of glaucoma,
although there is no strong evidence of their effectiveness.
Using an automated imaging quantitative test for glaucoma diagnosis may have advantages over visual
field testing in that the majority of people can be imaged.18
Comparison of glaucoma diagnostic technologies
In 1997, the Health Technology Assessment (HTA) programme funded a study entitled ‘The effectiveness of
the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and
monitoring glaucoma’.30 At the time, this study was the largest and most rigorous head-to-head comparison
of tests for diagnosing glaucoma. However, this study used the first prototypes of the HRT and GDx, now
outdated. Another serious limitation was the small study sample (250 participants), in addition to a
potentially biased selection of patients, as they were not consecutively selected.
A systematic review of the performance of technologies for detecting glaucoma as both screening and
diagnostic tests for glaucoma identified that the evidence is of poor quality and that no one test was
clearly superior.18 In this systematic review it was also found that populations studied were varied and
biased. Furthermore, only six studies performed a direct comparison of the available diagnostic instruments
(and including, on average, fewer than 300 patients), the threshold for definitions of glaucoma cases was
not consistent and there were no studies reporting on the performance of GDx and optical coherence
tomography (OCT) that met the inclusion criteria for this systematic review. However, the review did
suggest that some diagnostic technologies perform better than others (e.g. HRT performed relatively well),
but the credible intervals around the estimates were wide, reflecting considerable uncertainty, and,
therefore, it recommended that the available diagnostic tests be evaluated in an appropriately powered
directly comparative study.
In the published NICE guideline,26 the authors searched for evidence comparing the diagnostic
performance of HRT, GDx and OCT with expert clinical examination. No studies met the inclusion criteria
for the guideline review.
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Triage tests in secondary care eye services
Considerable NHS resources are required to assess all patients referred to hospital eye services with
glaucoma suspect. In June 2009, the chairman published on behalf of the Professional Standards
Committee of the Royal College of Ophthalmology a statement that the interpretation of NICE glaucoma
guidelines was putting considerable strain onto secondary care eye services through the increase in
false-positive referrals from community optometrists. The statement proposed that eye departments should
consider innovative and efficient clinics for the initial assessment of patients.31
If referrals could be triaged to identify suitable referrals and discharge unsuitable referrals in an effective
and cost-effective manner, the resources could be better utilised for patient eye care services. Imaging
technologies are being introduced into glaucoma services in both hospital and community settings, but
their role in the diagnostic pathway as triage, replacement or add-on tests has not been evaluated. The
tests to be evaluated in this study are the currently available imaging technologies with characteristics that
suggest that they could be valuable triage tests and that are in current use in the NHS. They do not require
patient input, are user-friendly,32 provide automated quantitative classifications and potentially could
reduce the need for an extensive examination by an expert glaucoma clinician. The diagnostic performance
of these imaging technologies has not been evaluated in a triage setting and in a robust manner.
Aim and research objectives
Aim
To assess the relative performance and the cost-effectiveness of new diagnostic imaging technologies,
as triage tests in secondary care, for identifying people with glaucoma.
Research objectives
Primary objective
To compare the performance of imaging technologies [HRT Moorfields regression analysis (HRT-MRA;
Heidelberg Engineering, Heidelberg, Germany), HRT glaucoma probability score (HRT-GPS; Heidelberg
Engineering, Heidelberg, Germany), GDx and OCT] as diagnostic and triage tests for patients referred to
hospital eye services with possible glaucoma. Triage tests include an imaging technology, VA and IOP.
Secondary objectives
(a) To explore alternative thresholds for determining test positivity.
(b) To evaluate the diagnostic performance of combinations of the imaging tests.
(c) To evaluate the performance of the tests across the spectrum of glaucoma (mild, moderate
and severe).
(d) To evaluate the cost-effectiveness of adopting individual tests or combination of tests as triage tests
compared with the current practice of diagnostic examination by a clinician in a secondary care setting.
(e) To evaluate patient preferences of different imaging technologies.
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Chapter 2 Methods
This chapter describes the Glaucoma Automated Tests Evaluation (GATE) study design and methods forthe diagnostic performance evaluation, and follows the standards for the reporting of diagnostic
accuracy studies (STARD).33 The methods for the health-economic evaluation are described separately
(see Chapter 6).
Overview of the study design
An overview of the GATE study design is shown in Figure 1. The GATE study is a pragmatic within-patient
comparative diagnostic evaluation of four imaging techniques for glaucoma in patients referred to hospital
eye services. Specifically, this study was designed to evaluate (1) diagnostic accuracy of imaging tests for
detecting glaucoma in an eye and (2) diagnostic accuracy of triage tests that consisted of a combination
of an imaging test, VA and IOP measurement, for identifying patients requiring referral to hospital eye services.
All patients recruited to the study received four different imaging tests (using three different devices),
which were compared with a reference standard (i.e. a comprehensive clinical examination). The study was
co-ordinated from a central study office in the Health Services Research Unit at the University of Aberdeen.
Approach
All new glaucoma referrals sent an invitation letter and patient information
sheet prior to first appointment at hospital (logged on clinic log)
Consent
Baseline and referral data collected
(research officer data collection form)
Not recruited
• Ineligible
• Declined
• Missed 
Index tests (imaging)
All patients imaged with all three imaging devices (random order)
giving four imaging test results
HRT-MRA  HRT-GPS GDx OCT (Spectralis)
Reference standard
Comprehensive clinical examination by ophthalmologist with glaucoma expertise,
masked to index test results 
Imaging preference collected
(participant preference questionnaire)
Biomicroscopy of optic nerve head, evaluation of VF with standard automated perimetry 
Humphrey 24-2 SITA strategy,a IOP measurement (GAT), evaluation of anterior chamber angle
 (clinician case report form)
FIGURE 1 Overview of study design. GAT, Goldman applanation tonometry; VF, visual field. a, Carl Zeiss Meditec,
Dublin, CA, USA.
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Participants
Inclusion criteria
Adult patients referred from community optometrists or general practitioners to hospital eye services with
any glaucoma-related findings, including those with OHT.
Exclusion criteria
Patients referred to hospital eye services because of other ocular disease; patients < 18 years old; patients
who could not give informed consent; patients who had already been diagnosed with glaucoma; and
patients referred from within secondary care.
Setting
Five NHS hospital eye services in the UK participated in this study: Aberdeen Royal Infirmary (Aberdeen),
Bedford Hospital (Bedfordshire), Hinchingbrooke Hospital (Cambridgeshire), Moorfields Eye Hospital
(London) and St Paul’s Eye Unit (Liverpool). The participating units consisted of three academic units of
different sizes and two district general hospitals (Hinchingbrooke and Bedford).
Identification of participants and recruitment process
Consecutive eligible patients referred from community optometrists to hospital eye services with a
glaucoma-related finding were identified by the research officer in each centre at the time of referral.
Patients were identified from their referral letter as being referred with a possible glaucoma diagnosis or
glaucoma-related finding, including high IOP, possible abnormalities in the optic disc or visual field tests,
and possible narrow anterior chamber angle. To ensure that a full cross-section of referrals were identified,
existing referral refinement schemes in two of the participating centres were suspended for the duration of
the study in order not to introduce selection bias. In the largest centre (Moorfields Eye Hospital) only those
patients booked to see a clinician trained in the study protocol to provide the reference standard were
identified as eligible. Information about this study was sent to potentially eligible patients together with
the date of the appointment (see Appendix 1). Patients were approached by the local research officer on
their first visit to hospital eye services to discuss the study and those patients who agreed to participate
and signed the consent form (see Appendix 1) were enrolled (i.e. before their consultation with the
ophthalmologist). Each research centre kept a clinic log of eligible patients invited (see Appendix 2), which
included patient demographics (age and sex) and, for those who declined to take part or were found to be
ineligible, reason for not taking part if given.
Diagnostic technologies being assessed (index tests)
Four diagnostic tests from three imaging devices were evaluated:
1. HRT-III, confocal laser scanning imaging technology, used by the Heidelberg Retinal Tomograph
(Heidelberg Engineering, Heidelberg, Germany), exploits the principle of confocal laser scanning to
allow quantitative structural information of the optic disc anatomy. The topographic image is derived
from multiple optical sections at consecutive focal depth planes. Each image consists of numerous
pixels, with each pixel corresponding to the retinal height at its location. Images are given a measure
of quality: the mean topography SD which the manufacturer recommends should be ≤ 40 µm. There
are two main classification tools to define normality/outside normal limits: (1) MRA,34 which requires the
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
user to draw a contour line to define the optic disc boundary, and (2) glaucoma probability score
(GPS),35 which is fully automated and independent of operator input.
i. The HRT-MRA produces an overall (‘global’) classification as well as by six segments (‘temporal’,
‘temporal superior’, ‘temporal inferior’, ‘nasal’, ‘nasal superior’ and ‘nasal inferior’) of the eye. Each a
classification of ‘within normal limits’, ‘borderline’ and ‘outside normal limits’ is given based on
whether or not the observed value is within the 95.0% prediction interval, between the 95.0% and
the 99.9% prediction interval or below the 99.9% prediction interval of the preset data, respectively.
The final classification is based on the most abnormal of any of the seven classifications. If any one of
these is ‘outside normal limits’ then the overall classification is ‘outside normal limit’. Where there is
no ‘outside normal limits’ but at least one ‘borderline’ then the final classification is ‘borderline’. Only
where the global and all six segment probabilities are ‘within normal limits’ is the final classification
‘within normal limits’.
2. HRT-GPS produces an overall probability of the presence of glaucoma (‘global’) and by segment (‘temporal’,
‘temporal superior’, ‘temporal inferior’, ‘nasal’, ‘nasal superior’ and ‘nasal inferior’) for each eye. The default
‘final’ classification is based on applying cut-off to the overall and six segment probabilities: < 0.28 is ‘within
normal limits’, ≥ 0.28 and < 0.65 is ‘borderline’ and ≥ 0.65 is ‘outside normal limits’.35 If any one of these
is ‘outside normal limits’ then overall classification is ‘outside normal limit’. Where there is none ‘outside
normal limits’ but at least one ‘borderline’ then the final classification is ‘borderline’. Only where the global
and all six segment probabilities are ‘within normal limits’ is the final classification ‘within normal limits’.
3. GDx-Enhanced Corneal Compensation (ECC) (Carl Zeiss Meditec, Dublin, CA, USA) scanning laser
polarimetry measures the RNFL thickness. Measurements are based on the birefringent properties of the
RNFL, which has its neurotubules disposed in an organised, parallel fashion. The software provides a
discriminating classifier of glaucoma/normality, the nerve fibre indicator (NFI) value, which is fully
automated and is calculated for each eye. The manufacturers’ reported cut-offs for the GDx-ECC NFI
value are based on 95% and 99% coverage of the normative database population and are 1–35
(‘normal’), 36–55 (‘abnormal 95’) and ≥ 56 (‘abnormal 99’).36 The difference between ‘abnormal 95’ and
‘abnormal 99’ may be viewed in a similar manner to the ‘borderline’ category for HRT-GPS, HRT-MRA
and OCT classifications. The temporal, superior, nasal, inferior, temporal (TSNIT) parameters used in the
calculation of the NFI are also produced overall and by eye segment (superior and inferior) and an
inter-eye symmetry is also produced. Images are given a quality figure, which the manufacturer
recommends should be ≥ 7. In this study, GDx-ECC measurements were made using either the GDx-Pro
(three centres) or the GDx-VCC with updated ECC module (two centres).
4. OCT: SD-OCT (Spectralis®, Heidelberg Engineering, Heidelberg, Germany) is an optical imaging
technique capable of providing high-resolution, cross-sectional imaging of the human retina in a
fashion analogous to B-scan ultrasonography but using light instead of sound. OCT uses the principles
of low-coherence interferometry using light echoes from the scanned structure to determine the
thickness of the tissue. The glaucoma detection software of the Spectralis® machine used in this study
produces an average RNFL thickness value for the global and six segments of the eye and automatically
compares sectors of RNFL thickness with a normative database. An overall assessment of ‘within
normal limits’, ‘borderline’ or ‘outside normal limits’ is produced34 based on the global classification and
the six individual segments. Inter-eye symmetry is also produced for each segment. Images are given a
quality figure, which the manufacturer recommends should be > 15.
Sample reports generated by each of the imaging tests are shown in Appendix 3.
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Reference standards
Eye level (for the diagnostic performance analysis)
The glaucoma diagnosis reference standard chosen for this study represents current clinical practice in the UK,
which consists of clinical examination (biomicroscopy) of the appearance of the optic nerve head and
evaluation of the visual field with standard automated perimetry Humphrey 24–2 SITA (Carl Zeiss Meditec,
Dublin, CA, USA) strategy by an ophthalmologist with glaucoma expertise. In addition, the clinician
measured the IOP and examined the anterior chamber angle. The imaging tests were not available to the
ophthalmologist when measuring the reference standard. The clinician recorded the status of each eye as
described in Table 1 (i.e. glaucoma, OHT, glaucoma suspect, other eye morbidities or normal). If a clinical
diagnosis could not be established at the first visit (e.g. unreliable visual field measurement requiring repeated
measurement at a further appointment), an inconclusive diagnosis was recorded. In order to ensure valid and
consistent application of the agreed reference standard, a limited number of consultant ophthalmologists
provided the reference standard (one or two clinicians in four centres, and five different clinicians at one
centre). Principal investigators collaborating in each of the participating units gathered at the start of the
project to review and agree on the reference standard (definitions of glaucoma, OHT, glaucoma suspect and
TABLE 1 Clinical diagnosis definitions
Diagnosis Definition
Glaucoma
Severe Evidence of glaucomatous optic neuropathya and a characteristic VF loss.b Severe: MD worse than or
equal to –12.01 dB
Moderate Evidence of glaucomatous optic neuropathya and a characteristic VF loss.b Moderate: MD between
–6.01 dB and –12 dB
Mild Evidence of glaucomatous optic neuropathya and a characteristic VF loss.b Mild: MD better than or
equal to –6 dB
Glaucoma suspect
Disc suspect Appearance suggestive of glaucomatous optic neuropathy but may also represent a variation of
normality, with normal VFs (with or without high IOP)
VF suspect VF loss suggestive of glaucoma, but may also represent a variation of normality, with normal
appearance of the optic disc (with or without high IOP)
VF and
disc suspect
Both the optic disc and VF have some features that resemble glaucoma but may also represent a
variation of normality (with or without high IOP)
OHT When both the VF and optic nerve appear normal in the presence of elevated pressure > 21mmHg
PAC Closed anterior chamber angle (appositionally or synechial) in at least 270°, and at least one of the
following: IOP > 21mmHg and/or presence of peripheral anterior synechiae. Both VF and optic nerve
appear normal
PAC suspect Closed anterior chamber angle (appositionally without any synechiae) in at least 270°, with IOP
≤ 21mmHg. Both VF and optic nerve appear normal
MD, mean deviation; PAC, primary angle closure; VF, visual field.
a Evidence of optic nerve damage from any of the following: optic disc or RNFL structural abnormalities; diffuse thinning,
focal narrowing or notching of the optic disc rim, especially at the inferior or superior poles; documented, progressive
thinning of the neuroretinal rim with an associated increase in cupping of the optic disc; diffuse or localised
abnormalities of the peripapillary RNFL, especially at the inferior or superior poles; disc rim or peripapillary RNFL
haemorrhages; optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
b Reliable VF abnormality considered a valid representation of the subject’s functional status. VF damage consistent with
RNFL damage (e.g. nasal step, arcuate field defect or paracentral depression in clusters of test sites). VF loss in one
hemifield that is different from the other hemifield, that is across the horizontal midline (in early/moderate cases).
Absence of other known explanations.
Note
Reference standard: for the eye-level analysis, reference standard positive was classified as a diagnosis of glaucoma.
Sensitivity analyses explored the diagnostic performance of the tests when also including glaucoma suspects in the
definition of reference standard positive (see Statistical analysis methods for full details).
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normal) and how to define the spectrum of the disease (mild, moderate and severe). For this purpose, training
material was used including a series of cases with glaucoma-related findings and also with normal subjects.
Clinicians who were incorporated into the study at a later date to recruit and provide the reference standard
were trained individually by the chief investigator with the same material.
For the eye-level analysis, reference standard positive was classified as a diagnosis of glaucoma based on
the ‘worse’ eye. Sensitivity analyses explored the diagnostic performance of the tests when also including
glaucoma suspects in the definition of reference standard positive along with using the ‘better’ eye (see
Statistical analysis methods for full details).
Patient level (for the triage performance analysis)
For each patient the clinical management decision made was recorded, that is ‘discharge’ or ‘do not
discharge’. Additionally, the reason for non-discharge [and which eye(s) it refers to] of ‘treatment’ or
‘monitoring’ was also collected. Clinicians were advised to follow NICE guidelines in deciding whether
to discharge or not.26
Outcomes
For each of the four tests (HRT-MRA, HRT-GPS, GDx and OCT) the following outcomes were measured.
Diagnostic performance of imaging technologies
The primary diagnostic performance outcomes were sensitivity and specificity. Secondary diagnostic performance
outcomes were likelihood ratio and diagnostic odds ratio (DOR). The overall diagnostic performance of
combinations of these four tests was also evaluated (HRT-MRA with each of the other three tests) as well as
their relative performance. The diagnostic performance of the tests (and corresponding combinations) was also
assessed according to the spectrum of glaucoma (mild, moderate and severe), as defined by the glaucoma expert.
Other outcomes
The proportions of indeterminacy results, low-quality imaging according to the manufacturer’s
recommendation and the participant’s preference regarding the four tests were recorded for each test.
Additionally, the number of participants who required pupil dilatation to perform the imaging was also
recorded. Dilatation was attributed to the first imaging technology. Where a high-quality test result was
not available for a participant (‘no result’), one of the following categorises applied:
(a) test performed and imaging report produced but quality is lower than manufacturer quality cut-off
(b) test performed and imaging report produced but no overall classification generated by machine
(c) test performed but there was a clear imaging artefact on the report
(d) test attempted but no imaging could be acquired from the patient’s eyes – no report generated
(e) missing imaging output (owing to study-related or data-collection issues).
Indeterminacy of the result was calculated as categories (b) to (d), divided by the total number of
non-missing cases. The proportion of low-quality imaging was (a) divided by the total number of non-missing
cases minus categories (a) to (d).
Diagnostic performance of a triage test (imaging test, visual acuity and
intraocular pressure measurement)
As for the diagnosis analyses, the primary diagnostic performance outcomes of the triage test were
sensitivity and specificity in correctly identifying patients who would be discharged from secondary care.
Clinicians were advised to follow NICE guidelines in deciding whether to discharge or not.26 Secondary
diagnostic performance outcomes included likelihood ratios and DOR.
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Delivery of interventions and data collection
Enrolled participants attended a diagnostic station for imaging (index test) and visual field measurement
immediately prior to their meeting with the ophthalmologist. In three centres (Hinchingbrooke, Bedford
and Liverpool), the visual field and imaging measurements took place on a separate day prior to the
ophthalmologist appointment (within 2 weeks). Pupils were not routinely dilated. However, in those
patients in whom adequate quality imaging could not be obtained, pupil dilatation could be used to try to
improve image quality. In exceptional circumstances, where dilatation was required in centres offering split
visits, some or all of the imaging tests could be delayed until the clinic appointment but always ahead of
the clinical reference standard. Imaging technicians and the patient were therefore masked to the patient’s
underlying condition at the time of testing. In the remaining two centres (Aberdeen and Moorfields) all
measurements were undertaken on the same day. All participants in each of the centres underwent testing
with the three imaging devices, in a random order (to avoid bias when collecting participant preference) in
one sitting. The random test order was automatically generated for each patient from the study website.
Imaging technicians employed at each centre performed the imaging tests. One to three technicians were
identified at each centre and trained in study procedures prior to recruitment (see Appendix 4). There was no
restriction on the same technician performing all imaging tests on an individual. Across all centres, most
technicians were experienced in performing the test prior to the study; if technicians were not already
experienced, they received training from the manufacturer or local imaging lead prior to collecting study data.
With the exception of HRT-MRA, which required an experienced user to identify a contour line at the optic
disc margin, all imaging tests generated the glaucoma classification automatically once an image had been
acquired. The research officer kept printed copies of the images and uploaded the imaging results to the
study website. Imaging reports were identified using a unique study number and date of birth.
The participant was asked to grade the tests in order of preference, or to record no preference, using a standard
form (see Appendix 2). Visual field measurements were undertaken with standard perimetry Humphrey SITA 24-2
strategy for each participant after all imaging tests had been completed. In exceptional circumstances, visual field
measurements were undertaken ahead of the imaging tests because of clinic demand for equipment. Participants
were then examined by an experienced glaucoma clinician who performed a comprehensive ocular examination
including IOP measurement with Goldmann applanation tonometry (GAT), gonioscopy and biomicroscopic
examination of the optic disc (with pupil dilated in patients without narrow anterior chamber angle) and
evaluated the visual field test results. The clinician provided the reference standard masked to the results of the
imaging technologies and completed a clinical data collection form (see Appendix 2).
The research officer collated the results for each participant (see Appendix 2) including a copy of the visual field
test, completed forms for each participant, uploaded the information onto the web page and posted original
consent forms to the central office. Information uploaded onto the web page included demographics, referral
IOP, refractive error, patient preference, need for pupil dilatation, and Humphrey visual field reliability and
global indices mean deviation (MD), pattern standard deviation (PSD) and visual field index (VFI).
Data management
A web-based secure study database was developed for the GATE study which research staff could access
remotely. Password-protected access was provided such that centres could view data only from their own
centre. All data collected during the course of the research were kept strictly confidential and accessed
only by members of the study team. Minimal patient details were recorded and were stored under the
guidelines of the 1998 Data Protection Act.37 Patients were allocated an individual study number and this
number was used to identify study paperwork. Study data were entered and imaging reports uploaded
onto the database by the research officer working in each centre. Whenever possible, drop-down boxes
were employed to select appropriate responses and minimise typographical errors. Automated range
checks and validation were built in to ensure that inappropriate values could not be recorded.
METHODS
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Staff in the study office monitored data centrally and worked closely with local research officers to ensure
that the data were as complete and accurate as possible. Missing forms and primary outcome data were
automatically identified on the study website and distributed to local research officers on a regular basis.
Uploaded imaging reports for each participant were checked by the central office, following an agreed
checklist, and errors flagged for correction to the appropriate research team on a regular basis. This
resulted in a low percentage of missing primary outcome data (1% reference standard: 1–3% imaging
data). The content of approximately 50 case report forms and imaging reports selected at random was
checked against entered data to ensure data entry accuracy. If consistent errors or discrepancies were
found, this triggered a further training session with the research officer to discuss and resolve data
collection and entry issues.
The chief investigator checked a random sample of HRT-MRA imaging reports from each centre (five
reports for each operator at each centre) for accurate location of the optic disc margin. A high error rate
(more than two of five checked) at one centre triggered a complete check of the data at that centre:
images with incorrectly placed contour lines were excluded from the default analysis and classified as
artefact, as described in Chapter 4.
Statistical analyses
Sample size
The sample size calculation and analysis were based on standard diagnostic accuracy study methods.38
The sensitivity and specificity of each of the automated imaging tests were compared. A 5% significance
level based on a two-sided test was used in the sample size calculations. A study of 897 individuals
would have 90% power to detect a difference in accuracy of 9% for the primary outcome of diagnosis of
glaucoma. This is based on conservative assumptions of a probability of disagreement of 0.18 (maximum
level possible), a glaucoma rate of 25% (as seen in similar populations) and a sensitivity of 86% (as found
in a systematic review for HRT18). Given this sample size, there would also be 80% power to detect a
6% difference in accuracy should the sensitivity be 93% (the current best estimate from meta analyses of
high-quality diagnostic studies). For specificity, we would have over 90% power to detect a 5% difference.
Based on current available evidence, a rate of 6% indeterminacy of tests results was assumed, which
increased the sample size to 954 in total. A sample of this size would be of sufficient size for other
measures of diagnostic performance [e.g. the sensitivity and specificity of individual technologies would be
estimated to 95% confidence intervals (CIs) of width 10% and 5%, respectively].
Overview of planned analyses
To address the primary objective, two sets of preplanned statistical analyses and sensitivity analyses of the
diagnostic performance were carried out. They were:
1. ‘glaucoma diagnosis’ analyses focused on the clinical diagnosis of glaucoma (see Chapter 4)
2. ‘triage’ analyses focused on the clinical discharge decision (see Chapter 5).
Glaucoma diagnosis analyses of diagnostic performance
The diagnostic performance of the four imaging tests (HRT-GPS and HRT-MRA outputs, GDx-ECC and
OCT) from three imaging devices for detecting glaucoma was calculated and compared. The ‘worse’ eye of
each participant as defined by the clinical reference standard was used in these analyses, except for one
sensitivity analysis, which used the ‘better’ eye of each participant. The reference standard was a clinical
diagnosis of glaucoma (mild, moderate or severe) by an ophthalmologist (see Reference standards).
Diagnosis was ranked in order of decreasing severity as severe glaucoma, moderate glaucoma, mild
glaucoma, glaucoma suspect (of any kind), primary angle closure (PAC), OHT or normal (including all other
diagnoses). The ‘worse’ eye, on the basis of comparing eyes using this ranking, was used. If the two eyes
had a similar spectrum of disease then a random eye was chosen. The primary analysis definition did not
include glaucoma suspects (whether disc- or visual field-based suspicion or both). The initial ‘positive’ test
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definition under the imaging assessment was a test result of ‘outside normal limits’ for HRT-MRA, HRT-GPS,
OCT and NFI≥ 56 for GDx, with borderline cases classified as ‘negative’.
Triage analyses of diagnostic performance
This set of analyses focused on the clinical decision for the management of a participant (discharged or not
discharged). The reference standard for these analyses was a person-level clinical decision (‘not discharged’
or ‘discharged’). ‘Not discharged’ was defined as a ‘positive’ test result for the reference standard. The
decision to ‘not discharge’ a patient may have been a result of the diagnosis of an eye condition which
needs treatment (glaucoma or otherwise) or the need for monitoring in one or both eyes. As VA and IOP
influence the clinical decision to discharge or not discharge a patient for conditions other than glaucoma
and are routinely collected, these data were incorporated and a composite triage test was defined. In these
analyses, the discharge status of the patient was compared with a composite ‘test’ which is a combination
of results from an imaging test, the measurement of IOP and VA.
Following the statistical analysis plan, the diagnosis results (according to diagnosis performance and
proportion of indeterminate tests) were considered prior to conduct of the triage analysis. Corresponding
triage analyses of all four imaging tests were then conducted according to the following definitions.
An ‘abnormal’ result for the imaging component was defined as including borderline as ‘abnormal’. An
‘abnormal’ result for the IOP measurement component was a pressure > 21mmHg as measured by the
ophthalmologist. Similarly, for VA, an ‘abnormal’ test result was defined as 6/12 or poorer as measured
prior to referral by an optometrist. The VA cut-off point (6/12) was chosen because below this level
patients would not be able to drive and would merit further investigation to justify the reduced vision. VA
was assumed not to be abnormal if it was not mentioned in the referral letter. The composite test was
classified as ‘abnormal’ if any of three components tests were judged to be abnormal for either eye.
Statistical analysis methods
Diagnostic performance analysis methods
Diagnostic measures (sensitivity, specificity, likelihood ratios and DORs) were calculated for each test with
appropriate CI.39,40 All analyses were conducted at a 5% (two-sided) significance level, with 95% CIs
produced where appropriate. Under the diagnoses analyses, the diagnostic performance (sensitivity and
specificity) of the alternative imaging tests was compared using McNemar’s test (default analyses only).38
Corresponding CIs for the paired difference were generated.41 No missing imaging, IOP or reference
standard data were imputed. VA was assumed not to meet the abnormal criteria if not reported.
Sensitivity analyses of diagnostic performance
A range of sensitivity analyses were conducted for the diagnosis and/or triage analyses. These were:
l Varying the imaging test cut-off to explore possible threshold effects. This was done by classifying
borderline as diseased for the overall classification and also by using the parameters reported by each
imaging test. A receiver operating characteristic (ROC) curve and the area under the curve (AUC)
with the corresponding 95% CI was calculated for each parameter using a non-parametric approach
(SAS, SAS Institute Inc., Cary, NC, USA; Logistic command). The results of the threshold assessment are
given in Appendix 5 (diagnosis analysis only).
l Varying the reference standard definition of abnormal (e.g. inclusion of glaucoma suspects for
diagnosis analyses) (both diagnosis and triage analyses).
l Removing the imaging quality requirement and/or assuming indeterminate results were abnormal
(both diagnosis and triage analyses).
l Using a combination of (two) tests for diagnostic performance. The choice of combinations was
informed by the individual imaging test glaucoma diagnosis analyses (diagnosis analysis only).
l Assess the impact of using ‘better’ eye instead of the ‘worse’ eye for each participant as defined by the
clinical reference standard (diagnosis analysis).
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
l Varying the IOP cut-off value for the pressure component of the test to be classified as ‘abnormal’.
A further analysis using a cut-off point of IOP> 25mmHg was carried out (triage analysis only).
l Using the referral IOP measurement instead of the ophthalmologist’s measurement to define the
positive IOP component of the triage test. For this analysis IOP> 21mmHg will be used as the cut-off
point for OHT (triage analysis only).
l Varying the threshold for the VA component of the composite test to be classified as ‘abnormal’ (triage
analyses only).
l Using a composite test without a VA component (i.e. only imaging and IOP components) (triage
analyses only).
Diagnostic analyses to populate the health economic model
A third set of analyses were produced in order to provide the most appropriate diagnostic performance
data to populate the economic model (see Appendix 6 for the results). Under these analyses, the reference
standard was detection of glaucoma and those ‘at risk’ of glaucoma (i.e. a patient who was a glaucoma
suspect of any kind, PAC or OHT). This is because people with these potential diagnoses need to remain
monitored in secondary care according to the NICE guidelines. Any modelled triage system would need to
reflect standard practice.26
Other outcomes
Two other outcomes were used to evaluate each of the four tests: indeterminacy of tests and participant
preferences. Indeterminacy of tests was quantified as the proportion of tests that are indeterminate for
each of the four imaging tests. This outcome was calculated in two ways: those which meet the
manufacturer’s suggested quality requirements and those for which a test result was produced.
Participants’ preference ranking of the three imaging technologies was summarised.
Patient and public involvement
Representatives from a UK-based charity for glaucoma patients, the International Glaucoma Society, were
involved in the study oversight throughout the project through the steering committee. This included
review and development of the study protocol and patient paperwork; monitoring the study progress;
review and discussion of the final results of the study, including the care pathways and sensitivity analyses
for the economic analyses, with particular reference to the patient perspective; and proposing further
research priorities, particularly the acceptability of this new model of care. Additionally, a patient with
glaucoma reviewed and commented on the lay summary of the report.
Study oversight and management arrangements
The University of Aberdeen sponsored the study. An independent Trial Steering Committee (TSC) was
established. The TSC comprised an independent chairperson (ophthalmologist and senior academic), three
further independent members (two ophthalmologists and the chief executive of a UK-based charity for
glaucoma patients, the International Glaucoma Association) and the study grant holders. The TSC met
approximately annually over the course of the study. A patient (IR) agreed to provide advice on certain
aspects of the study, but was not a member of the TSC. No data monitoring committee was used, as there
were no safety concerns; the diagnostic technologies under evaluation were non-invasive, they were
routinely performed in clinical settings and patient management did not change.
The day-to-day running of the study was the responsibility of the chief investigator (AAB) supported by the
research manager, research fellow and data support staff. A project management group consisting of the
coapplicants provided strategic, management and content expertise to the study.
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Ethical arrangements and regulatory approvals
The study and subsequent amendments were reviewed and given a favourable opinion by the North of
Scotland Research Ethics Committee (reference 10/S0801/58) and local research and development
departments. The study was conducted according to the principles of good clinical practice.
Protocol amendments after study initiation
A number of minor protocol revisions were made after study initiation (Box 1).
BOX 1 Versions of the study protocol
l Version 1, 28 July 2010.
l Version 1.1, 31 January 2011 (minor typographical changes).
l Version 1.2, 17 April 2012 (extension of recruitment time scale).
l Version 1.3, 11 April 2013 (extension of recruitment time scale).
l Version 1.4, 4 July 2013 (updated list of grant holders and TSC members).
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Chapter 3 Participant characteristics
This chapter provides an overview of the baseline characteristics of participants in the GATE study.
Recruitment of participants
Between April 2011 and July 2013, 2088 participants were identified as potentially eligible to take part in
the study: 2013 were sent letters of invitation and patient information sheets. Of those invited, 966 (48%)
agreed to take part, and 265 (13%) expressed a preference for not participating. Characteristics of
non-participants are detailed in Table 2.
Following consent, 11 participants were subsequently excluded from the study: 10 were ineligible (four
had pre-existing glaucoma, four were referred from secondary care and two were not referred for
glaucoma) and one person withdrew from the study. Therefore, 955 participants were available for the
index test comparison. Additionally, owing to administrative and research processes, imaging was not
implemented for all imaging tests in 12 participants, and these participants were excluded from all
analyses. The baseline measurements presented in this chapter relate to the remaining 943 participants.
Figure 2 shows a diagram of the enrollment following the STARD reporting guidelines. Full details of patient
flow through the diagnostic performance analysis are described within the results (see Chapters 4 and 5).
Aberdeen and Hinchingbrooke were the highest-recruiting centres (Table 3). Over two-thirds of GATE
participants were recruited from these two sites.
TABLE 2 Characteristics of non-participants
Characteristic Value
N 1122
Age (years),a mean (SD) 61.7 (15.1)
Female, n (%) 592 (52.8)
Reasons for not taking part, n (%)
Screened but not sent information sheet 75 (6.7)
Refusal 265 (23.6)
Equipment malfunction 33 (2.9)
Missed 93 (8.3)
Non-attendance 134 (11.9)
Other reason 247 (22.0)
Reason not given 275 (24.5)
a Age calculated as year of test – year of birth.
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Baseline characteristics of participants
Demographic characteristics of participants and non-participants were similar, with an average age slightly
above 60 years (Tables 2 and 4) and similar gender distribution. Among participants, nearly 90% were of
white British ethnicity (self-reported ethnicity; Table 4).
Ocular characteristics recorded in the referral letter from the optometrist are detailed in Table 5. In the
majority of referrals (77%), the optometrist had highlighted abnormalities in both eyes (referral eye).
The average IOP at referral was 20mmHg. Where the method of IOP measurement was reported on the
referral letter (52%), the most commonly reported method of measurement was non-contact tonometry.
Data on VA and refractive error at referral are summarised in Table 5.
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Imaging not performed 
for all four index tests
(n = 12)
FIGURE 2 Diagram showing recruitment to the study.
TABLE 3 Centre recruitment
Centre Participants recruited, n (%)
Aberdeen Royal Infirmary 353 (37.0)
Bedford Hospital 74 (7.7)
Hinchingbrooke Hospital NHS Trust 343 (35.9)
Moorfields Eye Hospital 157 (16.4)
Royal Liverpool Hospital 28 (2.9)
Total 955
PARTICIPANT CHARACTERISTICS
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TABLE 4 Baseline demographics of included participants
Characteristic
Value
All participants Glaucoma Non-glaucoma
N 943 158 770
Age (years), mean (SD) 60.5 (13.8) 67.4 (12.7) 59.2 (13.6)
Female, n (%) 482 (51.1) 74 (46.8) 401 (52.1)
Ethnicity,a n (%)
Black or Black Caribbean 25 (2.7) 4 (2.5) 21 (2.7)
Black or Black British-African 20 (2.1) 6 (3.8) 14 (1.8)
Asian or Asian British-Indian 18 (1.9) 5 (3.2) 13 (1.7)
Asian or Asian British-Pakistani 4 (0.4) 0 (0) 4 (0.5)
Chinese 1 (0.1) 1 (0.6) 0 (0)
Other Asian background 4 (0.4) 1 (0.6) 3 (0.4)
Mixed White and Black African 1 (0.1) 1 (0.6) 0 (0)
White British 826 (89.2) 140 (88.6) 686 (89.1)
Other 29 (3.1) 0 (0) 29 (3.8)
a There was no ethnicity recorded in 15 participants.
TABLE 5 Ocular characteristics of participants at referral
Characteristic
Referral eye, n/N (%)
Right 97/939 (10.3)
Left 116/939 (12.3)
Both eyes 725/939 (76.9)
Not answered 1/939 (0.1)
Method of IOP assessment, n/N (%)
Non-contact tonometry 260/943 (27.6)
GAT 231/943 (24.5)
Othera 452/943 (47.9)
IOP on referral (mmHg) Right eye Left eye
IOP, mean (SD) 19.6 (5.7), 918 19.9 (5.6), 918
Refraction
Mean sphere (dp), mean (SD), n 0.4 (3.3), 571 1.0 (3.6), 561
Myopia greater than –5 dp, n/N (%) 37/943 (3.9) 36/943 (3.8)
Hyperopia greater than +5 dp, n/N (%) 38/943 (4.0) 51/943 (5.4)
Astigmatism greater than 3 dp, n/N (%) 16/943 (1.7) 16/943 (1.7)
VA, mean (SD), n
BCVA, Snellen chart 1.0 (0.3), 925 1.0 (0.3), 926
LogMAR 0.0 (0.3), 925 0.0 (0.3), 926
BCVA, best corrected VA; logMAR, logarithm of the minimum angle of resolution.
a Includes those where the method of assessment was not recorded on referral.
DOI: 10.3310/hta20080 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 8
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Azuara-Blanco et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Reference standard diagnosis characteristics
Tables 6–14 describe the tests used to determine the reference standard and the diagnoses in the GATE
population. The average clinician IOP measured with GAT was similar to the referral IOP (see Table 6) and
highest among patients with OHT and glaucoma (see Table 7). Visual field testing was outside the
manufacturer-recommended reliability in one-quarter of participants. The average MD among those
diagnosed with glaucoma and with reliable visual field tests was –6.0 dB (SD 6.4 dB) in the right eye and
–7.5 dB (SD 6.8 dB) in the left eye (see Table 7).
Table 8 displays the diagnosis of the GATE population per eye according to the agreed reference standard
(see Chapter 2). The most common diagnosis (at approximately 40%) was ‘no glaucoma-related findings’.
Glaucoma was diagnosed in about 11% of eyes. Comorbidities were uncommon, except for cataract,
which was reported in approximately 8% of eyes (see Table 9).
Among those eyes with glaucoma, mild disease was most prevalent (above half), while severe glaucoma
was diagnosed in a relatively small proportion of eyes with the disease (28 out of 219 eyes, 12.8%;
see Table 10).
Over one-third of the GATE participants were discharged after the first visit (see Table 11). Table 13
describes the diagnosis by worse eye (ranked in the order shown) and by better eye. Glaucoma was
diagnosed in at least one eye in 16.8% of the GATE cohort and 6.5% had glaucoma in both eyes at
referral (see Table 12).
TABLE 6 Data from HES examination: VF and IOP
Characteristic Right eye Left eye
VF reliability,a n/N (%)
Reliable 706/941 (75.0) 707/940 (75.2)
Unreliable 212/941 (22.5) 210/940 (22.3)
Not done 23/941 (2.4) 23/940 (2.4)
Reliable VF measures, mean (SD), n
MD (dB) –1.9 (4.0), 703 –2.2 (4.1), 702
PSD (dB) 2.8 (2.6), 703 2.8 (2.6), 702
VFI (%) 95.0 (10.1), 688 94.9 (10.3), 682
VF measures including unreliable, mean (SD), n
MD (dB) –1.8 (4.0), 893 –2.0 (4.1), 887
PSD (dB) 2.8 (2.5), 893 2.8 (2.5), 887
VFI (%) 95.0 (10.2), 866 95.0 (10.1), 859
IOP: ophthalmologist GAT, mean (SD), n
IOP (mmHg) 19.2 (5.1), 932 19.3 (5.1), 932
HES, hospital eye service; VF, visual field.
a VF reliability as defined by Humphrey VF output.
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TABLE 7 Data from HES examination: IOP and MD by diagnosis
Diagnosis Right eye, mean (SD), n Left eye, mean (SD), n
IOP (mmHg) GAT
Glaucoma 23.0 (6.4), 116 22.6 (6.9), 103
Glaucoma suspect 17.9 (4.4), 201 18.8 (5.2), 194
OHT 25.2 (3.5), 122 25.2 (3.1), 123
PAC/PAC suspect 17.8 (4.1), 120 17.8 (3.8), 126
Normal 17.1 (3.2), 367 17.2 (3.1), 379
Reliable VF MD (dB)
Glaucoma –6.0 (6.4), 85 –7.5 (6.8), 77
Glaucoma suspect –2.2 (3.4), 150 –2.2 (3.4), 153
OHT –0.6 (2.2), 85 –0.8 (2.0), 92
PAC/PAC suspect –1.1 (3.0), 91 –1.4 (2.9), 89
Normal –1.1 (3.0), 280 –1.3 (3.0), 279
All VF MD (dB) including unreliable
Glaucoma –5.6 (6.1), 103 –7.2 (6.6), 89
Glaucoma suspect –2.2 (3.5), 195 –2.0 (3.3), 187
OHT –0.3 (2.3), 113 –0.7 (2.1), 111
PAC/PAC suspect –0.9 (2.9), 115 –1.3 (2.9), 121
Normal –1.1 (3.4), 352 –1.4 (3.4), 364
HES, hospital eye service; VF, visual field.
TABLE 8 Data from HES examination: diagnosis
Diagnosis Right eye, n (%) Left eye, n (%)
N 932 931
Glaucoma 116 (12.4) 103 (11.1)
Disc suspect 146 (15.6) 126 (13.5)
VF suspect 29 (3.1) 35 (3.8)
VF+ disc suspect 26 (2.8) 33 (3.5)
OHT 122 (13.0) 123 (13.2)
PAC 30 (3.2) 29 (3.1)
PAC suspect 90 (9.6) 97 (10.4)
No glaucoma-related findings 367 (39.2) 379 (40.7)
Undetermined 6 (0.6) 6 (0.6)
HES, hospital eye service; VF, visual field.
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TABLE 9 Data from HES examination: comorbidity
Comorbidity Right eye, n (%) Left eye, n (%)
N 936 936
Age-related macular degeneration 7 (0.7) 11 (1.2)
Cataract 78 (8.3) 70 (7.4)
Neurological 6 (0.6) 8 (0.8)
Other 65 (6.9) 63 (6.7)
HES, hospital eye service.
TABLE 10 Data from HES examination: glaucoma severity
Glaucoma severitya Right eye, n (%) Left eye, n (%)
N 116 103
Mild 69 (59.5) 53 (51.5)
Moderate 31 (26.7) 29 (28.2)
Severe 11 (9.5) 17 (16.4)
Severity not recorded 5 (4.3) 4 (3.9)
HES, hospital eye service.
a See Chapter 2 for severity definitions.
TABLE 11 Data from HES examination: action after first consultation
Action n (%)
N 933
Discharged – person level 357 (38.3)
For those not discharged Right eye Left eye
Treat 291 (31.2) 287 (30.8)
Monitor only 214 (22.9) 216 (23.2)
Repeat assessment required 33 (3.5) 39 (4.1)
Not recorded 37 (4.0) 33 (3.5)
HES, hospital eye service.
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TABLE 12 Data from HES examination: diagnosis by worse eye and better eye
Diagnosis/comorbidity/action Worse eye, n (%) Better eye, n (%)
N 932 931
Diagnosis by clinician
Glaucoma 158 (17.0) 61 (6.6)
Disc suspect 170 (18.2) 102 (11.0)
VF suspect 36 (3.9) 28 (3.0)
VF+ disc suspect 36 (3.9) 23 (2.5)
OHT 115 (12.3) 130 (14.0)
PAC 31 (3.3) 28 (3.0)
PAC suspect 83 (8.9) 104 (11.2)
No glaucoma-related findings 299 (32.1) 447 (48.0)
Undetermined 4 (0.4) 8 (0.8)
Comorbidity
Age-related macular degeneration 9 (1.0) 9 (1.0)
Cataract 75 (8.0) 73 (7.7)
Neurological 7 (0.7) 7 (0.7)
Other 68 (7.2) 60 (6.4)
Action
Treat 320 (33.9) 258 (27.4)
Monitor only 210 (22.3) 220 (23.3)
Repeat assessment required 39 (4.1) 33 (3.5)
HES, hospital eye service; VF, visual field.
TABLE 13 Data from HES examination: severity of disease by worse and better eye for those diagnosed
with glaucoma
Glaucoma severity Worse eye, n (%) Better eye, n (%)
N 158 61
Mild 78 (49.4) 19 (31.1)
Moderate 45 (28.5) 27 (44.3)
Severe 26 (16.5) 15 (24.6)
Severity not recorded 9 (5.7) 0 (0)
HES, hospital eye service.
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TABLE 14 Data from HES examination: glaucoma mechanism for those diagnosed with glaucoma or glaucoma
suspect, by worse and better eye
Clinical diagnosis Worse eye Better eye
Glaucoma, n/N (%) 158/936 (16.8) 61/936 (6.5)
Open angle, n 123 46
Angle closure, n 26 12
Other, n 1 0
Missing, n 8 3
Disc suspect, n/N (%) 170/936 (18.0) 102/936 (10.8)
Open angle, n 150 94
Angle closure, n 11 6
Other, n 2 0
Missing, n 7 2
VF suspect, n/N (%) 36/936 (3.8) 28/936 (3.0)
Open angle, n 27 21
Angle closure, n 6 5
Other, n 1 2
Missing, n 2 0
VF +disc suspect, n/N (%) 36/936 (3.8) 23/936 (2.4)
Open angle, n 33 21
Angle closure, n 3 2
Other, n 0 0
Missing, n 0 0
HES, hospital eye service; VF, visual field.
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Chapter 4 Diagnostic analysis results
Overview
This chapter reports the results of the diagnosis analyses which aimed to assess the diagnostic performance
of the four imaging tests (HRT-MRA, HRT-GPS, GDx and OCT) and the other outcomes associated with the
imaging tests (indeterminacy and participant preference). The results of the triage analyses are provided
in Chapter 5. The specific diagnostic performance analyses covered in this chapter are the default diagnosis
analysis (Table 15, ‘Default diagnostic analysis’), six sensitivity analyses (see Table 15, ‘Diagnosis sensitivity
analyses 1–6’) and the use of a combination of the imaging tests (see Table 15, ‘Combination of tests
analysis’) for a list with definitions. The default analysis was defined as one where the reference standard
definition of disease was a clinical diagnosis of glaucoma only. The imaging test definition of an abnormal
result was ‘outside normal limits’ for the overall classification of the imaging test (see Chapter 2).
TABLE 15 Diagnosis analyses
Analysis
Reference standard
definition of disease Abnormal test result
Handling of ‘no
result’ categories
Figure
number
Table
number
Default diagnostic
analysis
Glaucoma in the ‘worse’ eye Outside normal limits A–E excluded 3 16, 17,
18, 19
Diagnosis sensitivity
analysis 1
Glaucoma in the ‘worse’ eye Outside normal limits
or borderline
A–E excluded 4 22
Diagnosis sensitivity
analysis 2
Glaucoma or glaucoma
suspect in the ‘worse’ eye
Outside normal limits A–E excluded 5 23
Diagnosis sensitivity
analysis 3
Glaucoma or glaucoma
suspect in the ‘worse’ eye
Outside normal limits
or borderline
A–E excluded 6 24
Diagnosis sensitivity
analysis 4
Glaucoma or glaucoma
suspect in the ‘worse’ eye
Outside normal limits
or borderline
A imaging
classification
7 25
B–D abnormal
E excluded
Diagnosis sensitivity
analysis 5
Glaucoma in the ‘worse’ eye Outside normal limits A imaging
classification
8 26
B–D abnormal
E excluded
Diagnosis sensitivity
analysis 6
Glaucoma in the ‘better’ eye Outside normal limits A–E excluded 9 27
Combinations of
diagnosis imaging
tests
Glaucoma in the ‘worse’ eye Outside normal limits A–E excluded 10 28
No result categories: A, test performed and imaging report produced but quality is lower than manufacturer quality cut-off
point; B, test performed and imaging report produced but no overall classification generated by machine; C, test performed
but there was a clear imaging artefact on the report; D, test attempted but no imaging could be acquired from the
patient’s eyes – no report generated; E, missing imaging output (because of study-related or data-collection issues).
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Additionally, only cases where there was a good-quality image with an overall classification available were
included (see Chapter 2). The six sensitivity analyses assessed the impact of varying assumptions made in
the default analysis relating to the reference standard definition of disease (including all types of glaucoma
suspects as diseased), the definition of an abnormal test result (including borderline results as abnormal),
and how cases where the test did not produce an overall classification were handled in the analysis. In
addition to missing data, there were four test-related reasons why an overall classification may not have
been available (see Table 15, ‘Handling of no results categories’). Sensitivity analyses also assessed the
impact of removing the requirement of a ‘good’-quality image and using the provided assessment, along
with setting other cases which did not produce an overall classification result as abnormal.
The combination of test analyses investigated using pairs of imaging tests to produce a composite imaging
test result, under the same assumptions as the default analysis. Given the findings of the default and
sensitivity analyses, only three pairs of test combinations were evaluated: HRT-MRA with each of the other
tests. For all analyses, a STARD flow diagram33,38 was produced which shows the flow of participants.
The subset of participants who received all four tests and were considered in the statistical analyses is
separated out into three groups according to whether each imaging test result was ‘abnormal’, ‘normal’
or ‘no result’ (the imaging test result being not available because either the test was inconclusive or
because the result was missing). For each of these three groups, the group status according to the
reference standard (‘glaucoma present’ or ‘glaucoma absent’) for each participant is given or alternatively
the reference standard was stated to be missing or inconclusive. The final categorisations of the imaging
test result by reference standard status provides the four possible combinations (true and false positive,
and false and true negative) from which the diagnostic performance can be assessed. Sensitivity,
specificity, likelihood ratios and DOR are provided with associated 95% CIs summarised for each analysis.
Of the 966 (46%) who agreed to take part in GATE, 11 were excluded from the study: 10 were ineligible
and one person withdrew prior to participating in the study.
Additionally, owing to administrative and research processing errors, imaging was not implemented for all
four imaging tests in 12 participants and these participants were excluded from all analyses. The analyses
in this chapter pertain to the remaining 943 participants. Of these, no reference standard finding was
available for 11 participants, with an inconclusive finding in a further four cases.
Default diagnosis analysis
The results for the default diagnosis analysis are presented in three sections:
l diagnostic performance of the imaging tests
l paired comparisons of imaging tests
l diagnostic performance with restricted reference standard definition of disease.
Diagnostic performance of the imaging tests
For the default analysis, abnormal imaging test results were those classified as ‘outside normal limits’ and
the corresponding reference standard definition of disease was a diagnosis of glaucoma in the ‘worse’ eye.
Only participants with an imaging test output with an overall classification which met the manufacturer
quality criteria were included in the analysis.
The flow of study participants according to the default diagnosis analysis is shown in Figure 3, with the
corresponding number of abnormal, normal and no result cases by imaging test, and the corresponding
reference standard finding shown. Of the 943 patients for whom all four tests were performed, 158 were
classified as disease positive and 770 as disease negative. The reference standard was missing and
inconclusive for 11 and four participants, respectively. The diagnostic performance for the four tests is
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Reference standard definition: glaucoma
Test abnormal: outside normal limits
Handling of no result: A–E excluded 
No reference standard
HRT-MRA, n = 3
HRT-GPS, n = 2
GDx, n = 1
OCT, n = 2
No reference standard
HRT-MRA, n = 1
HRT-GPS, n = 2
GDx, n = 3
OCT, n = 2
No reference standard
HRT-MRA, n = 7
HRT-GPS, n = 7
GDx, n = 7
OCT, n = 7
Reference standard
HRT-MRA, n = 82
HRT-GPS, n = 84
GDx, n = 90
OCT, n = 45
Reference standard
HRT-MRA, n = 379
HRT-GPS, n = 339
GDx, n = 68
OCT, n = 272
Reference standard
HRT-MRA, n = 471
HRT-GPS, n = 509
GDx, n = 774
OCT, n = 615
Inconclusive
reference standard
HRT-MRA, n = 3
HRT-GPS, n = 0
GDx, n = 1
OCT, n = 1
Inconclusive
reference standard
HRT-MRA, n = 0
HRT-GPS, n = 3
GDx, n = 3
OCT, n = 3
Inconclusive
reference standard
HRT-MRA, n = 1
HRT-GPS, n = 1
GDx, n = 0
OCT, n = 0
Disease
present (TP)
HRT-MRA, n = 120
HRT-GPS, n = 110
GDx, n = 47
OCT, n = 113
Disease
absent (FP)
HRT-MRA, n = 256
HRT-GPS, n = 229
GDx, n = 20
OCT, n = 158
Disease
present (FN)
HRT-MRA, n = 18
HRT-GPS, n = 25
GDx, n = 87
OCT, n = 34
Disease present
HRT-MRA, n = 20
HRT-GPS, n = 23
GDx, n = 24
OCT, n = 11
Disease
absent (TN)
HRT-MRA, n = 453
HRT-GPS, n = 481
GDx, n = 684
OCT, n = 578
Disease absent
HRT-MRA, n = 61
HRT-GPS, n = 60
GDx, n = 66
OCT, n = 34
No result
HRT-MRA, n = 89
HRT-GPS, n = 91
GDx, n = 97
OCT, n = 52
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Imaging not performed
for all four index tests
(n = 12) 
Consented
(n = 966)
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Abnormal result
HRT-MRA, n = 382
HRT-GPS, n = 341
GDx, n = 69
OCT, n = 274
Normal result
HRT-MRA, n = 472
HRT-GPS, n = 511
GDx, n = 777
OCT, n = 617
FIGURE 3 Flow diagram: default diagnostic analysis. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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given in Table 16. The results showed a trade-off between detection of glaucoma and correctly identifying
non-glaucoma cases: HRT-MRA had the highest sensitivity (87.0%, 95% CI 80.2% to 92.1%) but the
lowest specificity (63.9%, 95% CI 60.2% to 67.4%), GDx had the lowest sensitivity (35.1%, 95% CI
27.0% to 43.8%) but the highest specificity (97.2%, 95% CI 95.6% to 98.3%) and the other two tests
provided intermediate results (HRT-GPS values were very similar to the HRT-MRA results and OCT had very
similar sensitivity and specificity values). Likelihood ratios (and 95% CI) showed evidence of being able to
both rule in and rule out the presence of glaucoma for all four imaging tests (CIs did not contain 1.0).
DORs ranged from 9.24 for HRT-GPS to 18.48 for GDx.
Paired comparisons of imaging tests
Table 17 shows the paired difference (with 95% CI) and corresponding McNemar’s test p-value for
comparisons between pairs of tests. There was evidence that the sensitivity of all tests differed from each
other except for HRT-GPS versus OCT.
The highest sensitivity was in HRT-MRA and the lowest sensitivity in GDx. Differences varied from –6.7%
(HRT-GPS vs. HRT-MRA) to 55.6% (HRT-MRA vs. GDx). Similarly there was evidence that all specificities
of all tests varied from each other (according to McNemar’s test);38 the 95% paired difference CI for
HRT-GPS versus HRT-MRA just overlapped with zero.
TABLE 16 Diagnostic performance: default diagnosis analysis
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 87.0 80.2 to 92.1
Specificity (%) 63.9 60.2 to 67.4
Positive likelihood ratio 2.41 2.14 to 2.71
Negative likelihood ratio 0.20 0.13 to 0.32
DOR 11.80 7.02 to 19.81
HRT-GPS Sensitivity (%) 81.5 73.9 to 87.6
Specificity (%) 67.7 64.2 to 71.2
Positive likelihood ratio 2.53 2.21 to 2.89
Negative likelihood ratio 0.27 0.19 to 0.39
DOR 9.24 5.82 to 14.67
GDx Sensitivity (%) 35.1 27.0 to 43.8
Specificity (%) 97.2 95.6 to 98.3
Positive likelihood ratio 12.35 7.57 to 20.14
Negative likelihood ratio 0.67 0.59 to 0.76
DOR 18.48 10.46 to 32.63
OCT Sensitivity (%) 76.9 69.2 to 83.4
Specificity (%) 78.5 75.4 to 81.4
Positive likelihood ratio 3.58 3.04 to 4.22
Negative likelihood ratio 0.29 0.22 to 0.40
DOR 12.16 7.97 to 18.54
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TABLE 17 Paired comparisons of sensitivity and specificity between the imaging tests
Tests compared Parameter Test Value (%) (95% CI) p-value (McNemar’s)
HRT-GPS vs. GDx Sensitivity HRT-GPS 81.1 (74.2 to 88.1) –
GDx 34.4 (26.0 to 42.9) –
Difference 46.7 (37.0 to 54.9) < 0.001
Specificity HRT-GPS 67.5 (64.0 to 71.1) –
GDx 97.5 (96.3 to 98.7) –
Difference –30.0 (–33.6 to –26.3) < 0.001
GDx vs. OCT Sensitivity GDx 36.4 (28.1 to 44.7) –
OCT 77.5 (70.3 to 84.7) –
Difference –41.1 (–49.2 to –31.6) < 0.001
Specificity GDx 97.5 (96.3 to 98.7) –
OCT 79.8 (76.8 to 82.8) –
Difference 17.7 (14.9 to 20.8) < 0.001
GDx vs. HRT-MRA Sensitivity GDx 33.1 (24.8 to 41.3) –
HRT-MRA 88.7 (83.1 to 94.3) –
Difference –55.6 (–63.8 to –45.6) < 0.001
Specificity GDx 97.3 (96.1 to 98.5) –
HRT-MRA 63.7 (60.1 to 67.4) –
Difference 33.6 (29.8 to 37.3) < 0.001
HRT-GPS vs. HRT-MRA Sensitivity HRT-GPS 81.3 (74.7 to 87.9) –
HRT-MRA 88.1 (82.6 to 93.5) –
Difference –6.7 (–13.2 to –0.6) < 0.001
Specificity HRT-GPS 67.8 (64.3 to 71.3) –
HRT-MRA 64.1 (60.5 to 67.6) –
Difference 3.7 (–0.1 to 7.5) < 0.001
HRT-MRA vs. OCT Sensitivity HRT-MRA 86.5 (80.7 to 92.3) –
OCT 75.2 (67.8 to 82.5) –
Difference 11.3 (3.4 to 19.2) < 0.001
Specificity HRT-MRA 63.9 (60.3 to 67.5) –
OCT 79.4 (76.4 to 82.4) –
Difference –15.5 (–19.8 to –11.2) < 0.001
HRT-GPS vs. OCT Sensitivity HRT-GPS 82.3 (75.7 to 88.9) –
OCT 75.4 (68.0 to 82.8) –
Difference 6.9 (–1.6 to 15.4) 0.106
Specificity HRT-GPS 67.7 (64.2 to 71.2) –
OCT 79.7 (76.7 to 82.7) –
Difference –12.0 (–16.3 to –7.6) < 0.001
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Impact of severity of disease
Two further analyses looked at the impact of changing the reference standard definition of disease to
moderate and severe glaucoma and to severe glaucoma only (see Chapter 2 for disease definitions). The
only change from the default analysis was in terms of the reference standard. The diagnostic performance
for the four imaging tests where the reference standard definition of disease was moderate and severe
glaucoma only is given in Table 18.
The results showed a trade-off between detection of glaucoma and correctly identifying non-glaucoma
cases: HRT-GPS had the highest sensitivity (92.7%, 95% CI 82.4% to 98.0%) but the second lowest
specificity (63.5%, 95% CI 60.1% to 66.9%), GDx had the lowest sensitivity (60.0%, 95% CI 45.9% to
73.0%) but the highest specificity (95.7%, 95% CI 94.0% to 97.0%) and the other two tests provided
intermediate results (HRT-MRA values were very similar to the HRT-GPS results and OCT had a similar
sensitivity but higher specificity). Likelihood ratios (and 95% CIs) showed evidence of being able to both
rule in and rule out the presence of glaucoma for all four imaging tests (CIs did not contain 1.0). DORs
ranged from 12.44 for HRT-MRA to 33.04 for GDx. Compared with the default analysis, the diagnostic
performances of GDx and OCT were both better and those of HRT-GPS and HRT-MRA poorer.
TABLE 18 Diagnostic performance: default diagnosis analysis (reference standard definition of disease of moderate
and severe glaucoma)
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 89.7 78.8 to 96.1
Specificity (%) 58.9 55.4 to 62.4
Positive likelihood ratio 2.18 1.93 to 2.46
Negative likelihood ratio 0.18 0.08 to 0.38
DOR 12.44 5.28 to 29.30
HRT-GPS Sensitivity (%) 92.7 82.4 to 98.0
Specificity (%) 63.5 60.1 to 66.9
Positive likelihood ratio 2.54 2.26 to 2.86
Negative likelihood ratio 0.11 0.04 to 0.29
DOR 22.22 7.95 to 62.12
GDx Sensitivity (%) 60.0 45.9 to 73.0
Specificity (%) 95.7 94.0 to 97.0
Positive likelihood ratio 13.82 9.32 to 20.47
Negative likelihood ratio 0.42 0.30 to 0.58
DOR 33.04 17.43 to 62.65
OCT Sensitivity (%) 89.1 78.8 to 95.5
Specificity (%) 73.9 70.7 to 76.9
Positive likelihood ratio 3.41 2.95 to 3.94
Negative likelihood ratio 0.15 0.07 to 0.30
DOR 23.02 10.34 to 51.25
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The diagnostic performance of the four imaging tests in cases where the reference standard definition of disease
was severe glaucoma only is given in Table 19. The results showed a trade-off between detection of glaucoma
and correct identification of non-glaucoma cases: OCT had the highest sensitivity (95.2%, 95% CI 76.2% to
99.9%) and the second highest specificity (70.9%, 95% CI 67.7% to 73.9%), GDx had the lowest sensitivity
(78.9%, 95% CI 54.4% to 93.9%) but the highest specificity (93.7%, 95% CI 91.8% to 95.2%) and the other
two tests provided intermediate results (HRT-GPS and HRT-MRA results were very similar and had a similar
sensitivity to OCT although a lower specificity). Likelihood ratios (and 95% CI) showed evidence of being able to
rule in the presence of glaucoma for all four imaging tests (CIs did not contain 1.0) but could not always rule out
the disease. DORs ranged from 23.63 for HRT-MRA to 48.69 for OCT. Compared with the default analysis, the
sensitivity of the tests was better and the specificity poorer.
TABLE 19 Diagnostic performance: default diagnosis analysis (reference standard definition of disease of
severe glaucoma)
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 94.7 74.0 to 99.9
Specificity (%) 56.8 53.3 to 60.2
Positive likelihood ratio 2.19 1.92 to 2.50
Negative likelihood ratio 0.09 0.01 to 0.63
DOR 23.63 3.14 to 177.85
HRT-GPS Sensitivity (%) 94.7 74.0 to 99.9
Specificity (%) 61.1 57.7 to 64.5
Positive likelihood ratio 2.44 2.13 to 2.79
Negative likelihood ratio 0.09 0.01 to 0.58
DOR 28.32 3.76 to 213.16
GDx Sensitivity (%) 78.9 54.4 to 93.9
Specificity (%) 93.7 91.8 to 95.2
Positive likelihood ratio 12.43 8.75 to 17.66
Negative likelihood ratio 0.22 0.09 to 0.54
DOR 55.31 3.76 to 172.63
OCT Sensitivity (%) 95.2 76.2 to 99.9
Specificity (%) 70.9 67.7 to 73.9
Positive likelihood ratio 3.27 2.84 to 3.77
Negative likelihood ratio 0.07 0.01 to 0.2
DOR 48.69 6.50 to 364.73
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Other outcomes
Indeterminacy results are shown in Table 20. GDx had the highest percentage of low-quality imaging
results, followed by HRT-GPS and HRT-MRA, with OCT giving the lowest percentage of low-quality results.
Table 21 shows the participants’ preference ranking of imaging tests (HRT-GPS and HRT-MRA have the
same results), time taken to conduct the test and the proportion who received dilatation. Participant
preference was collected for 890 participants (94%). Almost half of responders (48.2%) had no preference.
Among those participants who gave a preference, OCT was ranked as most preferred (27.6%), followed by
GDx (11.9%), and HRT-GPS/HRT-MRA had the lowest preference (5.1%). Average time taken to perform
the test varied from 5.2 minutes (OCT) to 7.6 minutes (HRT-GPS/HRT-MRA). More participants received
dilatation under HRT-GPS/HRT-MRA (2.2%) than the other two tests. No adverse events were reported
during the study.
TABLE 20 Classification and quality of imaging results (default analysis)
Class
HRT-MRA, n (%)
(N= 943)
HRT-GPS, n (%)
(N= 943)
GDx, n (%)
(N= 943)
OCT, n (%)
(N= 943)
Normal 319 (33.8) 310 (32.9) 640 (67.9) 447 (47.4)
Borderline 153 (16.2) 201 (21.3) 137 (14.5) 170 (18.0)
Abnormal 382 (40.5) 341 (36.2) 69 (7.3) 274 (29.1)
Indeterminacy (no result categories A–D) 58 (6.3) 75 (8.0) 79 (8.4) 40 (4.2)
Missing data (no result category E) 31 (3.2) 16 (1.7) 18 (1.9) 12 (1.3)
Qualitya N = 887 N = 887 N = 907 N = 906
Good quality 854 (96.3) 852 (96.1) 846 (93.3) 891 (98.3)
Low quality 33 (3.7) 35 (3.9) 61 (6.7) 15 (1.7)
a Excluding no result categories B–E.
TABLE 21 Participant preference, test conduct time and dilatation results
Test Order
Preference (n preferred)
n (%) (N= 890)
Test conduct time (minutes),
mean (SD)
Dilatation,
n (%) (N= 918)
HRT (MRA/GPS) 1 49 (5.1) N= 900 20 (2.2)
2 150 (15.6) 7.6 (5.0) –
3 229 (23.9) – –
GDx 1 114 (11.9) N= 886 16 (1.7)
2 162 (16.9) 7.5 (5.1) –
3 152 (15.8) – –
OCTa 1 265 (27.6) N= 904 6 (0.7)
2 116 (12.1) 5.2 (3.0) –
3 44 (4.6) – –
All Preference 462 (48.2) – –
a Three participants did not give a ranking for OCT.
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Diagnosis sensitivity analysis 1
Diagnosis sensitivity analysis 1 differed from the default analysis in that a borderline finding on the imaging
test was also classified as an abnormal result.
For diagnosis sensitivity analysis 1, abnormal imaging test results were those classified as ‘outside normal
limits’ and ‘borderline’, and the corresponding reference standard definition of disease was a diagnosis of
glaucoma in the ‘worse’ eye. Only participants with an imaging test output with an overall classification
which met the manufacturer quality cut-off point were included in the analysis.
The flow of study participants according to sensitivity analysis 1 is shown in Figure 4, with the corresponding
number of abnormal, normal and no result cases given by imaging test, and the corresponding reference
standard finding shown. Of the 943 patients in whom all four tests were performed, 158 were classified as
disease positive and 770 as disease negative. The reference standard was missing and inconclusive for
11 and four participants, respectively. The diagnostic performance for the four tests is given in Table 22.
The results showed a trade-off between detection of glaucoma and correctly identifying non-glaucoma
cases: HRT-MRA had the highest sensitivity (94.9%, 95% CI 89.8% to 97.9%) but the second lowest
specificity (43.9%, 95% CI 40.2% to 47.6%), GDx had the lowest sensitivity (60.4%, 95% CI 51.6% to
68.8%) but the highest specificity (82.8%, 95% CI 79.8% to 85.5%), and the other two tests provided
intermediate results (HRT-GPS values were very similar to the HRT-MRA results although marginally lower
and OCT had a high sensitivity and moderate specificity in relation to the other tests). Sensitivity was higher
for all tests than under the default analysis but with corresponding lower specificity. Likelihood ratios (and
95% CI) showed evidence of being able to both rule in and rule out the presence of glaucoma for all
four imaging tests (CIs did not contain 1.0). DORs ranged from 7.36 for GDx to 14.62 for HRT-MRA.
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Reference standard definition: glaucoma
Test abnormal: outside normal limits or borderline
Handling of no result: A–E excluded 
Abnormal result
HRT-MRA, n = 535
HRT-GPS, n = 542
GDx, n = 206
OCT, n = 444
No result
HRT-MRA, n = 89
HRT-GPS, n = 91
GDx, n = 97
OCT, n = 52
No reference standard
HRT-MRA, n = 3
HRT-GPS, n = 3
GDx, n = 3
OCT, n = 2
No reference standard
HRT-MRA, n = 1
HRT-GPS, n = 1
GDx, n = 1
OCT, n = 2
No reference standard
HRT-MRA, n = 7
HRT-GPS, n = 7
GDx, n = 7
OCT, n = 7
Reference standard
HRT-MRA, n = 82
HRT-GPS, n = 84
GDx, n = 90
OCT, n = 45
Reference standard
HRT-MRA, n = 532
HRT-GPS, n = 539
GDx, n = 203
OCT, n = 442
Reference standard
HRT-MRA, n = 318
HRT-GPS, n = 309
GDx, n = 639
OCT, n = 445
Inconclusive
reference standard
HRT-MRA, n = 3
HRT-GPS, n = 2
GDx, n = 1
OCT, n = 3
Inconclusive
reference standard
HRT-MRA, n = 0
HRT-GPS, n = 1
GDx, n = 3
OCT, n = 1
Inconclusive
reference standard
HRT-MRA, n = 1
HRT-GPS, n = 1
GDx, n = 0
OCT, n = 0
Disease
present (TP)
HRT-MRA, n = 131
HRT-GPS, n = 125
GDx, n = 81
OCT, n = 129
Disease
present (FN)
HRT-MRA, n = 7
HRT-GPS, n = 10
GDx, n = 53
OCT, n = 18
Disease
absent (FP)
HRT-MRA, n = 398
HRT-GPS, n = 412
GDx, n = 121
OCT, n = 310
Disease present
HRT-MRA, n = 20
HRT-GPS, n = 23
GDx, n = 24
OCT, n = 11
Disease
absent (TN)
HRT-MRA, n = 311
HRT-GPS, n = 298
GDx, n = 583
OCT, n = 426
Disease absent
HRT-MRA, n = 61
HRT-GPS, n = 60
GDx, n = 66
OCT, n = 34
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Imaging not performed
for all four index tests
(n = 12)
Consented
(n = 966)
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Normal result
HRT-MRA, n = 319
HRT-GPS, n = 310
GDx, n = 640
OCT, n = 447
FIGURE 4 Flow diagram: diagnostic sensitivity analysis 1. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Diagnosis sensitivity analysis 2
Diagnosis sensitivity analysis 2 differed from the default analysis in that the reference standard definition
of disease incorporated all participants with glaucoma suspect (irrespective of type). For diagnosis
sensitivity analysis 2, abnormal imaging test results were those classified as ‘outside normal limits’ and the
corresponding reference standard definition of disease was a diagnosis of glaucoma in the ‘worse’ eye.
Only participants with an imaging test output with an overall classification which met the manufacturer
quality cut-off point were included in the analysis.
The flow of study participants according to sensitivity analysis 2 is shown in Figure 5, with the
corresponding number of abnormal, normal and ‘no result’ cases by imaging test, and the corresponding
reference standard finding shown. Of the 943 patients in whom all four tests were performed, 400 were
classified as disease positive and 528 as disease negative. The reference standard was missing and
inconclusive for 11 and four participants, respectively. The diagnostic performance of the four tests is
given in Table 23. The results showed a trade-off between detection of glaucoma and correctly identifying
non-glaucoma cases: HRT-MRA had the highest sensitivity (74.0%, 95% CI 69.1% to 78.5%) but lowest
specificity (76.5%, 95% CI 72.5% to 80.1%), GDx had the lowest sensitivity (16.5%, 95% CI 12.8% to
20.8%) but the highest specificity (98.2%, 95% CI 96.5% to 99.2%) and the other two tests provided
TABLE 22 Diagnostic performance: diagnosis sensitivity analysis 1
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 94.9 89.8 to 97.9
Specificity (%) 43.9 40.2 to 47.6
Positive likelihood ratio 1.69 1.57 to 1.82
Negative likelihood ratio 0.12 0.06 to 0.24
DOR 14.62 6.74 to 31.73
HRT-GPS Sensitivity (%) 92.6 86.8 to 96.4
Specificity (%) 42.0 38.3 to 45.7
Positive likelihood ratio 1.60 1.47 to 1.73
Negative likelihood ratio 0.18 0.10 to 0.32
DOR 9.04 4.67 to 17.51
GDx Sensitivity (%) 60.4 51.6 to 68.8
Specificity (%) 82.8 79.8 to 85.5
Positive likelihood ratio 3.52 2.84 to 4.35
Negative likelihood ratio 0.48 0.39 to 0.59
DOR 7.36 4.95 to 10.96
OCT Sensitivity (%) 87.8 81.3 to 92.6
Specificity (%) 57.9 54.2 to 61.5
Positive likelihood ratio 2.08 1.88 to 2.31
Negative likelihood ratio 0.21 0.14 to 0.33
DOR 9.85 5.89 to 16.49
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Reference standard definition: glaucoma or glaucoma suspect
Test abnormal: outside normal limits
Handling of no result: A–E excluded
Abnormal result
HRT-MRA, n = 382
HRT-GPS, n = 341
GDx, n = 69
OCT, n = 274
Normal result
HRT-MRA, n = 472
HRT-GPS, n = 511
GDx, n = 777
OCT, n = 617
No result
HRT-MRA, n = 89
HRT-GPS, n = 91
GDx, n = 97
OCT, n = 52
No reference standard
HRT-MRA, n = 3
HRT-GPS, n = 2
GDx, n = 1
OCT, n = 2
No reference standard
HRT-MRA, n = 1
HRT-GPS, n = 2
GDx, n = 3
OCT, n = 2
No reference standard
HRT-MRA, n = 7
HRT-GPS, n = 7
GDx, n = 7
OCT, n = 7
Reference standard
HRT-MRA, n = 82
HRT-GPS, n = 84
GDx, n = 90
OCT, n = 45
Reference standard
HRT-MRA, n = 379
HRT-GPS, n = 339
GDx, n = 68
OCT, n = 272
Reference standard
HRT-MRA, n = 471
HRT-GPS, n = 509
GDx, n = 774
OCT, n = 615
Inconclusive
reference standard
HRT-MRA, n = 3
HRT-GPS, n = 0
GDx, n = 1
OCT, n = 1
Inconclusive
reference standard
HRT-MRA, n = 0
HRT-GPS, n = 3
GDx, n = 3
OCT, n = 3
Inconclusive
reference standard
HRT-MRA, n = 1
HRT-GPS, n = 1
GDx, n = 0
OCT, n = 0
Disease
present (TP)
HRT-MRA, n = 259
HRT-GPS, n = 232
GDx, n = 58
OCT, n = 192
Disease
present (FN)
HRT-MRA, n = 91
HRT-GPS, n = 121
GDx, n = 293
OCT, n = 189
Disease
absent (FP)
HRT-MRA, n = 117
HRT-GPS, n = 107
GDx, n = 9
OCT, n = 79
Disease present
HRT-MRA, n = 50
HRT-GPS, n = 47
GDx, n = 49
OCT, n = 19
Disease
absent (TN)
HRT-MRA, n = 380
HRT-GPS, n = 385
GDx, n = 478
OCT, n = 423
Disease absent
HRT-MRA, n = 31
HRT-GPS, n = 36
GDx, n = 41
OCT, n = 26
Eligible patients
(n = 2088)
Consented
(n = 966)
Not consented
(n = 1122)
Excluded  (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 5 Flow diagram: diagnostic sensitivity analysis 2. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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intermediate results (HRT-GPS had lower sensitivity than HRT-MRA but a slightly higher specificity and OCT
had the second lowest sensitivity but the second highest specificity values). Sensitivity was lower for all
tests than under the default analysis but with correspondingly higher specificity. Likelihood ratios (and
95% CI) showed evidence of being able to both rule in and rule out the presence of glaucoma for all
four imaging tests (CIs did not contain 1.0). DORs ranged from 5.44 for OCT to 10.51 for GDx.
Diagnosis sensitivity analysis 3
Diagnosis sensitivity analysis 3 differed from the default analysis in that a borderline finding on the imaging
test was classified as an abnormal test result and the reference standard definition of disease incorporated
all glaucoma suspects (irrespective of type).
For diagnosis sensitivity analysis 3, abnormal imaging test results were those classified as ‘outside normal
limits’ or ‘borderline’ and the corresponding reference standard definition of disease was a diagnosis of
glaucoma or glaucoma suspect in the ‘worse’ eye. Only participants with an imaging test output with an
overall classification which met the manufacturer quality cut-off point were included in the analysis.
The flow of study participants according to sensitivity analysis 3 is shown in Figure 6, with the corresponding
number of abnormal, normal and no result cases by imaging test, and the corresponding reference
TABLE 23 Diagnostic performance: diagnosis sensitivity analysis 2
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 74.0 69.1 to 78.5
Specificity (%) 76.5 72.5 to 80.1
Positive likelihood ratio 3.14 2.65 to 3.73
Negative likelihood ratio 0.34 0.28 to 0.41
DOR 9.24 6.74 to 12.68
HRT-GPS Sensitivity (%) 65.7 60.5 to 70.7
Specificity (%) 78.3 74.3 to 81.8
Positive likelihood ratio 3.02 2.51 to 3.63
Negative likelihood ratio 0.44 0.38 to 0.51
DOR 6.90 5.08 to 9.38
GDx Sensitivity (%) 16.5 12.8 to 20.8
Specificity (%) 98.2 96.5 to 99.2
Positive likelihood ratio 8.94 4.49 to 17.80
Negative likelihood ratio 0.85 0.81 to 0.89
DOR 10.51 5.13 to 21.54
OCT Sensitivity (%) 50.4 45.3 to 55.5
Specificity (%) 84.3 80.8 to 87.3
Positive likelihood ratio 3.20 2.56 to 4.01
Negative likelihood ratio 0.59 0.53 to 0.66
DOR 5.44 3.98 to 7.44
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Reference standard definition: glaucoma or glaucoma suspect
Test abnormal: outside normal limits or borderline
Handling of no result: A–E excluded 
Abnormal result
HRT-MRA, n = 535
HRT-GPS, n = 542
GDx, n = 206
OCT, n = 444
Normal result
HRT-MRA, n = 319
HRT-GPS, n = 310
GDx, n = 640
OCT, n = 447
No result
HRT-MRA, n = 89
HRT-GPS, n = 91
GDx, n = 97
OCT, n = 52
No reference standard
HRT-MRA, n = 3
HRT-GPS, n = 3
GDx, n = 3
OCT, n = 2
No reference standard
HRT-MRA, n = 1
HRT-GPS, n = 1
GDx, n = 1
OCT, n = 2
No reference standard
HRT-MRA, n = 7
HRT-GPS, n = 7
GDx, n = 7
OCT, n = 7
Reference standard
HRT-MRA, n = 82
HRT-GPS, n = 84
GDx, n = 90
OCT, n = 45
Reference standard
HRT-MRA, n = 532
HRT-GPS, n = 539
GDx, n = 203
OCT, n = 442
Reference standard
HRT-MRA, n = 318
HRT-GPS, n = 309
GDx, n = 639
OCT, n = 445
Inconclusive
reference standard
HRT-MRA, n = 3
HRT-GPS, n = 2
GDx, n = 1
OCT, n = 3
Inconclusive
reference standard
HRT-MRA, n = 0
HRT-GPS, n = 1
GDx, n = 3
OCT, n = 1
Inconclusive
reference standard
HRT-MRA, n = 1
HRT-GPS, n = 1
GDx, n = 0
OCT, n = 0
Disease
present (TP)
HRT-MRA, n = 311
HRT-GPS, n = 306
GDx, n = 137
OCT, n = 262
Disease
present (FN)
HRT-MRA, n = 39
HRT-GPS, n = 47
GDx, n = 214
OCT, n = 119
Disease
absent (FP)
HRT-MRA, n = 218
HRT-GPS, n = 231
GDx, n = 65
OCT, n = 177
Disease present
HRT-MRA, n = 50
HRT-GPS, n = 47
GDx, n = 49
OCT, n = 19
Disease
absent (TN)
HRT-MRA, n = 279
HRT-GPS, n = 261
GDx, n = 422
OCT, n = 325
Disease absent
HRT-MRA, n = 31
HRT-GPS, n = 36
GDx, n = 41
OCT, n = 26
Eligible patients
(n = 2088)
Consented
(n = 966)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Imaging not performed
for all four index tests
(n = 12) 
FIGURE 6 Flow diagram: diagnostic sensitivity analysis 3. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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standard finding shown. Of the 943 patients in whom all four tests were performed, 400 were classified
as disease positive and 528 as disease negative. The reference standard was missing and inconclusive for
11 and four participants, respectively. The diagnostic performance of the four tests is given in Table 24.
The results showed a trade-off between detection of glaucoma and correctly identifying non-glaucoma cases:
HRT-MRA had the highest sensitivity (88.9%, 95% CI 85.1% to 92.0%) but the second lowest specificity
(56.1%, 95% CI 51.6% to 60.6%), GDx had the lowest sensitivity (39.0%, 95% CI 33.9% to 44.4%) but
the highest specificity (86.7%, 95% CI 83.3% to 89.5%) and the other two tests provided intermediate
results (HRT-GPS values were very similar to the HRT-MRA results and OCT had very similar sensitivity and
specificity values). Sensitivity was slightly higher for GDx, HRT-GPS and HRT-MRA than under the default
analysis but with correspondingly lower specificity. OCT, however, had a slightly lower sensitivity and
specificity than under the default analysis.
Likelihood ratios (and 95% CI) showed evidence of being able to both rule in and rule out the presence
of glaucoma for all four imaging tests (CIs did not contain 1.0). DORs ranged from 4.04 for OCT to 10.21
for HRT-MRA.
TABLE 24 Diagnostic performance: diagnosis sensitivity analysis 3
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 88.9 85.1 to 92.0
Specificity (%) 56.1 51.6 to 60.6
Positive likelihood ratio 2.03 1.82 to 2.25
Negative likelihood ratio 0.20 0.15 to 0.27
DOR 10.21 7.00 to 14.88
HRT-GPS Sensitivity (%) 86.7 82.7 to 90.1
Specificity (%) 53.0 48.5 to 57.5
Positive likelihood ratio 1.85 1.67 to 2.05
Negative likelihood ratio 0.25 0.19 to 0.33
DOR 7.36 5.16 to 10.49
GDx Sensitivity (%) 39.0 33.9 to 44.4
Specificity (%) 86.7 83.3 to 89.5
Positive likelihood ratio 2.92 2.25 to 3.80
Negative likelihood ratio 0.70 0.64 to 0.77
DOR 4.16 2.96 to 5.83
OCT Sensitivity (%) 68.8 63.8 to 73.4
Specificity (%) 64.7 60.4 to 68.9
Positive likelihood ratio 1.95 1.70 to 2.24
Negative likelihood ratio 0.48 0.41 to 0.57
DOR 4.04 3.04 to 5.37
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Diagnosis sensitivity analysis 4
Diagnosis sensitivity analysis 4 has the same reference standard and definition of an abnormal imaging
test as sensitivity analysis 3 differing by including the imaging test-related ‘no result’ cases (the overall
classification was used irrespective of the quality indicator and the types were all classified as abnormal).
For diagnosis sensitivity analysis 4, abnormal imaging test results were those classified as ‘outside normal
limits’ or ‘borderline’ and the corresponding reference standard definition of disease was a diagnosis of
glaucoma or glaucoma suspect in the ‘worse’ eye. The analysis included participants with a low-quality
imaging output if a classification was given; other imaging test results which did not provide an overall
classification were included as abnormal.
The flow of study participants according to sensitivity analysis 4 is shown in Figure 7, with the corresponding
number of abnormal, normal and no result cases and the corresponding reference standard finding shown.
Of the 943 patients in whom all four tests were performed, 400 were classified as disease positive and
528 as disease negative. The reference standard was missing and inconclusive for 11 and four participants,
respectively. The diagnostic performance for the four tests is given in Table 25.
The results showed a trade-off between detection of glaucoma and correctly identifying non-glaucoma
cases: HRT-MRA had the highest sensitivity (89.2%, 95% CI 85.7% to 92.1%) but second lowest
specificity (55.1%, 95% CI 50.7% to 59.5%), GDx had the lowest sensitivity (41.9%, 95% CI 37.0% to
47.0%) but the highest specificity (85.6%, 95% CI 82.3% to 88.5%) and the other two tests provided
intermediate results (HRT-GPS values were similar to the HRT-MRA results and OCT had similar sensitivity
and specificity values). Sensitivity was higher for all tests than under the default analysis but with
correspondingly lower specificity. Likelihood ratios (and 95% CI) showed evidence of being able to both
rule in and rule out the presence of glaucoma for all four imaging tests (CIs did not contain 1.0). DORs
ranged from 3.89 for OCT to 10.19 for HRT-MRA.
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Reference standard positive: glaucoma or glaucoma suspect
Test abnormal: outside normal limits or borderline
Handling of no result: A imaging classification
         B–D abnormal
         E excluded 
Reference standard
HRT-MRA, n = 24
HRT-GPS, n = 9
GDx, n = 11
OCT, n = 5
Reference standard
HRT-MRA, n = 582
HRT-GPS, n = 606
GDx, n = 242
OCT, n = 478
Reference standard
HRT-MRA, n = 326
HRT-GPS, n = 317
GDx, n = 679
OCT, n = 449
Inconclusive
reference standard
HRT-MRA, n = 3
HRT-GPS, n = 3
GDx, n = 1
OCT, n = 3
Inconclusive
reference standard
HRT-MRA, n = 0
HRT-GPS, n = 1
GDx, n = 3
OCT, n = 1
Inconclusive
reference standard
HRT-MRA, n = 1
HRT-GPS, n = 0
GDx, n = 0
OCT, n = 0
Disease
present (TP)
HRT-MRA, n = 348
HRT-GPS, n = 348
GDx, n = 166
OCT, n = 279
Disease
present (FN)
HRT-MRA, n = 42
HRT-GPS, n = 51
GDx, n = 230
OCT, n = 120
Disease
absent (FP)
HRT-MRA, n = 231
HRT-GPS, n = 255
GDx, n = 75
OCT, n = 196
Disease present
HRT-MRA, n = 10
HRT-GPS, n = 1
GDx, n = 4
OCT, n = 1
Disease
absent (TN)
HRT-MRA, n = 284
HRT-GPS, n = 256
GDx, n = 446
OCT, n = 328
Disease absent
HRT-MRA, n = 13
HRT-GPS, n = 8
GDx, n = 7
OCT, n = 4
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Imaging not performed
for all four index tests
(n = 12)
Completed all four index tests
(n = 943)
Abnormal result
HRT-MRA, n = 585
HRT-GPS, n = 609
GDx, n = 245
OCT, n = 480
Normal result
HRT-MRA, n = 327
HRT-GPS, n = 318
GDx, n = 680
OCT, n = 451
Inconclusive result
HRT-MRA, n = 31
HRT-GPS, n = 16
GDx, n = 18
OCT, n = 12
No reference standard
HRT-MRA, n = 3
HRT-GPS, n = 3
GDx, n = 3
OCT, n = 2
No reference standard
HRT-MRA, n = 1
HRT-GPS, n = 1
GDx, n = 1
OCT, n = 2
No reference standard
HRT-MRA, n = 7`
HRT-GPS, n = 7
GDx, n = 7
OCT, n = 7
FIGURE 7 Flow diagram: diagnostic sensitivity analysis 4. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
DOI: 10.3310/hta20080 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 8
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Azuara-Blanco et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
Diagnosis sensitivity analysis 5
Diagnosis sensitivity analysis 5 differed from the default analysis in that the imaging test-related ‘no result’
cases were included as above for sensitivity analysis 4.
For sensitivity analysis 5, abnormal imaging test results were those classified as ‘outside normal limits’ and
the corresponding reference standard definition of disease was a diagnosis of glaucoma in the ‘worse’ eye.
The analysis included participants with a low-quality imaging output if a classification was given; other
imaging test results which did not provide an overall classification were included as abnormal.
The flow of study participants according to sensitivity analysis 5 is shown in Figure 8, with the corresponding
number of abnormal, normal and no result cases by imaging test, and the corresponding reference standard
finding shown. Of the 943 patients in whom all four tests were performed, 158 were classified as disease
positive and 770 as disease negative. The reference standard was missing and inconclusive for 11 and four
participants, respectively. The diagnostic performance of the four tests is given in Table 26. The results showed
a trade-off between detection of glaucoma and correctly identifying non-glaucoma cases: HRT-MRA had the
highest sensitivity (87.3%, 95% CI 81.0% to 92.0%) but lowest specificity (61.8%, 95% CI 58.2% to 65.3%),
GDx had the lowest sensitivity (37.6%, 95% CI 30.0% to 45.7%) but the highest specificity (95.4%, 95% CI
93.7% to 96.8%) and the other two tests provided intermediate results (HRT-GPS values were very similar to
TABLE 25 Diagnostic performance: diagnosis sensitivity analysis 4
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 89.2 85.7 to 92.1
Specificity (%) 55.1 50.7 to 59.5
Positive likelihood ratio 1.99 1.80 to 2.20
Negative likelihood ratio 0.20 0.15 to 0.26
DOR 10.19 7.08 to 14.66
HRT-GPS Sensitivity (%) 87.2 83.5 to 90.3
Specificity (%) 51.0 46.6 to 55.3
Positive likelihood ratio 1.78 1.62 to 1.96
Negative likelihood ratio 0.25 0.19 to 0.33
DOR 7.09 5.04 to 9.97
GDx Sensitivity (%) 41.9 37.0 to 47.0
Specificity (%) 85.6 82.3 to 88.5
Positive likelihood ratio 2.91 2.29 to 3.70
Negative likelihood ratio 0.68 0.62 to 0.74
DOR 4.29 3.13 to 5.89
OCT Sensitivity (%) 69.9 65.2 to 74.4
Specificity (%) 62.6 58.3 to 66.7
Positive likelihood ratio 1.87 1.64 to 2.12
Negative likelihood ratio 0.48 0.41 to 0.57
DOR 3.89 2.95 to 5.14
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Reference standard definition: glaucoma
Test abnormal: outside normal limits
Handling of no result: A imaging classification used
         B–D abnormal
         E excluded 
Abnormal result
HRT-MRA, n = 429
HRT-GPS, n = 400
GDx, n = 96
OCT, n = 305
Normal result
HRT-MRA, n = 483
HRT-GPS, n = 527
GDx, n = 829
OCT, n = 626
No result
HRT-MRA, n = 31
HRT-GPS, n = 16
GDx, n = 18
OCT, n = 12
No reference standard
HRT-MRA, n = 3
HRT-GPS, n = 2
GDx, n = 1
OCT, n = 2
No reference standard
HRT-MRA, n = 1
HRT-GPS, n = 2
GDx, n = 3
OCT, n = 2
No reference standard
HRT-MRA, n = 7
HRT-GPS, n = 7
GDx, n = 7
OCT, n = 7
Reference standard
HRT-MRA, n = 24
HRT-GPS, n = 9
GDx, n = 11
OCT, n = 5
Reference standard
HRT-MRA, n = 426
HRT-GPS, n = 398
GDx, n = 95
OCT, n = 303
Reference standard
HRT-MRA, n = 482
HRT-GPS, n = 525
GDx, n = 826
OCT, n = 624
Inconclusive
reference standard
HRT-MRA, n = 3
HRT-GPS, n = 0
GDx, n = 1
OCT, n = 1
Inconclusive
reference standard
HRT-MRA, n = 0
HRT-GPS, n = 4
GDx, n = 3
OCT, n = 3
Inconclusive
reference standard
HRT-MRA, n = 1
HRT-GPS, n = 0
GDx, n = 0
OCT, n = 0
Disease
present (TP)
HRT-MRA, n = 137
HRT-GPS, n = 131
GDx, n = 59
OCT, n = 123
Disease
present (FN)
HRT-MRA, n = 20
HRT-GPS, n = 27
GDx, n = 98
OCT, n = 35
Disease
absent (FP)
HRT-MRA, n = 286
HRT-GPS, n = 267
GDx, n = 35
OCT, n = 179
Disease present
HRT-MRA, n = 1
HRT-GPS, n = 0
GDx, n = 1
OCT, n = 0
Disease
absent (TN)
HRT-MRA, n = 462
HRT-GPS, n = 494
GDx, n = 725
OCT, n = 586
Disease absent
HRT-MRA, n = 22
HRT-GPS, n = 9
GDx, n = 10
OCT, n = 5
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 8 Flow diagram: diagnostic sensitivity analysis 5. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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the HRT-MRA results and OCT had very similar sensitivity and specificity values). Likelihood ratios (and 95% CI)
showed evidence of being able to both rule in and rule out the presence of glaucoma for all four imaging tests
(CIs did not contain 1.0). DORs ranged from 8.96 for HRT-GPS to 12.47 for GDx.
Diagnosis sensitivity analysis 6
Diagnosis sensitivity analysis 6 differed from the default analysis in that the diagnosis of the participants’
‘better’ eye according to the reference standard was used. Abnormal imaging test results were those
classified as ‘outside normal limits’ and the corresponding reference standard definition of disease was a
diagnosis of glaucoma. Only participants with an imaging test output with an overall classification which
met the manufacturer quality cut-off point were included in the analysis.
The flow of study participants according to sensitivity analysis 6 is shown in Figure 9, with the corresponding
number of abnormal, normal and ‘no result’ cases by imaging test, and the corresponding reference standard
finding shown. Of the 943 patients in whom all four tests were performed, 61 were classified as disease
positive and 862 as disease negative. The reference standard was missing and inconclusive for 12 and
8 participants, respectively. The diagnostic performance of the four tests is given in Table 27. The results
showed a trade-off between detection of glaucoma and correctly identifying non-glaucoma cases:
HRT-GPS had the highest sensitivity (82.4%, 95% CI 69.1% to 91.6%) but also the second lowest specificity
TABLE 26 Diagnostic performance: diagnosis sensitivity analysis 5
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 87.3 81.0 to 92.0
Specificity (%) 61.8 58.2 to 65.3
Positive likelihood ratio 2.28 2.05 to 2.54
Negative likelihood ratio 0.21 0.14 to 0.31
DOR 11.07 6.77 to 18.09
HRT-GPS Sensitivity (%) 82.9 76.1 to 88.4
Specificity (%) 64.9 61.4 to 68.3
Positive likelihood ratio 2.36 2.10 to 2.66
Negative likelihood ratio 0.26 0.19 to 0.37
DOR 8.96 5.78 to 13.94
GDx Sensitivity (%) 37.6 30.0 to 45.7
Specificity (%) 95.4 93.7 to 96.8
Positive likelihood ratio 8.16 5.57 to 11.95
Negative likelihood ratio 0.65 0.58 to 0.74
DOR 12.47 7.81 to 19.2
OCT Sensitivity (%) 77.8 70.6 to 84.1
Specificity (%) 76.6 73.4 to 80.0
Positive likelihood ratio 3.33 2.86 to 3.88
Negative likelihood ratio 0.29 0.22 to 0.39
DOR 11.50 7.63 to 17.35
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Reference standard definition: glaucoma in ‘best eye’
Test abnormal: outside normal limits
Handling of no result: A imaging classification used
         B–D abnormal
         E excluded 
Abnormal result
HRT-MRA, n = 324
HRT-GPS, n = 301
GDx, n = 42
OCT, n = 205
Normal result
HRT-MRA, n = 540
HRT-GPS, n = 555
GDx, n = 809
OCT, n = 687
No result
HRT-MRA, n = 79
HRT-GPS, n = 87
GDx, n = 92
OCT, n = 51
No reference standard
HRT-MRA, n = 3
HRT-GPS, n = 2
GDx, n = 1
OCT, n = 2
No reference standard
HRT-MRA, n = 1
HRT-GPS, n = 2
GDx, n = 3
OCT, n = 2
No reference standard
HRT-MRA, n = 8
HRT-GPS, n = 8
GDx, n = 8
OCT, n = 8
Reference standard
HRT-MRA, n = 71
HRT-GPS, n = 79
GDx, n = 84
OCT, n = 43
Reference standard
HRT-MRA, n = 321
HRT-GPS, n = 299
GDx, n = 41
OCT, n = 203
Reference standard
HRT-MRA, n = 539
HRT-GPS, n = 553
GDx, n = 806
OCT, n = 685
Inconclusive
reference standard
HRT-MRA, n = 4
HRT-GPS, n = 1
GDx, n = 1
OCT, n = 2
Inconclusive
reference standard
HRT-MRA, n = 3
HRT-GPS, n = 4
GDx, n = 4
OCT, n = 4
Inconclusive
reference standard
HRT-MRA, n = 1
HRT-GPS, n = 3
GDx, n = 3
OCT, n = 2
Disease
present (TP)
HRT-MRA, n = 43
HRT-GPS, n = 42
GDx, n = 14
OCT, n = 39
Disease
present (FN)
HRT-MRA, n = 12
HRT-GPS, n = 9
GDx, n = 38
OCT, n = 16
Disease
absent (FP)
HRT-MRA, n = 274
HRT-GPS, n = 256
GDx, n = 26
OCT, n = 162
Disease present
HRT-MRA, n = 6
HRT-GPS, n = 10
GDx, n = 9
OCT, n = 6
Disease
absent (TN)
HRT-MRA, n = 524
HRT-GPS, n = 540
GDx, n = 764
OCT, n = 665
Disease absent
HRT-MRA, n = 64
HRT-GPS, n = 66
GDx, n = 72
OCT, n = 35
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 9 Flow diagram: diagnostic sensitivity analysis 6. FN, false negative; FP, false positive; TN, true negative,
TP, true positive.
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(67.8%, 95% CI 64.5% to 77.1%), GDx had the lowest sensitivity (26.9%, 95% CI 15.6% to 41.0%) but
the highest specificity (96.7%, 95% CI 95.2% to 97.8%) and the other two tests provided intermediate
results (HRT-MRA had a slightly lower sensitivity and specificity than HRT-GPS but a slightly higher specificity
and OCT had the second lowest sensitivity but the second highest specificity values). Sensitivity was slightly
lower for all HRT-MRA, GDx and OCT than under the default analysis but with a slightly higher specificity.
HRT-GPS has very similar sensitivity analysis results to the default (primary) analysis. Likelihood ratios (and
95% CI) showed evidence of being able to both rule in and rule out the presence of glaucoma for all
four imaging tests (CIs did not contain 1.0). DORs ranged from 6.85 for HRT-MRA to 10.83 for GDx.
Combinations of imaging tests
The HRT-MRA test was combined with the other imaging tests to form three combined tests and the
diagnostic performance was assessed. The reference standard and the definition of an abnormal imaging
test result was the same as for the default analysis (abnormal imaging test ‘outside normal limits’;
reference standard diagnosis of glaucoma in the ‘worse’ eye; and only participants with an imaging test
output with an overall classification which met the manufacturer quality cut-off point were included in the
analysis). The corresponding flow of study participants is shown in Figure 10, with the corresponding
number of abnormal, normal and no results cases by combination imaging test and the corresponding
reference standard finding shown. The diagnostic performance of the four tests is given in Table 28.
TABLE 27 Diagnostic performance: diagnosis sensitivity analysis 6
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA Sensitivity (%) 78.2 65.0 to 88.2
Specificity (%) 65.7 62.3 to 69.0
Positive likelihood ratio 2.28 1.92 to 2.70
Negative likelihood ratio 0.33 0.20 to 0.55
DOR 6.85 3.55 to 13.21
HRT-GPS Sensitivity (%) 82.4 69.1 to 91.6
Specificity (%) 67.8 64.5 to 71.1
Positive likelihood ratio 2.56 2.18 to 3.01
Negative likelihood ratio 0.26 0.14 to 0.47
DOR 9.84 4.72 to 20.53
GDx Sensitivity (%) 26.9 15.6 to 41.0
Specificity (%) 96.7 95.2 to 97.8
Positive likelihood ratio 8.18 4.55 to 14.70
Negative likelihood ratio 0.76 0.64 to 0.89
DOR 10.83 5.23 to 22.39
OCT Sensitivity (%) 70.9 57.1 to 82.4
Specificity (%) 80.4 77.5 to 83.1
Positive likelihood ratio 3.62 2.91 to 4.50
Negative likelihood ratio 0.36 0.24 to 0.55
DOR 10.01 5.45 to 18.35
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Reference standard definition: glaucoma
Test abnormal: outside normal limits
Handling of no result: A–E excluded 
Abnormal result
HRT-GPS + HRT-MRA, n = 457
HRT-MRA + OCT, n = 447
HRT-MRA + GDx, n = 365
Normal result
HRT-GPS + HRT-MRA, n = 380
HRT-MRA + OCT, n = 383
HRT-MRA + GDx, n = 433
No result
HRT-GPS + HRT-MRA, n = 106
HRT-MRA + OCT, n = 113
HRT-MRA + GDx, n = 145
No reference standard
HRT-GPS + HRT-MRA, n = 3
HRT-MRA + OCT, n = 3
HRT-MRA + GDx, n = 3
No reference standard
HRT-GPS + HRT-MRA(HRT), n = 1
HRT-MRA + OCT, n = 1
HRT-MRA + GDx, n = 1
No reference standard
HRT-GPS + HRT-MRA, n = 7
HRT-MRA + OCT, n = 7
HRT-MRA + GDx, n = 7
Reference standard
HRT-GPS + HRT-MRA, n = 99
HRT-MRA + OCT, n = 106
HRT-MRA + GDx, n = 138
Reference standard
HRT-GPS + HRT-MRA, n = 454
HRT-MRA + OCT, n = 444
HRT-MRA + GDx, n = 362
Reference standard
HRT-GPS + HRT-MRA, n = 379
HRT-MRA + OCT, n = 382
HRT-MRA + GDx, n = 432
Inconclusive
reference standard
HRT-GPS + HRT-MRA, n = 3
HRT-MRA + OCT, n = 3
HRT-MRA + GDx, n = 3
Inconclusive
reference standard
HRT-GPS + HRT-MRA, n = 0
HRT-MRA + OCT, n = 0
HRT-MRA + GDx, n = 0
Inconclusive
reference standard
HRT-GPS + HRT-MRA, n = 1
HRT-MRA + OCT, n = 1
HRT-MRA + GDx, n = 1
Disease
present (TP)
HRT-GPS + 
HRT-MRA,
n = 122
HRT-MRA + OCT,
n = 122
HRT-MRA + GDx,
n = 111
Disease
present (FN)
HRT-GPS + 
HRT-MRA,
n = 12
HRT-MRA + OCT,
n = 11
HRT-MRA + GDx,
n = 13
Disease
absent (FP)
HRT-GPS + 
HRT-MRA,
n = 329
HRT-MRA + OCT,
n = 319
HRT-MRA + GDx,
n = 248
Disease present
HRT-GPS + 
HRT-MRA,
n = 24
HRT-MRA + OC,
n = 25
HRT-MRA + GDx,
n = 34
Disease
absent (TN)
HRT-GPS + 
HRT-MRA,
n = 367
HRT-MRA + OCT,
n = 371
HRT-MRA + GDx,
n = 419
Disease absent
HRT-GPS + 
HRT-MRA,
n = 74
HRT-MRA + OCT,
n = 80
HRT-MRA + GDx,
n = 103
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed all four index tests
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 10 Flow diagram: combination of imaging tests. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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The results showed a trade-off between detection of glaucoma and correctly identifying non-glaucoma
cases: HRT-MRA combined with OCT had the highest sensitivity (91.7%, 95% CI 85.7% to 95.8%) but the
second lowest specificity (53.8%, 95% CI 50.0% to 57.5%) and HRT-MRA combined with GDx had the
lowest sensitivity (89.5%, 95% CI 82.7% to 94.3%) but the highest specificity (62.8%, 95% CI 59.0% to
66.5%). Likelihood ratios (and 95% CI) showed evidence of being able to both rule in and rule out the
presence of glaucoma all three combination imaging tests (CIs did not contain 1.0). DORs ranged from
11.34 for HRT-MRA combined with HRT-GPS, to 14.43 for HRT-MRA combined with GDx.
Discussion
The diagnostic performance of four imaging tests (HRT-MRA, HRT-GPS, GDx and OCT) for the detection of
glaucoma was compared for the GATE population of referrals to a glaucoma clinic in secondary care. The
sensitivity and specificity of the four imaging tests for the default diagnosis analysis and sensitivity analyses
(see Table 15 for details) are summarised in Figures 11 and 12, respectively.
All four imaging tests had some value in terms of ruling in and ruling out the presence of glaucoma. However,
the diagnostic performance of the imaging tests differed in the ability to correctly diagnose glaucoma
(sensitivity) and non-glaucoma cases (specificity). HRT-MRA had the highest sensitivity across analyses, except
when the reference standard diagnosis was moderate and severe glaucoma only, when HRT-GPS was higher,
but at a cost of lower specificity compared with other tests. In contrast, GDx consistently had the best specificity
but the lowest sensitivity. HRT-GPS results were typically similar to HRT-MRA as might be expected given
that their analysis is based on the same imaging machine. The sensitivity of OCT was generally of a similar
magnitude to its specificity. When the reference standard definition of disease excluded mild glaucoma,
OCT displayed better diagnostic performance than HRT-GPS and HRT-MRA, with GDx providing the
best specificity. The choice of which imaging test is to be preferred reflects the inherent trade-off regarding
diagnostic testing, when the desire not to miss glaucoma when present must be balanced again the desire to
correctly identify those who are without disease.
TABLE 28 Diagnostic performance: diagnostic performance of test combinations
Test Diagnostic parameter Point estimate 95% CI
HRT-MRA+HRT-GPS Sensitivity (%) 91.0 84.9 to 95.3
Specificity (%) 52.7 48.9 to 56.5
Positive likelihood ratio 1.93 1.75 to 2.12
Negative likelihood ratio 0.17 0.10 to 0.29
DOR 11.34 6.15 to 20.90
HRT-MRA+GDx Sensitivity (%) 89.5 82.7 to 94.3
Specificity (%) 62.8 59.0 to 66.5
Positive likelihood ratio 2.41 2.14 to 2.70
Negative likelihood ratio 0.17 0.10 to 0.28
DOR 14.43 7.95 to 26.17
HRT-MRA+OCT Sensitivity (%) 91.7 85.7 to 95.8
Specificity (%) 53.8 50.0 to 57.5
Positive likelihood ratio 1.98 1.80 to 2.18
Negative likelihood ratio 0.15 0.09 to 0.27
DOR 12.90 6.84 to 24.34
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FIGURE 11 Summary of the sensitivity of imaging tests across all diagnosis analyses. SA, sensitivity analyses.
HRT-MRA
HRT-GPS
GDx
OCT
SA 4SA 3SA 2SA 1Default SA 5 SA 6
Sp
ec
if
ic
it
y 
(%
)
Analyses
0
10
20
30
40
50
60
70
80
90
100
FIGURE 12 Summary of the specificity of imaging tests across all diagnosis analyses. SA, sensitivity analyses.
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The non-diagnostic outcomes tended to favour OCT. OCT had the lowest number of low-quality imaging
results, with GDx having the highest. Average time taken to conduct the tests was lowest for OCT with
the other tests taking a similar length of time. Less dilatation was required for OCT, followed by GDx then
the HRT tests. Considering the time taken and need for dilatation, patient preference tended to favour
OCT followed by GDx, although almost one-half of participants did not have a preference.
Glaucome Automated Test Evaluation was a large prospective paired diagnostic study and provided
diagnostic tests in this desired setting. This is reflected in the precision in which the sensitivity and specificity
were calculated with differences between every pair of tests identified for one if not both sensitivity and
specificity. McNemar’s test38 was used to compare the sensitivity and specificity of the tests. Following the
rationale of others in effectiveness studies, the paired comparisons were not adjusted for multicomparisons.
Even if such a correction were to have been applied such was the strength of evidence there would still be
evidence of differences in the diagnostic performance of the different imaging tests.
A number of sensitivity analyses were carried out to assess the robustness of the findings of the default analysis.
Varying the test definition of an abnormal imaging result by including the borderline category was carried out;
this had the anticipated impact of improving the detection of glaucoma, although at the expense of more
participants without glaucoma being falsely classified as having glaucoma. This resulted in very high detection
of glaucoma for HRT-MRA, HRT-GPS and OCT but with low to moderate diagnosis of non-glaucoma cases.
GDx provided moderate performance for both detecting glaucoma and correctly diagnosing non-glaucoma
cases. Additionally, the impact of also seeking to diagnose glaucoma suspect (based on optic disc and/or visual
field findings as described in Chapter 2) was assessed both with and without classifying borderline imaging
findings as abnormal. When the test definition of abnormal incorporated the borderline category, the net
impact was a slight increase in sensitivity for GDx, HRT-GPS and HRT-MRA, with the sensitivity of OCT slightly
reduced compared with the default analysis, suggesting that the OCT test deals less well with glaucoma
suspect cases. The diagnostic performance on the better eye gave similar results, although with generally a
lower sensitivity and slightly higher specificity than for the worse eye. HRT-GPS diagnostic performance for
these data was remarkably similar to when the worse eye was used.
Finally, the impact of using a combination of tests was assessed. Given the findings of the default diagnosis
analysis and associated sensitivity analyses, this was restricted to an assessment of whether or not using another
imaging test in addition to HRT-MRA appeared to be beneficial. Although the additional use of another test led
to improved detection of glaucoma, the improvement was marginal and smaller than the loss in terms of the
handling of non-diseased cases and although the use of two tests in combination did have some benefit in
terms of reducing the number of no result cases, the change in diagnostic performance coupled with the
additional practical and cost implications in terms of training and staff time, and an additional requirement of
equipment (for two of the three combinations) suggests that the use of a single test is to be preferred.
A number of assumptions underpinned the analysis and interpretation of the results. Most importantly, the
reference standard was assumed to be perfect although it is widely recognised that diagnosis of glaucoma
is difficult and uncertainty exists even among specialists. While consensus was sought through structured
training, some assessor differences may have remained between the sites. Additionally, the diagnosis and
clinical management of patients with glaucoma suspect is uncertain; in particular, the risk of conversion of
such individuals is not known. Nevertheless, the findings provide evidence reflective of current clinical
practice in NHS glaucoma clinics.
A number of areas for further research are clear. Further investigation of varying the results of the imaging
tests beyond the standard options could be undertaken, as the recommended classification may not be the
one best suited to the population that GATE recruited from. The definition and clinical management
of glaucoma suspects is also an area in which further research is needed, in particular quantifying the
proportion that will convert or will be discharged from clinical care over subsequent years. Finally,
the diagnosis value of using an imaging test explicitly in a triage scenario with the additional use of an IOP
measurement and VA to form a composite triage test requires evaluation.
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Chapter 5 Triage analysis results
Overview
This chapter reports the results of the triage analyses, which aimed to assess the diagnostic performance of
the four imaging tests in a triage setting. The specific diagnostic performance analyses covered in this chapter
are the default triage analysis (Table 29, Default triage analysis) along with eight sensitivity analyses (see
Table 29, Triage sensitivity analyses 1–8) for a list with definitions. A further set of three analyses specifically
to inform the economic model are described in Appendix 6. The default triage analysis was defined as one
in which the reference standard was the person-level clinical decision (‘not discharged’ or ‘discharged’).
TABLE 29 Triage analyses
Analysis
Reference standard
definition Test abnormal
Handling of ‘no
result’ categories
Figure
number
Table
number
Default triage
analysis
Not discharged Imaging (outside normal
limits) or IOP > 21mmHg
or VA 6/12 or poorer
A–D for referral 13 30, 31
E excluded
Triage sensitivity
analysis 1
Not discharged Imaging (outside normal
limits or borderline) or IOP
> 21mmHg or VA 6/12
or poorer
A–D for referral 14 32
E excluded
Triage sensitivity
analysis 2
Not discharged Imaging (outside normal
limits) or IOP > 21mmHg
or VA 6/12 or poorer
A use imaging
classification
15 33
B for referral
C–E excluded
Triage sensitivity
analysis 3
Not discharged Imaging (outside normal
limits or borderline) or IOP
> 21mmHg or VA 6/12
or poorer
A use imaging
classification
16 34
B for referral
C–E excluded
Triage sensitivity
analysis 4
Not discharged Imaging (outside normal
limits) or IOP > 21mmHg
(referred IOP) or VA 6/12
or poorer
A–D for referral 17 35
E excluded
Triage sensitivity
analysis 5
Not discharged Imaging (outside normal
limits) or VA 6/12
or poorer
A–D for referral 18 36
E excluded
Triage sensitivity
analysis 6
Not discharged Imaging (outside normal
limits) or IOP > 21mmHg
A–D for referral 19 37
E excluded
Triage sensitivity
analysis 7
Not discharged Imaging (outside normal
limits) or IOP > 26mmHg
or VA 6/12 or poorer
A–D for referral 20 38
E excluded
Triage sensitivity
analysis 8
Not discharged Imaging (outside normal
limits) or IOP > 21mmHg
or VA 6/18 or poorer
A–D for referral 21 39
E excluded
No result categories: A, test performed and imaging report produced but quality is lower than manufacturer quality cut-off;
B, test performed and imaging report produced but no overall classification generated by machine; C, test performed but
there was a clear imaging artefact on the report; D, test attempted but no imaging could be acquired from the patient’s
eyes – no report generated; E, missing imaging (because of study-related or data-collection issues).
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The test was defined as categorising a patient as requiring to be referred on (‘for referral’) if any of the
elements of the composite triage test (imaging, IOP and/or VA) were themselves ‘abnormal’: imaging outside
normal limits on the overall classification of the imaging test (see Chapter 2), IOP > 21mmHg or VA of 6/12
or poorer under the default triage analysis.
If the imaging test did not produce an overall classification or its quality was poor, the imaging test result
was again defined as abnormal and, therefore, the patient was classified as ‘for referral’. The eight
sensitivity analyses assessed the impact of varying assumptions made in the default triage analysis relating
to the definition of a positive test result, modifying or removing the IOP and/or VA components of the
triage test, and how cases where the test did not produce an overall classification were handled in
the analysis.
The analyses in this chapter pertain to the 943 participants remaining in the study (see Chapter 4). The
reference standard was available for 933 cases. For all analyses, a STARD diagram shows the flow of
participants. The subset of participants who received all four tests and were considered in the statistical
analyses are separated out into three groups according to whether each triage test result was ‘abnormal’,
‘normal’ or ‘no result’ (the triage test result was not available because either the test was inconclusive or the
result was missing). For each of these three groups the group status according to the reference standard
(‘discharged’ or ‘not discharged’) for each participant is given or alternatively the reference standard was
stated to be missing or inconclusive. The final categorisations of the triage test result by reference standard
status provides the four possible combinations (true and false positive, false and true negative) from which
the diagnostic performance was assessed. Sensitivity, specificity, likelihood ratios and DOR are provided with
associated 95% CIs for each analysis.
Default triage analysis
The results for the default triage analysis are presented in two sections:
l diagnostic performance of the triage tests, and
l paired comparisons of triage tests.
Diagnostic performance of the triage tests
For the default triage analysis, the triage test is classified as abnormal if (1) the imaging test result is
classified as ‘outside normal limits’, (2) IOP is > 21mmHg or (3) VA is 6/12 or poorer. Imaging test results
that did not provide an overall classification were included as abnormal. The corresponding reference
standard definition is a clinical decision not to discharge the patient.
The flow of study participants according to the default triage analysis is shown in Figure 13, with the
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 576
were not discharged and 357 were discharged and the discharge status was missing for 10 participants.
The diagnostic performance of the four tests is given in Table 30. The results showed a trade-off between
the detection of patients who need to be referred and the discharge of those who do not need to be
referred: HRT-GPS had the highest sensitivity (86.0%, 95% CI 82.8% to 88.7%) but lowest specificity
(39.1%, 95% CI 34.0% to 44.5%), GDx had the lowest sensitivity (64.7%, 95% CI 60.7% to 68.7%) but
the highest specificity (53.6%, 95% CI 48.2% to 58.9%), and the other two tests provided intermediate
results [HRT-MRA values were very similar to the HRT-GPS results, as might be expected given that they
use the same machine, and OCT had lower sensitivity (75.4%, 95% CI 71.9 to 78.9) but higher specificity
(41%, 95% CI 35.8 to 46.3) values than HRT-GPS and HRT-MRA]. Likelihood ratios (and 95% CI) showed
evidence of being able to both rule in and rule out the presence of glaucoma for all four triage tests
(CIs did not contain 1.0). DORs ranged from 2.12 for GDx and OCT to 3.94 for HRT-GPS.
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For referral
IOP + VA + MRA (HRT), n = 711
IOP + VA + GPS (HRT), n = 708
IOP + VA + GDx, n = 535
IOP + VA + OCT, n = 643
Not for referral
IOP + VA + MRA (HRT), n = 202
IOP + VA + GPS (HRT), n = 221
IOP + VA + GDx, n = 394
IOP + VA + OCT, n = 290
No result
IOP + VA + MRA (HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
IOP + VA + MRA, n = 5
IOP + VA + GPS, n = 5
IOP + VA + GDx, n = 4
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 4
IOP + VA + GPS, n = 4
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 1
IOP + VA + GPS, n = 1
IOP + VA + GDx, n = 0
IOP + VA + OCT, n = 0
Reference standard
IOP + VA + MRA, n = 29
IOP + VA + GPS,  n = 13
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA, n = 706
IOP + VA + GPS, n = 703
IOP + VA + GDx, n = 531
IOP + VA + OCT, n = 638
Reference standard
IOP + VA + MRA, n = 198
IOP + VA + GPS, n = 217
IOP + VA + GDx, n = 388
IOP + VA + OCT, n = 285
Not discharged (TP)
IOP + VA + MRA, n = 481
IOP + VA + GPS, n = 490
IOP + VA + GDx, n = 369
IOP + VA + OCT, n = 429
Not discharged (FN)
IOP + VA + MRA, n = 81
IOP + VA + GPS, n = 80
IOP + VA + GDx, n = 201
IOP + VA + OCT, n = 140
Discharged (FP)
IOP + VA + MRA, n = 225
IOP + VA + GPS, n = 213
IOP + VA + GDx, n = 162
IOP + VA + OCT, n = 209
Not discharged
IOP + VA + MRA, n = 14
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 7
Discharged (TN)
IOP + VA + MRA, n = 117
IOP + VA + GPS, n = 137
IOP + VA + GDx, n = 187
IOP + VA + OCT, n = 145
Discharged
IOP + VA + MRA, n = 15
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 3
Reference standard definition: not discharged
For referral: imaging (outside normal limits)
or IOP > 21 mmHg or VA 6/12 or poorer
Handling of no result categories: A–D for referral
        E excluded 
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test 
(imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 13 Flow diagram: default triage analysis. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Paired comparisons of imaging tests
Table 31 shows the paired difference (with 95% CI) and corresponding McNemar’s tests p-value for
comparisons between pairs of tests. There was evidence that the sensitivity of all tests differed from each
other, except for HRT-GPS versus HRT-MRA.
The highest sensitivity was found in HRT-GPS and HRT-MRA, and HRT-MRA and GDx had the lowest
sensitivity. Differences varied from 0.2% (HRT-GPS vs. HRT-MRA) to 21.3%. (HRT-GPS vs. GDx). Similarly,
there was evidence that specificities for all the tests varied from each other (according to McNemar’s test),
except for HRT-GPS versus OCT.
TABLE 30 Diagnostic performance: default triage analysis
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 85.6 82.4 to 88.4
Specificity (%) 34.2 29.20 to 39.5
Positive likelihood ratio 1.3 1.20 to 1.41
Negative likelihood ratio 0.4 0.33 to 0.54
DOR 3.09 2.23 to 4.27
HRT-GPS Sensitivity (%) 86.0 82.8 to 88.7
Specificity (%) 39.1 34.0 to 44.5
Positive likelihood ratio 1.41 1.29 to 1.55
Negative likelihood ratio 0.36 0.28 to 0.46
DOR 3.94 2.86 to 5.42
GDx Sensitivity (%) 64.7 60.7 to 68.7
Specificity (%) 53.6 48.2 to 58.9
Positive likelihood ratio 1.39 1.23 to 1.59
Negative likelihood ratio 0.66 0.57 to 0.76
DOR 2.12 1.62 to 2.78
OCT Sensitivity (%) 75.4 71.6 to 78.9
Specificity (%) 41.0 35.8 to 46.3
Positive likelihood ratio 1.28 1.16 to 1.41
Negative likelihood ratio 0.60 0.50 to 0.73
DOR 2.13 1.60 to 2.83
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TABLE 31 Paired comparisons of sensitivity and specificity between the triage tests
Tests compared Diagnostic parameter Test Value, % (95% CI) p-value (McNemar’s)
HRT-GPS vs. GDx Sensitivity HRT-GPS 85.8 (82.9 to 88.7) –
GDx 64.5 (60.6 to 68.5) –
Difference 21.3 (17.7 to 24.9) < 0.0001
Specificity HRT-GPS 39.6 (34.4 to 44.7) –
GDx 53.8 (48.5 to 59.0) –
Difference –14.2 (–19.0 to –9.2) < 0.0001
GDx vs. OCT Sensitivity GDx 64.8 (60.9 to 68.8) –
OCT 75.1 (71.6 to 78.7) –
Difference –10.3 (–13.5 to –7.0) < 0.0001
Specificity GDx 53.4 (48.2 to 58.7) –
OCT 41.1 (35.9 to 46.3) –
Difference 12.4 (7.9 to 16.7) < 0.0001
GDx vs. HRT-MRA Sensitivity GDx 64.9 (61.0 to 68.9) –
HRT-MRA 85.4 (82.5 to 88.4) –
Difference –20.5 (–24.3 to –16.7) < 0.0001
Specificity GDx 53.3 (47.9 to 58.6) –
HRT-MRA 34.3 (29.3 to 39.4) –
Difference 18.9 (13.8 to 23.9) < 0.0001
HRT-GPS vs. HRT-MRA Sensitivity HRT-GPS 85.7 (82.8 to 88.6) –
HRT-MRA 85.5 (82.6 to 88.4) –
Difference 0.2 (–2.4 to 2.8) 0.8907
Specificity HRT-GPS 39.3 (34.1 to 44.5) –
HRT-MRA 34.3 (29.3 to 39.3) –
Difference 5.0 (0.3 to 9.6) < 0.0001
HRT-MRA vs. OCT Sensitivity HRT-MRA 85.6 (82.7 to 88.5) –
OCT 75.2 (71.6 to 78.8) –
Difference 10.4 (7.1 to 13.8) < 0.0001
Specificity HRT-MRA 34.2 (29.2 to 39.2) –
OCT 40.9 (35.7 to 46.1) –
Difference –6.7 (–12.2 to –1.2) 0.0171
HRT-GPS vs. OCT Sensitivity HRT-GPS 86.1 (83.2 to 88.9) –
OCT 75.3 (71.8 to 78.9) –
Difference 10.8 (7.4 to 14.2) < 0.0001
Specificity HRT-GPS 39.1 (34.0 to 44.3) –
OCT 41.1 (36.0 to 46.3) –
Difference –2.0 (–7.4 to 3.5) 0.4726
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Triage sensitivity analysis 1
Triage sensitivity analysis 1 differed from the default triage analysis in that a borderline finding on the
imaging test was also classified as an abnormal result.
For triage sensitivity analysis 1, the triage test is classified as abnormal if (1) the imaging test result is
classified as ‘outside normal limits’ or ‘borderline’, (2) IOP is > 21mmHg or (3) VA is 6/12 or poorer.
Imaging test results which did not provide an overall classification were included as abnormal. The
corresponding reference standard definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 1 is shown in Figure 14, with the
corresponding numbers of referral, not for referral and no result cases by triage test, and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 576 were
not discharged and 357 were discharged and the discharge status was missing for 10 participants. The
diagnostic performance for the four tests is given in Table 32. The results generally showed a trade-off
between the detection of patients who need to be referred and the discharge of those who do not need to
be referred: HRT-GPS had the highest sensitivity (94.0%, 95% CI 91.8% to 95.8%) but second lowest
specificity (24.9%, 95% CI 20.4% to 29.7%), GDx had the lowest sensitivity (74.9%, 95% CI 71.1% to
78.4%) but the highest specificity (45%, 39.7% CI 39% to 50.4%), and the other two tests provided
intermediate results (HRT-MRA values were very similar though marginally inferior to the HRT-GPS results,
and OCT had lower sensitivity (84.2%, 95% CI 80.9 to 87.1) but slightly higher specificity than HRT-GPS and
HRT-MRA). Likelihood ratios (and 95% CI) showed evidence of being able to both rule in and rule out the
presence of glaucoma for all four triage tests (CIs did not contain 1.0). DORs ranged from 2.04 for OCT
to 5.21 for HRT-GPS.
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For referral
IOP + VA + MRA (HRT), n = 788
IOP + VA + GPS (HRT), n = 805
IOP + VA + GDx, n = 624
IOP + VA + OCT, n = 741
Not for referral
IOP + VA + MRA (HRT), n = 125
IOP + VA + GPS (HRT), n = 124
IOP + VA + GDx, n = 305
IOP + VA + OCT, n = 192
No result
IOP + VA + MRA(HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
IOP + VA + MRA, n = 7
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 5
IOP + VA + OCT, n = 6
No reference standard
IOP + VA + MRA, n = 2
IOP + VA + GPS, n = 3
IOP + VA + GDx,n = 5
IOP + VA + OCT, n = 4
No reference standard
IOP + VA + MRA, n = 1
IOP + VA + GPS, n = 1
IOP + VA + GDx, n = 0
IOP + VA + OCT, n = 0
Reference standard
IOP + VA + MRA, n = 29
IOP + VA + GPS, n = 13
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA, n = 781
IOP + VA + GPS,  n = 799
IOP + VA + GDx, n = 619
IOP + VA + OCT, n = 735
Reference standard
IOP + VA + MRA, n = 123
IOP + VA + GPS, n = 121
IOP + VA + GDx, n = 300
IOP + VA + OCT, n = 188
Not discharged (TP)
IOP + VA + MRA, n = 521
IOP + VA + GPS, n = 536
IOP + VA + GDx, n = 427
IOP + VA + OCT, n = 479
Not discharged (FN)
IOP + VA + MRA, n = 41
IOP + VA + GPS, n = 34
IOP + VA + GDx, n = 143
IOP + VA + OCT, n = 90
Discharged (FP)
IOP + VA + MRA, n = 260
IOP + VA + GPS, n = 263
IOP + VA + GDx, n = 192
IOP + VA + OCT, n = 256
Not discharged
IOP + VA + MRA, n = 14
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 7
Discharged (TN)
IOP + VA + MRA, n = 82
IOP + VA + GPS, n = 87
IOP + VA + GDx, n = 157
IOP + VA + OCT, n = 98
Discharged
IOP + VA + MRA, n = 15
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 3
Reference standard definition: not discharged
For referral: imaging (outside normal limits or
borderline) or IOP > 21 mmHg or VA 6/12 or poorer
Handling of no result categories: A–D for referral
      E excluded 
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 14 Flow diagram: triage sensitivity analysis 1. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Triage sensitivity analysis 2
Triage sensitivity analysis 2 has the same reference standard and definition of abnormal test result as the
default analysis but did not include all no result cases (see Table 33).
For triage sensitivity analysis 2, the triage test is classified as abnormal if (1) the imaging test result is
classified as ‘outside normal limits’, (2) IOP is > 21mmHg or (3) VA is 6/12 or poorer. Poor-quality imaging
test results were included, and those where an image was acquired but no classification generated were
included as abnormal. All other missing imaging results were excluded. The corresponding reference
standard definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 2 is shown in Figure 15, with the
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 481
were not discharged and 562 were discharged and the discharge status was missing for 10 participants.
The diagnostic performance for the four tests is given in Table 33. The results generally showed a trade-off
between the detection of patients who need to be referred and the discharge of those who do not need
to be referred: HRT-GPS had the highest sensitivity (84.6%, 95% CI 81.4% to 87.5%) but the second
lowest specificity (39.7%, 95% CI 34.6% to 45.1%), GDx had the lowest sensitivity (61.1%, 95% CI
56.9% to 65.1%) but the highest specificity (59.0%, 95% CI 53.7% to 64.2%) and the other two tests
provided intermediate results [HRT-MRA values were very similar, although slightly inferior to the HRT-GPS
TABLE 32 Diagnostic performance: triage sensitivity analysis 1
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 92.7 90.2 to 94.7
Specificity (%) 24.0 19.5 to 28.9
Positive likelihood ratio 1.2 1.14 to 1.30
Negative likelihood ratio 0.30 0.21 to 0.43
DOR 4.01 2.68 to 6.00
HRT-GPS Sensitivity (%) 94.0 91.8 to 95.8
Specificity (%) 24.9 20.4 to 29.7
Positive likelihood ratio 1.25 1.17 to 1.33
Negative likelihood ratio 0.24 0.17 to 0.35
DOR 5.21 3.42 to 7.96
GDx Sensitivity (%) 74.9 71.1 to 78.4
Specificity (%) 45.0 39.7 to 50.4
Positive likelihood ratio 1.36 1.22 to 1.51
Negative likelihood ratio 0.56 0.46 to 0.67
DOR 2.44 1.84 to 3.24
OCT Sensitivity (%) 84.2 80.9 to 87.1
Specificity (%) 27.7 23.1 to 32.7
Positive likelihood ratio 1.16 1.08 to 1.51
Negative likelihood ratio 0.57 0.44 to 0.74
DOR 2.04 1.47 to 2.82
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For referral
IOP + VA + MRA (HRT), n = 702
IOP + VA + GPS (HRT), n = 698
IOP + VA + GDx, n = 495
IOP + VA + OCT, n = 637
Not for referral
IOP + VA + MRA (HRT), n = 211
IOP + VA + GPS (HRT), n = 231
IOP + VA + GDx, n = 434
IOP + VA + OCT, n = 296
No result
IOP + VA + MRA (HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
IOP + VA + MRA, n = 4
IOP + VA + GPS, n = 5
IOP + VA + GDx, n = 4
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 5
IOP + VA + GPS, n = 4
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 1
IOP + VA + GPS, n = 1
IOP + VA + GDx, n = 0
IOP + VA + OCT, n = 0
Reference standard
IOP + VA + MRA, n = 29
IOP + VA + GPS, n = 13
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA, n = 698
IOP + VA + GPS, n = 693
IOP + VA + GDx, n = 491
IOP + VA + OCT, n = 632
Reference standard
IOP + VA + MRA, n = 206
IOP + VA + GPS, n = 227
IOP + VA + GDx, n = 428
IOP + VA + OCT, n = 291
Not discharged (TP)
IOP + VA + MRA, n = 474
IOP + VA + GPS, n = 482
IOP + VA + GDx, n = 348
IOP + VA + OCT, n = 427
Not discharged (FN)
IOP + VA + MRA, n = 88
IOP + VA + GPS, n = 88
IOP + VA + GDx, n = 222
IOP + VA + OCT, n = 142
Discharged (FP)
IOP + VA + MRA, n = 224
IOP + VA + GPS, n = 211
IOP + VA + GDx, n = 143
IOP + VA + OCT, n = 205
Not discharged
IOP + VA + MRA, n = 14
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 7
Discharged (TN)
IOP + VA + MRA, n = 118
IOP + VA + GPS, n = 139
IOP + VA + GDx, n = 206
IOP + VA + OCT, n = 149
Reference standard definition: not discharged
For referral: imaging (outside normal limits) 
or IOP > 21 mmHg or VA 6/12 or poorer
Handling of no result categories: A classification used
     B for referral
     C–E excluded 
Inconclusive
reference standard
(n = 0)
Discharged
IOP + VA + MRA, n = 15
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 3
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test 
(imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 15 Flow diagram: triage sensitivity analysis 2. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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results, and OCT had the second lowest sensitivity (75.0%, 95% CI 71.3% to 78.5%) but the second
highest specificity (42.1%, 95% CI 36.9% to 47.4%) values]. Likelihood ratios (and 95% CI) showed
evidence of being able to both rule in and rule out the presence of glaucoma for all four triage tests (CIs
did not contain 1.0). DORs ranged from 2.19 for GDx to 3.61 for OCT.
Triage sensitivity analysis 3
Triage sensitivity analysis 3 was the same as triage sensitivity analysis 2 except that ‘borderline’ test results
were also classified as abnormal.
For triage sensitivity analysis 3, the triage test is classified as abnormal if (1) the imaging test result is classified
as ‘outside normal limits’ or ‘borderline’, (2) IOP is > 21mmHg or (3) VA is 6/12 or poorer. Poor-quality
imaging test results were included, and those where an image was acquired but no classification generated
were included as abnormal. All other missing imaging results were excluded. The corresponding reference
standard definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 3 is shown in Figure 16, with
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 481
were not discharged and 562 were discharged and the discharge status was missing for 10 participants.
TABLE 33 Diagnostic performance: triage sensitivity analysis 2
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 84.3 81.1 to 87.2
Specificity (%) 34.5 29.5 to 39.8
Positive likelihood ratio 1.29 1.18 to 1.40
Negative likelihood ratio 0.45 0.36 to 0.58
DOR 2.84 2.06 to 3.90
HRT-GPS Sensitivity (%) 84.6 81.4 to 87.5
Specificity (%) 39.7 34.6 to 45.1
Positive likelihood ratio 1.40 1.28 to 1.54
Negative likelihood ratio 0.39 0.31 to 0.49
DOR 3.61 2.64 to 4.93
GDx Sensitivity (%) 61.1 56.9 to 65.1
Specificity (%) 59.0 53.7 to 64.2
Positive likelihood ratio 1.49 1.29 to 1.72
Negative likelihood ratio 0.66 0.58 to 0.76
DOR 2.26 1.72 to 2.96
OCT Sensitivity (%) 75.0 71.3 to 78.5
Specificity (%) 42.1 36.9 to 47.4
Positive likelihood ratio 1.30 1.17 to 1.43
Negative likelihood ratio 0.59 0.49 to 0.72
DOR 2.19 1.65 to 2.90
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For referral
IOP + VA + MRA (HRT), n = 786
IOP + VA + GPS (HRT), n = 801
IOP + VA + GDx, n = 595
OP + VA + OCT, n = 738
Not for referral
IOP + VA + MRA (HRT), n = 127
IOP + VA + GPS (HRT), n = 128
IOP + VA + GDx, n = 334
IOP + VA + OCT, n = 195
No result
IOP + VA + MRA (HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
IOP + VA + MRA, n = 7
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 5
IOP + VA + OCT, n = 6
No reference standard
IOP + VA + MRA, n = 2
IOP + VA + GPS, n = 3
IOP + VA + GDx, n = 5
IOP + VA + OCT, n = 4
No reference standard
IOP + VA + MRA, n = 1
IOP + VA + GPS, n = 1
IOP + VA + GDx, n = 0
IOP + VA + OCT, n = 0
Reference standard
IOP + VA + MRA, n = 29
IOP + VA + GPS, n = 13
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA, n = 779
IOP + VA + GPS, n = 795
IOP + VA + GDx, n = 590
IOP + VA + OCT, n = 732
Reference standard
IOP + VA + MRA, n = 125
IOP + VA + GPS, n = 125
IOP + VA + GDx, n = 329
IOP + VA + OCT, n = 191
Not discharged (TP)
IOP + VA + MRA, n = 519
IOP + VA + GPS, n = 532
IOP + VA + GDx, n = 412
IOP + VA + OCT, n = 479
Not discharged (FN)
IOP + VA + MRA, n = 43
IOP + VA + GPS, n = 38
IOP + VA + GDx, n = 158
IOP + VA + OCT, n = 90
Discharged (FP)
IOP + VA + MRA, n = 260
IOP + VA + GPS, n = 263
IOP + VA + GDx, n = 178
IOP + VA + OCT, n = 253
Not discharged
IOP + VA + MRA, n = 14
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 7
Discharged (TN)
IOP + VA + MRA, n = 82
IOP + VA + GPS, n = 87
IOP + VA + GDx, n = 171
IOP + VA + OCT, n = 101
Discharged
IOP + VA + MRA, n = 15
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 3
Reference standard definition: not discharged
For referral: imaging (outside normal limits or
borderline or IOP > 21 mmHg or VA 6/12 or poorer
Handling of no result categories: A classification used
      B for referral
      C–E excluded 
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 16 Flow diagram: triage sensitivity analysis 3. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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The diagnostic performance for the four tests is given in Table 34. The results generally showed a trade-off
between the detection of patients who need to be referred and the discharge of those who do not need
to be referred: HRT-GPS had the highest sensitivity (93.3%, 95% CI 91.0% to 95.2%) but second lowest
specificity (24.9%, 95% CI 20.4% to 29.7%), GDx had the lowest sensitivity (72.3%, 95% CI 68.4% to
75.9%) but the highest specificity (49.0%, 95% CI 43.6% to 54.4%) and the other two tests provided
intermediate results [HRT-MRA values were very similar to the HRT-GPS results, although slightly inferior,
and OCT had the second lowest sensitivity (84.2%, 95% CI 80.9% to 87.1%) but the second highest
specificity]. Likelihood ratios (and 95% CI) showed evidence of being able to both rule in and rule out the
presence of glaucoma for all four triage tests (CIs did not contain 1.0). DORs ranged from 2.12 for OCT to
4.63 for HRT-GPS.
TABLE 34 Diagnostic performance: triage sensitivity analysis 3
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 92.3 89.8 to 94.4
Specificity (%) 24.0 19.5 to 28.9
Positive likelihood ratio 1.21 1.14 to 1.03
Negative likelihood ratio 0.32 0.23 to 0.45
DOR 3.81 2.56 to 5.67
HRT-GPS Sensitivity (%) 93.3 91.0 to 95.2
Specificity (%) 24.9 20.4 to 29.7
Positive likelihood ratio 1.24 1.16 to 1.32
Negative likelihood ratio 0.27 0.19 to 0.38
DOR 4.63 3.08 to 6.97
GDx Sensitivity (%) 72.3 68.4 to 75.9
Specificity (%) 49.0 43.6 to 54.4
Positive likelihood ratio 1.42 1.26 to 1.59
Negative likelihood ratio 0.57 0.48 to 0.67
DOR 2.51 1.90 to 3.31
OCT Sensitivity (%) 84.2 80.9 to 87.1
Specificity (%) 28.5 23.9 to 33.5
Positive likelihood ratio 1.18 1.09 to 1.27
Negative likelihood ratio 0.55 0.43 to 0.71
DOR 2.12 1.54 to 2.93
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Triage sensitivity analysis 4
Triage sensitivity analysis 4 differed from the default triage analysis in that referral IOP > 21mmHg rather
than clinician IOP > 21mmHg was used to identify abnormal tests. The triage test is classified as abnormal
if (1) the imaging test result is classified as ‘outside normal limits’, (2) referral IOP is> 21mmHg or (3) VA is
6/12 or poorer. Imaging test results which did not provide an overall classification were included as
abnormal. The corresponding reference standard definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 4 is shown in Figure 17, with the
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 481
were not discharged and 562 were discharged and the discharge status was missing for 10 participants.
The diagnostic performance for the four tests is given in Table 35. The results generally showed a trade-off
between the detection of patients who need to be referred and the discharge of those who do not need
to be referred: HRT-GPS had the highest sensitivity (86.5%, 95% CI 83.4% to 89.2%) but second lowest
specificity (24.0%, 95% CI 19.6% to 28.8%), GDx had the lowest sensitivity (67.2%, 95% CI 63.2% to
71.0%) but the highest specificity (35.8%, 95% CI 30.8% to 41.1%) and the other two tests provided
intermediate results (HRT-MRA values were very similar to the HRT-GPS results, although slightly inferior,
and OCT had the second lowest sensitivity (76.8%, 95% CI 73.1% to 80.2%) but the second highest
specificity (27.7%, 95% CI 23.1% to 32.7%). Likelihood ratios (and 95% CI) showed evidence of being
able to both rule in and rule out the presence of glaucoma for all four triage tests (CIs did not contain
1.0). DORs ranged from 1.14 for GDx to 2.02 for HRT-GPS.
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For referral
IOP + VA + MRA (HRT), n = 767
IOP + VA + GPS (HRT), n = 766
IOP + VA + GDx, n = 615
IOP + VA + OCT, n = 702
Not for referral
IOP + VA+MRA (HRT), n = 146
IOP + VA+GPS (HRT), n = 163
IOP + VA+GDx, n = 314
IOP + VA+OCT, n = 231
No result
IOP + VA + MRA (HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
IOP + VA + MRA, n = 7
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 9
No reference standard
IOP + VA + MRA, n = 2
IOP + VA + GPS, n = 2
IOP + VA + GDx, n = 2
IOP + VA + OCT, n = 1
No reference standard
IOP + VA + MRA, n = 1
IOP + VA + GPS, n = 1
IOP + VA + GDx, n = 0
IOP + VA + OCT, n = 0
Reference standard
IOP + VA + MRA, n = 29
IOP + VA + GPS, n = 13
IOP + VA + GD, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA, n = 760
IOP + VA + GPS, n = 759
IOP + VA + GDx, n = 607
IOP + VA + OCT, n = 693
Reference standard
IOP + VA + MRA, n = 144
IOP + VA + GPS, n = 161
IOP + VA + GDx, n = 312
IOP + VA + OCT, n = 230
Not discharged (TP)
IOP + VA + MRA, n = 486
IOP + VA + GPS, n = 493
IOP + VA + GDx, n = 383
IOP + VA + OCT, n = 437
Not discharged (FN)
IOP + VA + MRA, n = 76
IOP + VA + GPS, n = 77
IOP + VA + GDx, n = 187
IOP + VA + OCT, n = 132
Discharged (FP)
IOP + VA + MRA, n = 274
IOP + VA + GPS, n = 266
IOP + VA + GDx, n = 224
IOP + VA + OCT, n = 256
Not discharged
IOP + VA + MRA, n = 14
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 7
Discharged (TN)
IOP + VA + MRA, n = 68
IOP + VA + GPS, n = 84
IOP + VA + GDx, n = 125
IOP + VA + OCT, n = 98
Discharged
IOP + VA + MRA, n = 15
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 3
Reference standard definition: not discharged
For referral: imaging (outside normal limits) or
referral IOP > 21 mmHg or VA 6/12 or poorer
Handling of no result categories: A–D for referral
      E excluded 
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test 
(imaging + referral IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 17 Flow diagram: triage sensitivity analysis 4. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Triage sensitivity analysis 5
Triage sensitivity analysis 5 differed from the default triage analysis in that the IOP component was
removed from the composite triage test. The triage test is classified as abnormal if the imaging test result is
classified as (1) ‘outside normal limits’ or (2) VA is 6/12 or poorer. Imaging test results which did not
provide an overall classification were included as abnormal. The corresponding reference standard
definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 5 is shown in Figure 18, with the
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 933 participants in whom all four tests were performed, 481
were not discharged and 562 were discharged. The discharge status was missing for 10 participants. The
diagnostic performance for the four tests is given in Table 36. The results generally showed a trade-off
between the detection of patients who need to be referred and the discharge of those who do not need
to be referred: HRT-MRA had the highest sensitivity (68.9%, 95% CI 64.9% to 72.7%) but the lowest
specificity (52.3%, 95% CI 46.9% to 57.7%), GDx had the lowest sensitivity (32.8%, 95% CI 29.0% to
36.8%) but the highest specificity (81.1%, 95% CI 76.6% to 85.1%) and the other two tests provided
intermediate results (HRT-GPS values were very similar to the HRT-MRA results and OCT had the second
lowest sensitivity but the second highest specificity). Likelihood ratios (and 95% CI) showed evidence of
being able to both rule in and rule out the presence of glaucoma for all four triage tests (CIs did not
contain 1.0). DORs ranged from 1.80 for OCT to 2.91 for HRT-GPS.
TABLE 35 Diagnostic performance: triage sensitivity analysis 4
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 86.5 83.4 to 89.2
Specificity (%) 19.9 15.8 to 24.5
Positive likelihood ratio 1.08 1.01 to 1.15
Negative likelihood ratio 0.68 0.50 to 0.92
DOR 1.59 1.11 to 2.27
HRT-GPS Sensitivity (%) 86.5 83.4 to 89.2
Specificity (%) 24.0 19.6 to 28.8
Positive likelihood ratio 1.14 1.06 to 1.22
Negative likelihood ratio 0.56 0.43 to 0.74
DOR 2.02 1.43 to 2.85
GDx Sensitivity (%) 67.2 63.2 to 71.0
Specificity (%) 35.8 30.8 to 41.1
Positive likelihood ratio 1.05 0.95 to 1.15
Negative likelihood ratio 0.92 0.76 to 1.10
DOR 1.14 0.86 to 1.51
OCT Sensitivity (%) 76.8 73.1 to 80.2
Specificity (%) 27.7 23.1 to 32.7
Positive likelihood ratio 1.06 0.98 to 1.15
Negative likelihood ratio 0.84 0.67 to 1.05
DOR 1.27 0.94 to 1.72
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For referral
VA + MRA (HRT), n = 555
VA + GPS (HRT), n = 546
VA + GDx, n = 257
VA + OCT, n = 426
Not for referral
VA + MRA (HRT), n = 358
VA + GPS (HRT), n = 383
VA + GDx, n = 672
VA + OCT, n = 507
No result
VA + MRA (HRT), n = 30
VA + GPS (HRT), n = 14
VA + GDx, n = 14
VA + OCT, n = 10
No reference standard
VA + MRA, n = 5
VA + GPS, n = 5
VA + GDx, n = 4
VA + OCT, n = 5
No reference standard
VA + MRA, n = 4
 VA + GPS, n = 4
VA + GDx, n = 6
VA + OCT, n = 5
No reference standard
VA + MRA, n = 1
VA + GPS, n = 1
VA + GDx, n = 0
VA + OCT, n = 0
Reference standard
VA + MRA, n = 29
VA + GPS,  n = 13
VA + GDx, n = 14
VA + OCT, n = 10
Reference standard
VA + MRA, n = 550
VA + GPS, n = 541
VA + GDx, n = 253
VA + OCT, n = 421
Reference standard 
VA + MRA, n = 354
VA + GPS, n = 379
VA + GDx, n = 666
VA + OCT, n = 502
Not discharged (TP)
VA + MRA, n = 387
VA + GPS,  n = 391
VA + GDx, n = 187
VA + OCT, n = 291
Not discharged (FN)
VA + MRA, n = 175
VA + GPS, n = 179
VA + GDx, n = 383
VA + OCT, n = 278
Discharged (FP)
VA + MRA, n = 163
VA + GPS, n = 150
VA + GDx, n = 66
VA + OCT, n = 130
Not discharged
VA + MRA, n = 14
VA + GPS, n = 6
VA + GDx, n = 6
VA + OCT, n = 7
Discharged (TN)
VA + MRA, n = 179
VA + GPS, n = 200
VA + GDx, n = 283
VA + OCT, n = 224
Inconclusive
reference standard
(n = 0) 
Discharged
VA + MRA, n = 15
VA + GPS, n = 7
VA + GDx, n = 8
VA + OCT, n = 3
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
Reference standard definition: not discharged
For referral: imaging (outside normal limits)
or VA 6/12 or poorer
Handling of no result categories: A–D for referral
                                                         E excluded 
FIGURE 18 Flow diagram: triage sensitivity analysis 5. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Triage sensitivity analysis 6
Triage sensitivity analysis 6 differed from the default triage analysis in that the VA component was
removed from the composite triage test. The triage test is classified as abnormal if (1) the imaging test
result is classified as ‘outside normal limits’ or (2) IOP is > 21mmHg. Imaging test results which did not
provide an overall classification were included as abnormal. The corresponding reference standard
definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 6 is shown in Figure 19, with
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 481
were not discharged and 562 were discharged and the discharge status was missing for 10 participants.
The diagnostic performance for the four tests is given in Table 37. The results generally showed a trade-off
between the detection of patients who need to be referred and the discharge of those who do not need
to be referred: HRT-MRA had the highest sensitivity (84.9%, 95% CI 81.9% to 87.7%) but second lowest
specificity (37.4%, 95% CI 32.3% to 42.8%), GDx had the lowest sensitivity (60.5%, 95% CI 56.4% to
64.6%) but the highest specificity (57.6%, 95% CI 52.2% to 62.8%), and the other two tests provided
intermediate results (HRT-GPS values were very similar to the HRT-MRA results and OCT had the second
lowest sensitivity but the second highest specificity). Likelihood ratios (and 95% CI) showed evidence of
being able to both rule in and rule out the presence of glaucoma for all four triage tests (CIs did not
contain 1.0). DORs ranged from 2.03 for OCT to 3.97 for HRT-GPS.
TABLE 36 Diagnostic performance: triage sensitivity analysis 5
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 68.9 64.9 to 72.7
Specificity (%) 52.3 46.9 to 57.7
Positive likelihood ratio 1.44 1.28 to 1.64
Negative likelihood ratio 0.59 0.51 to 0.70
DOR 2.43 1.84 to 3.20
HRT-GPS Sensitivity (%) 68.6 64.6 to 72.4
Specificity (%) 57.1 51.8 to 62.4
Positive likelihood ratio 1.60 1.40 to 1.83
Negative likelihood ratio 0.55 0.47 to 0.64
DOR 2.91 2.21 to 3.84
GDx Sensitivity (%) 32.8 29.0 to 36.8
Specificity (%) 81.1 76.6 to 85.1
Positive likelihood ratio 1.73 1.36 to 2.22
Negative likelihood ratio 0.83 0.77 to 0.89
DOR 2.09 1.52 to 2.88
OCT Sensitivity (%) 51.1 47.0 to 55.3
Specificity (%) 63.3 58.0 to 68.3
Positive likelihood ratio 1.39 1.19 to 1.63
Negative likelihood ratio 0.77 0.69 to 0.87
DOR 1.80 1.37 to 2.37
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For referral
IOP + MRA (HRT), n = 696
IOP + GPS (HRT), n = 689
IOP + GDx, n = 497
IOP + OCT, n = 608
Not for referral
IOP + MRA (HRT), n = 217
IOP + GPS (HRT), n = 240
IOP + GDx, n = 432
IOP + OCT, n = 325
No result
IOP + MRA (HRT), n = 30
IOP + GPS (HRT), n = 14
IOP + GDx, n = 14
IOP + OCT, n = 10
No reference standard
IOP + MRA, n = 5
IOP + GPS, n = 4
IOP + GDx, n = 4
IOP + OCT, n = 5
No reference standard
IOP + MRA, n = 4
IOP + GPS, n = 5
IOP + GDx, n = 6
IOP + OCT, n = 5
No reference standard
IOP + MRA, n = 1
IOP + GPS, n = 1
IOP + GDx, n = 0
IOP + OCT, n = 0
Reference standard
IOP + MRA, n = 29
IOP + GPS, n = 13
IOP + GDx, n = 14
IOP + OCT, n = 10
Reference standard
IOP + MRA, n = 691
IOP + GPS, n = 685
IOP + GDx, n = 493
IOP + OCT, n = 605
Reference standard
IOP + MRA, n = 213
IOP + GPS, n = 235
IOP + GDx, n = 426
IOP + OCT, n = 320
Not discharged (TP)
IOP + MRA, n = 477
IOP + GPS, n = 482
IOP + GDx, n = 345
IOP + OCT, n = 407
Not discharged (FN)
IOP + MRA, n = 85
IOP + GPS, n = 88
IOP + GDx, n = 225
IOP + OCT, n = 162
Discharged (FP)
IOP + MRA, n = 214
IOP + GPS, n = 203
IOP + GDx, n = 148
IOP + OCT, n = 196
Not discharged
IOP + MRA, n = 14
IOP + GPS, n = 6
IOP + GDx, n = 6
IOP + OCT, n = 7
Reference standard definition: not discharged
For referral: imaging (outside normal limits)
or IOP > 21mmHg
Handling of no result categories: A–D for referral
                   E excluded 
Discharged (TN)
IOP + MRA, n = 128
IOP + GPS, n = 147
IOP + GDx, n = 201
IOP + OCT, n = 158
Inconclusive
reference standard
(n = 0)
Discharged
IOP + MRA, n = 15
IOP + GPS, n = 7
IOP + GDx, n = 8
IOP + OCT, n = 3
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + IOP)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 19 Flow diagram: triage sensitivity analysis 6. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Triage sensitivity analysis 7
Triage sensitivity analysis 7 differed from the default triage analysis in that a higher IOP threshold of
26mmHg rather than 21mmHg was used to identify abnormal tests. The triage test is classified as
abnormal if (1) the imaging test result is classified as ‘outside normal limits’, (2) IOP is > 26mmHg or (3) VA
is 6/12 or poorer. Imaging test results which did not provide an overall classification were included as
abnormal. The corresponding reference standard definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 7 is shown in Figure 20, with the
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 481
were not discharged and 562 were discharged and the discharge status was missing for 10 participants.
The diagnostic performance for the four tests is given in Table 38. The results generally showed a trade-off
between the detection of patients who need to be referred and the discharge of those who do not need
to be referred: HRT-MRA had the highest sensitivity (77.2%, 95% CI 73.5% to 80.6%) but second lowest
specificity (51.8%, 95% CI 46.3% to 57.2%), GDx had the lowest sensitivity (47.9%, 95% CI 43.7% to
52.1%) but the highest specificity (79.1%, 95% CI 74.4% to 81.2%), and the other two tests provided
intermediate results (HRT-GPS values were very similar to the HRT-MRA results and OCT had very similar
sensitivity and specificity). Likelihood ratios (and 95% CI) showed evidence of being able to both rule in
and rule out the presence of glaucoma for all four triage tests (CIs did not contain 1.0). DORs ranged from
2.61 for OCT to 4.03 for HRT-GPS.
TABLE 37 Diagnostic performance: triage sensitivity analysis 6
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 84.9 81.6 to 87.7
Specificity (%) 37.4 32.3 to 42.8
Positive likelihood ratio 1.36 1.24 to 1.48
Negative likelihood ratio 0.40 0.32 to 0.48
DOR 3.36 2.44 to 4.61
HRT-GPS Sensitivity (%) 84.6 81.3 to 87.4
Specificity (%) 42.0 36.8 to 47.4
Positive likelihood ratio 1.46 1.32 to 1.60
Negative likelihood ratio 0.37 0.29 to 0.46
DOR 3.97 2.91 to 5.41
GDx Sensitivity (%) 60.5 56.4 to 64.6
Specificity (%) 57.6 52.2 to 62.8
Positive likelihood ratio 1.43 1.24 to 1.64
Negative likelihood ratio 0.69 0.60 to 0.79
DOR 2.08 1.59 to 2.73
OCT Sensitivity (%) 71.5 67.6 to 75.2
Specificity (%) 44.6 39.4 to 50.0
Positive likelihood ratio 1.29 1.16 to 1.44
Negative likelihood ratio 0.64 0.54 to 0.76
DOR 2.03 1.53 to 2.67
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For referral
IOP + VA + MRA (HRT), n = 604
IOP + VA + GPS (HRT), n = 590
IOP + VA + GDx, n = 350
IOP + VA + OCT, n = 491
Not for referral
IOP + VA + MRA (HRT), n = 309
IOP + VA + GPS (HRT), n = 339
IOP + VA + GDx, n = 579
IOP + VA + OCT, n = 442
No result
IOP + VA + MRA (HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
IOP + VA + MRA, n = 5
IOP + VA + GPS, n = 5
IOP + VA + GDx, n = 4
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 4
IOP + VA + GPS, n = 4
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 1
IOP + VA + GPS, n = 1 
IOP + VA + GDx, n = 0
IOP + VA + OCT, n = 0
Reference standard
IOP + VA + MRA, n = 29
IOP + VA + GPS, n = 13
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA, n = 599
IOP + VA + GPS, n = 585
IOP + VA + GDx, n = 346
IOP + VA + OCT, n = 486
Reference standard
IOP + VA + MRA, n = 305
IOP + VA + GPS, n = 335
IOP + VA + GDx, n = 573
IOP + VA + OCT, n = 437
Not discharged (TP)
IOP + VA + MRA, n = 434
IOP + VA + GPS, n = 432
IOP + VA + GDx, n = 273
IOP + VA + OCT, n = 351
Not discharged (FN)
IOP + VA + MRA, n = 128
IOP + VA + GPS, n = 138
IOP + VA + GDx, n = 297
IOP + VA + OCT, n = 218
Discharged (FP)
IOP + VA + MRA, n = 165
IOP + VA + GPS, n = 153
IOP + VA + GDx, n = 73
IOP + VA + OCT, n = 135
Not discharged
IOP + VA + MRA, n = 14
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 7
Discharged (TN)
IOP + VA + MRA, n = 177
IOP + VA + GPS, n = 197
IOP + VA + GDx, n = 276
IOP + VA + OCT, n = 219
Reference standard definition: not discharged
For referral: imaging (outside normal limits)
or IOP > 26 mmHg or VA 6/12 or poorer
Handling of no result categories: A–D for referral
                   E excluded 
Inconclusive
reference standard
(n = 0)
Discharged
IOP + VA + MRA, n = 15
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 3
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 20 Flow diagram: triage sensitivity analysis 7. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Triage sensitivity analysis 8
Triage sensitivity analysis 8 differed from the default triage analysis in that a higher VA threshold of VA 6/18
or poorer was used to identify abnormal tests. The triage test is classified as abnormal if (1) the imaging
test result is classified as ‘outside normal limits’, (2) IOP is > 21mmHg or (3) VA is 6/18 or poorer. Imaging
test results which did not provide an overall classification were included as abnormal. The corresponding
reference standard definition is a clinical decision not to discharge the patient.
The flow of study participants according to triage sensitivity analysis 8 is shown in Figure 21, with the
corresponding numbers of referral, not for referral and no result cases by triage test and the corresponding
reference standard finding shown. Of the 943 participants in whom all four tests were performed, 481 were
not discharged and 562 were discharged and the discharge status was missing for 10 participants. The
diagnostic performance for the four tests is given in Table 39. The results showed a trade-off between the
detection of patients who need to be referred and the discharge of those who do not need to be referred:
HRT-MRA had the highest sensitivity (85.1%, 95% CI 81.8% to 87.9%) but lowest specificity (35.1%,
95% CI 30.0% to 40.4%), GDx had the lowest sensitivity (61.9%, 95% CI 57.8% to 65.9%) but the highest
specificity (55.6%, 95% CI 50.2% to 60.9%) and the other two tests provided intermediate results (HRT-GPS
values were very similar to the HRT-MRA results, and OCT had the second lowest sensitivity (72.9%, 95% CI
69.1% to 76.5%) but the second highest specificity (42.9%, 95% CI 37.7% to 48.3%). Likelihood ratios (and
95% CI) showed evidence of being able to both rule in and rule out the presence of glaucoma for all four
triage tests (CIs did not contain 1.0). DORs ranged from 2.03 for OCT to 3.80 for HRT-GPS.
TABLE 38 Diagnostic performance: triage sensitivity analysis 7
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 77.2 73.5 to 80.6
Specificity (%) 51.8 46.3 to 57.2
Positive likelihood ratio 1.60 1.42 to 1.80
Negative likelihood ratio 0.44 0.37 to 0.53
DOR 3.64 2.72 to 4.86
HRT-GPS Sensitivity (%) 75.8 72.1 to 79.3
Specificity (%) 56.3 50.9 to 61.6
Positive likelihood ratio 1.73 1.53 to 1.97
Negative likelihood ratio 0.43 0.36 to 0.51
DOR 4.03 3.03 to 5.36
GDx Sensitivity (%) 47.9 43.7 to 52.1
Specificity (%) 79.1 74.4 to 81.2
Positive likelihood ratio 2.29 1.84 to 2.86
Negative likelihood ratio 0.66 0.60 to 0.72
DOR 3.48 1.99 to 3.43
OCT Sensitivity (%) 61.7 57.6 to 65.7
Specificity (%) 61.9 56.6 to 66.9
Positive likelihood ratio 1.62 1.40 to 1.87
Negative likelihood ratio 0.62 0.54 to 0.71
DOR 2.61 1.99 to 3.43
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For referral
IOP + VA + MRA (HRT), n = 705
IOP + VA + GPS (HRT), n = 697
IOP + VA + GDx, n = 512
IOP + VA + OCT, n = 622
Not for referral
IOP + VA + MRA (HRT), n = 208
IOP + VA + GPS (HRT), n = 232
IOP + VA + GDx, n = 417
IOP + VA + OCT, n = 311
No result
IOP + VA + MRA (HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
IOP + VA + MRA, n = 5
IOP + VA + GPS, n = 4
IOP + VA + GDx, n = 4
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 4
IOP + VA + GPS, n = 5
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 5
No reference standard
IOP + VA + MRA, n = 1
IOP + VA + GPS, n = 1
IOP + VA + GDx, n = 0
IOP + VA + OCT, n = 0
Reference standard
IOP + VA + MRA, n = 29
IOP + VA + GPS, n = 13
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA, n = 700
IOP + VA + GPS, n = 693
IOP + VA + GDx, n = 508
IOP + VA + OCT, n = 617
Reference standard
IOP + VA + MRA, n = 204
IOP + VA + GPS, n = 227
IOP + VA + GDx, n = 411
IOP + VA + OCT, n = 306
Not discharged (TP)
IOP + VA + MRA, n = 478
IOP + VA + GPS,  n = 484
IOP + VA + GDx, n = 353
IOP + VA + OCT, n = 451
Not discharged (FN)
IOP + VA + MRA, n = 84
IOP + VA + GPS, n = 86
IOP + VA + GDx, n = 217
IOP + VA + OCT, n = 154
Discharged (FP)
IOP + VA + MRA, n = 222
IOP + VA + GPS, n = 209
IOP + VA + GDx, n = 155
IOP + VA + OCT, n = 202
Not discharged
IOP + VA + MRA, n = 14
IOP + VA + GPS, n = 6
IOP + VA + GDx, n = 6
IOP + VA + OCT, n = 7
Discharged (TN)
IOP + VA + MRA, n = 120
IOP + VA + GPS, n = 141
IOP + VA + GDx, n = 194
IOP + VA + OCT, n = 152
Reference standard definition: not discharged
For referral: imaging (outside normal limits) or 
IOP > 21mmHg or VA 6/18 or poorer
Handling of no result categories: A–D for referral
                   E excluded 
Inconclusive
reference standard
(n = 0)
Discharged
IOP + VA + MRA, n = 15
IOP + VA + GPS, n = 7
IOP + VA + GDx, n = 8
IOP + VA + OCT, n = 3
Inconclusive
reference standard
(n = 0)
Inconclusive
reference standard
(n = 0)
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 21 Flow diagram: triage sensitivity analysis 8. FN, false negative; FP, false positive; TN, true negative;
TP, true positive.
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Discussion
Four composite triage (imaging, IOP measurement and VA assessment) tests were compared with regard to
their diagnostic performance for determining who should be referred for further assessment or discharged
using the GATE population of referrals to a glaucoma clinic in secondary care.
The sensitivity and specificity of the four triage tests incorporating each of the imaging technologies along
with IOP and VA for the default triage analysis and sensitivity analyses (see Table 29 for details) are
summarised in Figures 22 and 23, respectively.
All four triage tests had value in terms of ruling in and ruling out the need for referral on to a consultant
ophthalmologist. The diagnostic performance of the triage tests differed with substantial differences in the
ability to correctly detect those who need to be referred and those who do not. HRT-GPS and HRT-MRA
consistently had the highest sensitivities across analyses but at a cost of lower specificity than other tests.
HRT-GPS had the slightly higher specificity. In contrast, GDx consistently had the best specificity, although
the lowest sensitivity. HRT-GPS results were typically similar to HRT-MRA. OCT generally had similar levels
of sensitivity and specificity. The choice of which triage test is to be preferred reflects the inherent trade-off
regarding diagnostic testing, where the desire to refer onwards when referral is needed must be balanced
again the desire to discharge those who do not need a further assessment. A formal assessment of this
trade-off and the consequences in terms of health outcome and costs is covered in Chapters 6 and 7.
TABLE 39 Diagnostic performance: triage sensitivity analysis 8
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 85.1 81.8 to 87.9
Specificity (%) 35.1 30.0 to 40.4
Positive likelihood ratio 1.31 1.20 to 1.43
Negative likelihood ratio 0.43 0.33 to 0.54
DOR 3.08 2.23 to 4.24
HRT-GPS Sensitivity (%) 84.9 81.7 to 87.8
Specificity (%) 40.3 35.1 to 45.6
Positive likelihood ratio 1.42 1.30 to 1.56
Negative likelihood ratio 0.37 0.30 to 0.47
DOR 3.80 2.78 to 5.19
GDx Sensitivity (%) 61.9 57.8 to 65.9
Specificity (%) 55.6 50.2 to 60.9
Positive likelihood ratio 1.39 1.22 to 1.59
Negative likelihood ratio 0.68 0.60 to 0.79
DOR 2.04 1.55 to 2.67
OCT Sensitivity (%) 72.9 69.1 to 76.5
Specificity (%) 42.9 37.7 to 48.3
Positive likelihood ratio 1.28 1.15 to 1.42
Negative likelihood ratio 0.63 0.53 to 0.76
DOR 2.03 1.53 to 2.68
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FIGURE 22 Summary of the sensitivity of the composite test across all triage analyses. SA, sensitivity analysis.
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FIGURE 23 Summary of the specificity of the composite test across all triage analyses. SA, sensitivity analysis.
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The triage was formed from three components, an imaging test as evaluated in Chapter 4, a measurement
of IOP and VA measurement. The elements were combined in an additive manner where an individual
was referred if any one of the three components met the relevant referral criteria. A number of sensitivity
analyses were carried out to assess the robustness of the findings of this default triage analysis. Varying
the imaging test definition of a positive result by including the borderline category of imaging test result
was carried out; this had the expected impact of improving the detection of glaucoma, although at
the cost of more non-glaucoma cases being falsely identified as having glaucoma. This resulted in very
high detection of glaucoma for HRT-MRA, HRT-GPS and high sensitivities for GDx and OCT but the
consequence of lower specificities (GDx had a higher specificity value than the other three triage tests).
Additionally, the impact of using the classification from the imaging test when the quality criterion was not
met was assessed. The impact was at most a small reduction in sensitivity with an increase in specificity
(only GDx had more than a nominal change in values). The added value of the IOP and VA components
was assessed by dropping one of the components, varying the cut-off point used to define abnormality,
and, for the IOP component, using the referral IOP measurement in place of the ophthalmologist’s.
Removal of the IOP component had a noticeable impact on the diagnostic performance with exclusion
leading to a reduction in sensitivity, although a gain in specificity. Modifying the IOP cut-off value changed
the balance in terms of sensitivity and specificity as expected. When the referral IOP was used in place
of the ophthalmologist’s IOP the specificity was reduced. Such an impact is unsurprising given the known
variability in IOP measurements42 and the use of an absolute cut-off will lead to a regression to the
mean effect when another measurement is taken (in this case by a different observer). Removing the VA
component had very little impact on the diagnostic accuracy with a slight reduction in the sensitivity and
corresponding increase in specificity. This impact may have been limited by the method of data collection
(referral letter quotation) as opposed to complete data capture of a new VA measurement.
A number of assumptions underpinned the analyses and interpretation of these results in addition to those
highlighted previously for diagnoses analyses. The reference standard here was the clinical decision to
discharge or not, which will vary to some degree between individual clinicians and centres according to
policies and practices (perhaps most noteworthy for individuals with glaucoma suspect). Components of
the triage test were combined in an additive manner which reflects an implicit desire to favour sensitivity
over specificity. No other options were assessed, although arguably this approach reflects clinical practice.
The use of the ophthalmologist’s measurement does not reflect the reality of how a triage system would
be implemented where, if a measurement was taken in hospital eye services, it would be by another
individual (e.g. a technician). Using the referral IOP did have a substantial impact, although most if not all
of this impact might be attributed to the inevitable variability between measurements taken at different
times by different observers and the impact of regression to the mean. The finding does suggest there is
value in taking a measurement upon referral to hospital eye services.
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Chapter 6 Economic evaluation methods
The objective of this chapter is to present the economic evaluation of four automated optic nerve andRNFL imaging tests (HRT-MRA, HRT-GPS, GDx and OCT), hereafter referred to as imaging technologies.
These were evaluated in the GATE study as triage diagnostic stations in hospital eye services (secondary
care), compared with current practice, for patients referred to hospital eye services for possible glaucoma.
The triage diagnostic station included an imaging test, a VA test and an IOP measurement.
The model
The cost-effectiveness of the different imaging technologies and their subsequent care management
pathways was assessed using a multistate Markov model. As glaucoma is a chronic condition, which
progresses slowly over time, the model reflects the timing of both diagnostic testing and disease
progression. This approach allowed modelling of the logical and temporal sequence of events
(e.g. diagnosis or monitoring visits) following the initial diagnostic strategy.
Typically, Markov models have states (Markov states) in which individuals stay for a period of time called
a ‘cycle’. The cycle must be a period relevant to the condition considered (e.g. 6 months, 1 year). At the
end of each cycle, individuals can remain in the state in which they started the cycle or move to a different
state. The probabilities of moving from one state to another are called transition probabilities. In each
state, the model will assign costs and benefits for each individual according to different interventions
and/or time spent in the state. In these models, there must be at least one absorbing state, typically death,
from which the individual will not be able to leave. The sum of the cost in each year and the product of
the utilities in each year were summed over 50 years of the simulated patient cohort to compute total cost
and quality-adjusted life-year (QALY) for that cohort.
The purpose of this model was to compare and contrast different imaging technologies (used as part of a
wider triage station) for the identification of patients who should be referred for a clinician-led diagnostic
examination. We can thus compare and contrast these with standard care where all patients receive a
clinician-led diagnosis based on clinical examination and visual field assessment (automated perimetry). The
model was constructed such that different sensitivities and specificities of each diagnostic strategy would
determine if glaucoma was correctly identified or not, the health state patients would move to and the
associated progression of any underlying glaucoma. The consequences could then be considered in terms
of the monetary costs (of testing and subsequent management of the patient’s condition) to the NHS and
in terms of the effects on quality of life (by assigning utility weights). Combining these data with
information of the probabilities of events occurring over time-enabled cost, patient outcomes and QALYs
to be estimated for a hypothetical cohort of patients undergoing each triage strategy.
The results of the model are presented in Chapter 7 and are presented as incremental cost per QALYs
and incorporate (1) costs (of testing) and diagnostic outcomes, (2) costs (of testing and subsequent
management) and (3) QALYs.
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Figure 24 shows the possible health states in ovals, while the arrows show the possible directions in which
individuals can move at the end of each cycle, depending on the transition probabilities. The states
considered in the model were those thought to reflect possible paths for individuals classified as normal,
at risk of glaucoma or suffering from glaucoma at different stages (see Figure 24). Each state, other than
normal and death, is divided into two categories. The treated states on the right-hand side of Figure 24
represent those individuals whose condition has been identified and is being treated, and the untreated
states on the left-hand side represent those individuals whose condition has not yet been identified and
thus who are not receiving treatment. The treatment health states refer to treated disease at each stage of
glaucoma. The modality of treatment, IOP-lowering eye drops, laser or surgery or any combination thereof,
is not specified for a glaucoma-related treatment state. A treatment state refers to any modality or
combination treatment for each stage of glaucoma severity. There are three treatment states for the three
stages of manifest glaucoma and a treatment state for sight impairment. The ‘at risk of glaucoma’
treatment state includes those individuals who are suspected of having glaucoma and those who have
OHT and PAC. Among the ‘at risk of glaucoma’ group, we have assumed that all patients with OHT will be
treated in the same way and that treatment incorporates annual outpatient appointments for observation,
with all OHT individuals receiving continuous latanoprost (eye drops, once a day).
Depending on their underlying condition, individuals will start in the model in a normal state, an untreated
‘at risk of glaucoma’ state or an untreated glaucoma disease state (mild, moderate, severe or sight
impaired). Each individual will then enter a diagnosis process that will differ according to the compared
strategies used to diagnose their condition (i.e. for current practice in the form of consultant-led diagnosis
and care or a triage station including one of the imaging technologies under consideration; see Figure 24).
The sensitivity and specificity of each diagnostic strategy determine the Markov state an individual will
move to. In particular, it will determine if an individual enters a treated or untreated disease state and the
possible transitions associated with these. In general, as time passes, the normal or ‘at risk of glaucoma’
individuals could develop glaucoma, while those with glaucoma could progress to a more severe disease
state until they eventually become visually impaired.
Normal
At risk of
glaucoma
At risk of
glaucoma
Mild
glaucoma
Mild
glaucoma
Moderate
glaucoma
Moderate
glaucoma
Severe
glaucoma
Severe
glaucoma
Sight
impaired
Sight
impaired
DeathTreatedUntreated
FIGURE 24 Schematic diagram of model states and possible transitions.
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Glaucoma is not reversible and this is reflected in the model (see Figure 24). However, individuals can
return to a normal state after a number of model cycles within the ‘at risk of glaucoma’ Markov state.
The absorbing state in the model is death. Any individual can move into this state from any other state
in the model.
The model allows for a cohort of the population, some with glaucoma, to pass through different diagnostic
strategies. The intuitive idea behind the model is to identify the strategy that leads to the largest proportion
of individuals with glaucoma being correctly diagnosed and being in treatment to reduce disease
progression and visual loss.
Definition of health states used in the model
Glaucoma states were defined in terms of severity of disease, namely mild, moderate and severe glaucoma,
and sight impaired. The agreed glaucoma severity definitions used for the GATE study data collection were
used for the economic model (Table 40). Furthermore, an additional disease state defined as ‘at risk of
glaucoma’ was included in the model to represent those individuals who do not have manifest glaucoma
but have a higher risk of developing glaucoma (glaucoma suspects, those with OHT and those with PAC).
TABLE 40 Definition of health states for the economic evaluation
Health state Definition
‘At risk of glaucoma’ health state: glaucoma suspect, OHT or PAC
Glaucoma suspect Either the optic disc or VF, or both, have some features that are suggestive of glaucoma
but may also represent a variation of normality (with or without high IOP)
OHT Both the VF and optic nerve appear normal in the presence of elevated pressure > 21mmHg
PAC Closed anterior chamber angle (appositionally or synechial) in at least 270°, and at least one
of the following: IOP > 21mmHg and/or presence of peripheral anterior synechiae.
Both VF and optic nerve appear normal
‘Glaucoma’: different health states according to MD index of the VF test
‘Mild glaucoma’ Evidence of glaucomatous optic neuropathy and a characteristic VF loss. MD better than or
equal to –6 dB
‘Moderate glaucoma’ Evidence of glaucomatous optic neuropathy and a characteristic VF loss. MD between
–6.01 dB and –12 dB
‘Severe glaucoma’ Evidence of glaucomatous optic neuropathy and a characteristic VF loss. MD worse than or
equal to –12.01 dB
‘Sight impaired’ health state: sight impaired and severely sight impaired
Sight impaired Poor VA (3/60 to 6/60) with full field of vision; or slightly reduced VA (up to 6/24) and
reduced field of vision or blurriness/cloudiness in central vision; or relatively good VA
(up to 6/18) but significantly reduced field of vision
Severely sight impaired Very poor VA (less than 3/60) with full field of vision; or poor VA (between 3/60 and 6/60)
and severely reduced field of vision; or slightly reduced VA (6/60 or better) and significantly
reduced field of vision
VF, visual field.
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Description of the health-care diagnostic strategies and
management pathways considered within the model
The care pathways modelled within the Markov model following diagnosis were developed in consultation
with the study team and the independent steering committee members. The main study team for this
element of the work comprised two ophthalmologists (AA-B, JB), and three health economists (RH, PM, JG),
and a health services researcher (KB). Over a number of meetings, the group mapped out the sequence of
events for patients potentially eligible for treatment or monitoring following the diagnostic strategies under
consideration. Additional information came from our previous models in this area, notably our model
comparing alternative screening strategies for OAG18 reviewed guidelines and expert opinion. These care
pathways were then presented to the steering committee and revised to reflect the comments received.
Current practice care pathway
Patients enter the model as a cohort who have been identified with signs of, for example possible
glaucoma or OHT by a community optometrist or GP and who have been referred to secondary care.
Within hospital eye services, all individuals will see a nurse, who will perform a VA examination, and a
technician, who will perform a visual field test. All individuals will then see a clinician (typically an
ophthalmologist), who will measure IOP (using GAT), look at the visual field results and perform a fundus
examination to examine the optic disc and the posterior retina. Figure 25 shows the care pathway.
Considering all the clinical information, the clinician will decide on a diagnosis as described in Chapter 2.
For the purpose of the model, these diagnoses have been grouped into five health states (described further
in Table 40): mild glaucoma, moderate glaucoma, severe glaucoma, at risk of glaucoma and normal.
Furthermore, the ‘at risk of glaucoma’ health state includes those with a diagnosis of OHT or glaucoma
suspect or PAC.
Individuals who are diagnosed by the clinician to be in the normal health state are discharged from
secondary care. Individuals diagnosed with glaucoma remain in secondary care under treatment and enter
the relevant glaucoma-treated health state. Individuals diagnosed as ‘at risk of glaucoma’ also remain in
secondary care and enter into the ‘at risk of glaucoma’ treatment state. The subset of ‘at risk of glaucoma’
patients with OHT are all assumed to be undergoing treatment.
Diagnosis at HESsReferral for possible
glaucoma
Normal
At risk of glaucoma
Glaucoma
Nurse: VA
Technician: VF
Clinician: 
     IOP
     Fundus exam
     VF results
Clinician
diagnosis
Normal
At risk of glaucoma
Glaucoma
FIGURE 25 Care pathway: current practice. HES, hospital eye service; VF, visual field.
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Triage care pathway
As described in Chapter 2, the triage pathway used IOP, imaging and VA to identify patients who could
be discharged from secondary care if all tests were normal. IOP and VA are routinely collected in primary
and/or secondary care and used to inform the clinical decision-making process as to whether to discharge
a patient or not. At hospital eye services the individuals will be seen by a nurse that will perform VA
examination and IOP measurement. They will also be seen by a technician who will perform the index
(imaging) test (HRT-MRA, HRT-GPS, GDx or OCT depending on triage strategy). Figure 26 shows the care
pathway for the triage strategies.
The results of these three examinations are combined into a composite triage test result as follows. If any
of the VA or IOP or imaging test results is abnormal, then the composite test is assumed to be positive or
abnormal. Only if all three tests (VA, IOP and imaging test) are normal is the composite test result negative
or normal. Individuals with normal (negative) composite triage test results are discharged from secondary
care. Individuals with abnormal (positive) test results are referred to the clinician to make a diagnosis.
Definitions of abnormal (positive) test results for the elements of the composite test are as follows:
IOP> 21mmHg, VA 6/12 or worse, imaging technology classification abnormal or borderline.
Individuals who have been discharged with normal (negative) composite triage test results can be either
truly normal (true negative) or have been incorrectly diagnosed as normal when they do in fact have
disease (false negative). Individuals with an abnormal (positive) composite triage test result are then
referred to the clinician, who will make a definitive diagnosis. Perfect information by the clinician is
assumed in the model; therefore, individuals will be correctly identified as having glaucoma (e.g. mild,
moderate, severe or visually impaired), as being at risk of glaucoma or without any of these conditions
(e.g. normal). Normal individuals are discharged while all others are kept under monitoring or observation.
The perfect information assumption is explored in sensitivity analysis with the possibility of misdiagnoses by
the clinician (e.g. false-positive and false-negative results).
Referral for possible
glaucoma
1. Triage station at HESs
2. Diagnosis at HESs for those referred
Normal
At risk of glaucoma
Glaucoma
Technician: VF
Ophthalmologist: 
     IOP
     Fundus exam
     VF results
Nurse: VA and IOP
Technician: imaging
Composite triage test Composite test
normal
Composite test
abnormal
Discharged
Refer on to clinician
for diagnosis (see 2 below)
Clinician
diagnosis At risk of glaucoma
Glaucoma
Normal – discharged
FIGURE 26 Care pathway: triage strategies. HES, hospital eye service; VF, visual field.
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Model strategies
Five diagnostic strategies are explicitly considered in the model (see Table 41). The comparator in the model
reflects the current practice. In this strategy, all patients referred to secondary care for possible glaucoma
see a clinician for diagnosis of their condition.
Four diagnostic imaging technologies (HRT-MRA, HRT-GPS, GDx, OCT) used as part of a composite triage
test which includes an assessment of IOP and VA are evaluated within the model. The diagnostic strategies
and associated care pathways used in the economic model are summarised in Table 41.
Estimation of parameters used within the model
This section summarises the parameter values used in the economic evaluation model.
Data regarding the cohort in terms of prevalence, incidence and progression are reported first, followed by
diagnostic triage test performance data, with subsequent sections regarding data on cost and utilities
also reported.
Cohort data: prevalence, incidence and progression data
Table 42 shows data on prevalence, incidence and progression of glaucoma used in the model.
Prevalence data and proportion of glaucoma subjects by severity of disease were based on the GATE study
population (see Chapter 3). Incidence data and progression data as well as relative rate of progression
between treated and untreated individuals were obtained from previous models of glaucoma management
and surveillance.18,42,43 The annual probability of having an eye test was informed by Burr et al.,18 who
used data on eye test, sex and age from the British Household Panel Survey45 to estimate the annual
probabilities in different age groups of having an eye test by a community optometrist. We used the
average of two probabilities estimated in the report, 0.248 per year for those in the 40–59 years range
and 0.3769 per year for those in the 60–75 years age range, to give 0.312 visits per year.
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Test performance data
Table 43 shows data on the test performances of each of the triage strategies that incorporated the
different diagnostic technologies plus IOP and VA measurement and the current strategy in the form of
clinician diagnosis. Although the imaging technology is used to define the strategy, all performance
measures are calculated based on a composite test result which combines imaging, IOP and VA test results
(see Appendix 6).
For current clinical practice, diagnosis by a clinician was assumed to be 100% sensitive and specific.
The remaining composite test performances for detecting glaucoma, ‘at risk of glaucoma’ and normal
individuals were informed by statistical analysis of the GATE study specifically carried out to inform the
economic model. Triage accuracy data for the four triage strategies (e.g. sensitivity and specificity) were
calculated for glaucoma, ‘at risk of glaucoma’ and normal groups (see Appendix 6).
Estimation of costs used within the model
All costs were estimated based on resource-use inputs and unit costs for the 2012–13 financial year and
are reported in UK pounds sterling. With the exception of treatment costs, which were taken from the
literature, costs included in the model were estimated using a micro-costing exercise or using NHS
Reference Costs.22 The data used in this exercise were then subsequently checked by the steering
committee members. Specific costs to the NHS relevant to the diagnostic strategies, subsequent treatment
pathways and events included diagnostic imaging, staff time, treatment, equipment and capital costs. With
the exception of capital costs, which were sourced from specific commercial providers, most unit costs
were sourced from NHS Reference Costs,22 Unit Costs of Health and Social Care46 and Agenda for Change.47
Where costs were not reported in 2012–13 values, they were inflated by the Hospital and Community
Health Sector inflation index.46
TABLE 42 Cohort data: prevalence, incidence and progression
Probability Value Source
Cohort start age (years) 40 Base-case assumption
Prevalence of glaucoma 0.17 GATE study
Proportion of normal 0.412 GATE study
Prevalence of ‘at risk of glaucoma’ 0.418 GATE study
Proportion of mild glaucoma 0.523 GATE study
Proportion of moderate glaucoma 0.302 GATE study
Proportion of severe glaucoma 0.174 GATE study
Progression to mild glaucoma from
‘at risk of glaucoma’
0.002 Expert opinion from clinical experts
in the research team (AA-B and JB)
Progression to moderate glaucoma 0.129 Burr et al. 201443
Progression to severe glaucoma 0.048 Burr et al. 201443
Progression to sight impaired 0.042 Burr et al. 201443
Reduction in risk of progression from any
medical treatment for glaucoma
0.65 Burr et al. 201443
Mortality Various Interim life tables44
Incidence of glaucoma
50 years old 0.0003 Burr et al. 200718
60 years old 0.0008 Burr et al. 200718
70 years old 0.00181 Burr et al. 200718
80 years old 0.00414 Burr et al. 200718
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All capital costs for each of the diagnostic imaging technologies were costed using current market prices
obtained from various commercial providers to the NHS (see explanations below in the Costs of diagnosis
pathway: triage strategies section). These initial outlay costs were annuitised over the useful working
lifespan of the piece of equipment (assumed to be 10 years for all equipment) applying an annual discount
factor of 3.5%47 to account for the opportunity cost of the investment over time.
The equivalent annual cost of each piece of equipment was divided by its estimated maximum number of
uses per annum (from NHS providing units and expert opinion) to give cost per use estimates.
Tables 44–46 show the cost estimates used in the model for diagnosis by current practice, diagnosis by the
triage strategies and treatment costs.
TABLE 43 Accuracy parameters of the triage test used in the model
Probability Value Source
Sensitivity for all glaucoma individuals
HRT-MRA 0.99 GATE study
HRT-GPS 0.99 GATE study
GDx 0.88 GATE study
OCT 0.97 GATE study
Sensitivity for all ‘at risk of glaucoma’ individuals
HRT-MRA 0.97 GATE study
HRT-GPS 0.97 GATE study
GDx 0.77 GATE study
OCT 0.87 GATE study
Specificity for all normal individuals
HRT-MRA 0.30 GATE study
HRT-GPS 0.28 GATE study
GDx 0.51 GATE study
OCT 0.35 GATE study
Sensitivity and specificity of current practice (diagnosis by an ophthalmologist) for all individuals
(glaucoma, ‘at risk of glaucoma’ and normal)
Sensitivity 1 Assumption
Specificity 1 Assumption
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TABLE 44 Costs of current practice diagnosis used in the model
Costs Value (£) Source
Nurse-led VA test 2.45 Agenda for Change47
Technician VF test 2.72 Agenda for Change47
Ophthalmology first outpatient appointment 106 NHS Reference Costs22
VF, visual field.
TABLE 45 Costs of triage strategies used in the model
Costs Value (£) Source
Triage appointment costs
Nurse-led VA and IOP test 2.45 Agenda for Change47
Technician-led index test (e.g. OCT, GDx or HRT) 2.72 Agenda for Change47
Capital cost OCT diagnostic technology 1.32 Micro-costed
Capital cost of HRT-III (GPS and MRA) and
GDx diagnostic technologies
0.79 Micro-costed
Appointment costs for those triaged and referred to the clinician
Technician VF test 2.72 Agenda for Change47
Ophthalmology first outpatient appointment 106 NHS Reference Costs22
VF, visual field.
TABLE 46 Annual cost of treatment
Costs Value (£) Source
Glaucoma-related treatment costs
Glaucoma mild treatment 499.80 Burr et al. 200718
Glaucoma moderate treatment 562.87 Burr et al. 200718
Glaucoma severe treatment 447.44 Burr et al. 200718
Sight impaired annual cost 796.11 Burr et al. 200718
‘At risk of glaucoma’ state treatment costs
Multiprofessional follow-up ophthalmology
outpatient appointment
87.00 NHS Reference Costs22
Latanoprost 23.64 British National Formulary49
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Costs of diagnosis pathway: current practice
The costs of the current practice diagnostic pathway are presented in Table 44. At hospital eye services, all
individuals see a nurse, who will perform a VA examination, and a technician, who will perform a visual
field test. It was assumed that the VA test would take 10 minutes of a band 5 (mid-point scale) nurse’s
time and the visual field test would take 15 minutes of a band 3 (mid-point scale) technician’s time. The
unit costs for these were taken from Agenda for Change47 and inflated to 2012–13 prices. All individuals
will then see a clinician, and the cost of this was based on the NHS Reference Cost (HRG WF01B) of a first
consultant-led ophthalmology outpatient appointment.
Costs of diagnosis pathway: triage strategies
The costs of the GATE triage diagnostic strategies are specified in Table 45. All individuals will see a nurse, who
will perform a VA and an IOP test. It was assumed that this would take 10 minutes of a band 5 (mid-point
scale) nurse’s time. All patients would then go on to have one of the four index tests (diagnostic technologies).
We assumed that these imaging tests would be performed by a band 3 technician (mid-point scale) and would
take 15 minutes of staff time. As stated previously, the unit costs of staff time were calculated from Agenda for
Change46 and inflated to 2012–13 values.
The capital costs for the UK for the OCT Spectralis® (Heidelberg Engineering, Heidelberg, Germany) and
HRT-III diagnostic imaging technologies and associated installation and maintenance costs were obtained
from Heidelberg Engineering Ltd (www.HeidelbergEngineering.co.uk) (Tosh Vadhia, Regional Business
Manager – South, 2013, personal communication). These initial outlay costs were annuitised over the
useful working lifespan of the piece of equipment (assumed to be 10 years for all equipment) applying an
annual discount factor of 3.5%47 to account for the opportunity cost of the investment over time. The
equivalent annual cost of each piece of equipment was divided by its estimated maximum number of uses
per annum (from NHS providing units and expert opinion) to give cost per use estimates. The expected
number of uses per annum was based on 253 working days per year, with each use taking a 15-minute
slot over a 7.5 hour working day. This assumption was based on information provided by Moorfields Eye
Hospital NHS Foundation Trust (Edward White, Chief Ophthalmology Technician, 2013, personal
communication). During the course of the study, we were unable to obtain data on capital cost of the GDx
diagnostic technology. As such, we assumed that, because of the competitive nature of the pricing from
suppliers to the NHS, this technology had the same capital, installation and associated maintenance
contract costs as the HRT-III machine.
In each triage diagnostic strategy, patients who were diagnosed with a positive composite test result were
referred for a first consultant-led ophthalmology outpatient appointment, the cost of which was based on
NHS Reference Costs (HRG WF01B).22 This outpatient visit would also involve visual field testing by a
technician (costs as for the standard care strategy detailed above). Thereafter, those who were identified
by the ophthalmologist as being normal were then assumed to be discharged from secondary care.
Costs of treatment
Table 46 shows costs of treatment, which are separated into two distinct categories: those related to
glaucoma-related states (mild, moderate, severe and sight impaired) and those for the ‘at risk of
glaucoma’ state.
The costs of treating the glaucoma-related states (mild, moderate, severe, sight impaired) were taken from
a related study18 and inflated to 2013–14 prices. The authors used costs estimates based on the study of
Traverso et al.,50 which was a Europe-based study and includes data for the UK by severity of glaucoma.
Treatment costs related to the ‘at risk of glaucoma’ state (i.e. individuals who are glaucoma suspects or
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diagnosed with OHT) were based on a number of assumptions and expert opinion and were micro-costed
to get an average annual cost per patient. It was assumed that all individuals in the ‘at risk of glaucoma’
state would be given an annual multiprofessional follow-up ophthalmology outpatient appointment, the
cost of which was taken from NHS Reference Costs (WF02 A).22 Furthermore, it was assumed that all
individuals with OHT would be treated (based on advice from our expert advisory group) with latanoprost
for the rest of their lives or until their condition progressed, with annual costs of £23.64.49
Estimation of utilities used within the model
Quality-adjusted life-years are calculated by weighting life-years with utility values, to reflect individuals’
preferences for the health-related quality of life that they experience. There are various methods and tools
that can be used to elicit utility values. NICE recommends, in its methods guide,48 the use of the European
Quality of Life-5 Dimensions (EQ-5D).
Previous research by members of the study team used the EQ-5D to value quality-of-life states for those
with mild, moderate or severe glaucoma and sight impaired and these data were used in the model
to value time in these health states. The EQ-5D 3 Level data were obtained from responses from
640 participants with OHT and glaucoma sampled from a secondary glaucoma service.42 Similar to the
study by Burr et al.,42 who suggested that the degree of visual impairment for mild glaucoma is minimal,
it was assumed that the score for those individuals in the ‘at risk of glaucoma’ state would be the same as
the score for those with mild glaucoma. Table 47 shows the utility weights used in the model.
Validation of the model
Our model was developed from that successfully used by Burr et al.18 Developing the model from a
pre-existing model meant that much of the structure had been previously validated. However, this
approach also meant that there was no scope to make methodological changes to the way the previous
model was implemented. Therefore, the Markov model was developed in TreeAge (TreeAge Software, Inc.,
Williamstown, MA, USA) 2013 using the same core structures and transition probabilities as Burr et al.18
TreeAge is a frequently used tool for the type of model used in the economic evaluation and allows the
documentation of our model and simplifies its use by other researchers.
To validate the model structure where changes were made to that of Burr et al.,18 a simple Markov model
was developed in R (The R Foundation for Statistical Computing, Vienna, Austria) in order to make
comparisons with the model developed in TreeAge.
TABLE 47 Utility weights used in the model
Health state Utility weight Source/note
Normal 1 Assumption
Mild glaucoma 0.8371 Burr et al. 201242
Moderate glaucoma 0.7919 Burr et al. 201242
Severe glaucoma 0.7156 Burr et al. 201242
Sight impaired 0.5367 Burr et al. 201242
At risk of glaucoma 0.8371 Assumed equal to glaucoma
mild individuals
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Base-case analysis
The base-case analysis was run for a cohort of 40-year-old males. Although the choice of this start age
was arbitrary, it was felt that it covered the range over which diagnostic strategies for glaucoma might be
considered, and would cover most of prevalent cases of glaucoma, which is an age-related disease.
Sex-specific variables were not available for any of the model parameters except for mortality, and a
decision was made to use male mortality rates in the base-case analysis, consistent with good modelling
practice, as they are a conservative assumption for this enhanced case detection study. The model was run
for a range of possible prevalence values and for a 50-year time horizon. Cycle length was set at 1 year.
Costs are presented in 2012–13 UK pounds sterling and effectiveness in QALYs. A discount rate of 3.5%
for costs and benefits was used following guidelines for technology assessment by NICE.48 The results are
presented in incremental cost-effectiveness ratios (ICERs). This measure is a ratio of the difference in costs
divided by the difference in the effectiveness between two alternative strategies. These data can be
interpreted as how much society would have to pay for an extra unit of effectiveness. Central to the
assessment of cost-effectiveness is the value that society would put on gaining an additional QALY. NICE
states that ‘Below a most plausible ICER of £20,000 per QALY, judgements about the acceptability of a
technology as an effective use of NHS resources are based primarily on the cost-effectiveness estimate.’48
Between £20,000 per QALY and £30,000 per QALY, judgements about the acceptability of the technology
should take into account factors such as
l the degree of uncertainty surrounding the calculation of ICERs
l the innovative nature of the technology
l the particular features of the condition and population receiving the technology
l where appropriate, the wider societal costs and benefits.
Above an ICER of £30,000 per QALY, the case for supporting the technology on these factors has to be
increasingly strong.47 In the absence of a more definitive statement this report focuses on a willingness-to-pay
threshold of £30,000 for a QALY.
Sensitivity analysis
We addressed uncertainty by conducting deterministic (e.g. one-way) sensitivity analyses. In consultation
with the independent advisory group, the following deterministic sensitivity analyses were considered:
1. The base-case analysis assumed that the annual probability of having an eye test is 31.2%. All patients
who are discharged by the diagnosing clinician or discharged by the triage station for the triage
strategies would therefore be expected to be picked up in the community and would return to the
secondary care triage station approximately every 3 years. In this analysis, based on clinical opinion,
the impact of changing this probability and thus the diagnostic screening interval within a range of
1–10 years inclusive was explored.
2. In the base case, the diagnostic triage strategies were micro-costed and included staff time and capital
costs of the diagnostic technologies. However, owing to the relatively large cost differential of these
triage strategies compared with current practice, it was deemed appropriate to explore the effects on
cost-effectiveness of introducing an NHS Reference Cost for a non-consultant-led first outpatient
appointment (£85) to the costs of the triage strategies. This was further varied from £10 to £85 in
£5 intervals to explore if this changed either the diagnostic strategies that were deemed cost-effective
or the magnitude of effect.
3. The base-case analysis included a cohort of men with an age of 40 years to be modelled for 50 years.
The impact of modelling older cohorts of men was explored by varying the start age from 45 to
70 years in 10-year intervals.
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4. The base-case analysis was conducted on the basis that all glaucoma patients and those at risk of
glaucoma (including glaucoma suspects, OHT and PAC) would be monitored and treated depending on
their definitive diagnosis. It was discussed and agreed in a meeting between the study team and the
independent steering committee that there was a need to explore the effects of a hypothetical
secondary care service where those patients diagnosed as ‘at risk’ would be discharged from the
service, thus potentially reducing the diagnostic, monitoring and/or treatment costs.
5. The base-case analysis assumed that clinicians were 100% sensitive and specific in their diagnosis of
patients. The sensitivity and specificity was varied between 0.85 and 1 to explore the impact for
patients who would not always being seen in secondary care by an ophthalmologist with glaucoma
expertise and thus having 100% diagnostic accuracy.
6. A threshold analysis was conducted in order to explore the impact of increasing the costs of the triage
strategies and discharging those patients that are given a diagnosis of ‘at risk of glaucoma’.
7. The base-case analysis incorporated point estimates for the sensitivities and specificities of each of the
imaging technologies that were estimated from the GATE study. We varied sensitivity and specificity of
each triage strategy to create a best-case diagnostic scenario (+ 10% sensitivity and + 5% specificity)
and a worse-case diagnostic scenario (–10% sensitivity and –5% specificity) for each of the imaging
technologies as shown in Table 48 to explore the impact on the ICERs. These values were decided on
by the research study team on the basis of variations in the CIs in the base-case analysis.
8. The base-case analysis assumed the prevalence of glaucoma in the referred population, which was
estimated from the GATE study. However, no referral refinement schemes were in place during the
GATE study. Other measures to improve the accuracy of glaucoma referrals are constantly being
explored, with a reduction in false-positive rates. The impact of adding an imaging-based composite
triage system to a referred population with lower false-positives rates was explored by decreasing the
proportion of normal diagnoses in the cohort from 0.412 to 0.212 and increasing the glaucoma
prevalence from 0.17 to 0.27 and the ‘at-risk’ group from 0.418 to 0.518.
9. The base-case analysis assumed that the utility weights for the ‘at-risk’ health state were the same as
mild glaucoma in the absence of literature addressing this issue. We explored the impact of a utility
weight for the ‘at-risk’ health state being the same as normal health state.
TABLE 48 Alternative best case and worse case sensitivity and specificity values used to explore uncertainties in
point estimates
Technology ‘Glaucoma’ sensitivity ‘At-risk’ sensitivity ‘Normal’ specificity
HRT-MRA
Base case 0.99 0.97 0.3
Best case 1 1 0.35
Worst case 0.89 0.87 0.25
HRT-GPS
Base case 0.99 0.97 0.28
Best case 1 1 0.33
Worst case 0.89 0.87 0.23
GDx
Base case 0.88 0.77 0.51
Best case 0.98 0.87 0.56
Worst case 0.78 0.67 0.46
OCT
Base case 0.97 0.87 0.35
Best case 1 0.97 0.4
Worst case 0.87 0.77 0.3
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Chapter 7 Economic evaluation results
This chapter reports the results of the cost–utility analysis for four alternative triage strategies thatincorporate each of the imaging tests evaluated in the GATE study (combined with IOP and VA data) to
identify appropriate referrals to hospital eye services, compared with current practice, which is that all
referred patients undergo assessment and diagnosis by a clinician in hospital eye services. Expected cost
and expected QALYs, as well as ICERs, are presented for the base-case analysis and for sensitivity analyses
conducted to explore uncertainties. Unless stated, ICERs are reported against the next least costly
non-dominated strategy.
Base-case analysis
The base-case analysis was conducted for a cohort of male patients with a starting age of 40 years, who
were assumed to have an eye test approximately once every 3 years, and clinicians in hospital eye services
were assumed to have perfect diagnostic ability. Table 49 shows the cost-effectiveness results for the
base-case analysis. All triage strategies were less costly than the current strategy, but the triage strategies
resulted in fewer expected QALYs than the current strategy when a perfect diagnosis by the clinician was
assumed. Triage with GDx was the strategy with lowest expected cost, followed, in order, by triage with
OCT, HRT-MRA and HRT-GPS. Triage with OCT was extendedly dominated (i.e. a combination of triage
with GDx or HRT-MRA could, in theory, produce more QALYs at lower expected costs than triage only
with OCT alone). Triage with HRT-GPS strategy was dominated by HRT-MRA (i.e. HRT-GPS was more costly
but did not produce more QALYs than HRT-MRA). This is further illustrated in Figure 27.
Incremental cost-effectiveness ratios were calculated for all non-dominated strategies. The ICER reported
for current practice (£156,985) represents the comparison between HRT-MRA and current practice. It
should be noted that the interpretation of this ICER is slightly different from the usual case. In moving
from current practice to HRT-MRA, savings would be expected, but at the expense of lost QALYs.
The usual willingness-to-pay threshold value for an additional QALY has been stated to be around £30,000
for the UK.47 However, it is not clear what decision rule should be applied when resources are saved in
exchange for fewer QALYs. One possible interpretation is that of a similar threshold (e.g. £30,000 saved at
the expense of a QALY), and this has been adopted in this chapter. Therefore, with this interpretation,
adopting a triage with HRT-MRA strategy would be worthwhile (e.g. resources would be freed and could
be used elsewhere in the health-care system to obtain QALYs at the threshold value of £30,000
per QALY).
TABLE 49 Incremental cost-effectiveness ratios: base case
Intervention Cost (£) QALYs ICER
GDx 2791 19.7701 –
OCT 2917 19.7746 Extendedly dominateda
HRT-MRA 2952 19.7771 22,904
HRT-GPS 2961 19.7771 Dominatedb
Current practice 3084 19.778 156,985
a Extendedly dominated: a combination of a less costly and less effective intervention and a more costly and more
effective intervention would be more efficient.
b Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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As shown in Figure 27, the results show that GDx is the least costly, least effective strategy and that OCT is
extendedly dominated by GDx and HRT-MRA. This means that if it was possible to provide a mix of GDx
and HRT-MRA, then a combination of provision of these two strategies would be dominant. Therefore, in
economic evaluation we can disregard OCT from further consideration. In considering if it is worthwhile
providing HRT-MRA in preference to GDx, we refer to the ICER. Relative to GDx, the ICER of HRT-MRA is
£22,904 and is below the typical £30,000 value considered to be cost-effective in the UK.48 In other
words, moving from a triage strategy with HRT-MRA to GDx would save only £22,904 but at the expense
of a QALY. Given the £30,000 threshold, any saved resources would not be sufficient to allow the QALY
lost to be regained elsewhere.
Sensitivity analyses
A number of sensitivity analyses were performed as described in the methods (see Chapter 6).
Changes to the annual probability of having an eye test
The base-case analysis assumed that the annual probability of having an eye test by a community
optometrist is 31.2%. All patients who are discharged by the diagnosing clinician, or by the triage station
for the triage strategies (false negatives), would therefore be expected to be picked up in the community
and subsequently referred back to the triage station at hospital eye services approximately every 3 years.
We assumed that the community optometrist would identify a potential abnormality and subsequently
refer the patient back to hospital eye services. In this sensitivity analysis, the impact of changing the annual
probability of attending a community optometrist was explored. The annual probability was varied from
10% to 100% inclusive, corresponding to a return period decreasing from 10 years to 1 year. Note that,
as the annual probability increases, the time to return to community optometrist decreases. As shown in
Table 50, as the annual probability increases, both costs and QALYs increase but the savings realised (at
the expense of a QALY) decrease. For instance, for HRT-MRA changing from a 20% probability (once every
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FIGURE 27 Base-case cost-effectiveness analysis results.
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TABLE 50 Incremental cost-effectiveness ratios for the cohort of 40-year-old males by varying annual probabilities
of having a community optometrist eye test
Probability (%) Strategy Cost (£) QALYs ICER
10 GDx 1853 19.7253 –
OCT 1960 19.7295 25,407
HRT-MRA 1989 19.7313 15,503
HRT-GPS 1992 19.7313 Dominateda
Current practice 2038 19.7320 71,187
20 GDx 2451 19.7527 –
OCT 2564 19.7165 Dominateda
HRT-MRA 2596 19.7596 20,876
HRT-GPS 2602 19.7596 Dominateda
Current practice 2684 19.7604 106,392
30 GDx 2763 19.7686 –
OCT 2886 19.7731 27,427
HRT-MRA 2921 19.7756 13,738
HRT-GPS 2930 19.7756 Dominateda
Current practice 3048 19.7765 150,869
40 GDx 2972 19.7794 –
OCT 3111 19.7837 32,321
HRT-MRA 3149 19.7862 15,635
HRT-GPS 3162 19.7862 Dominateda
Current practice 3317 19.7870 208,159
50 GDx 3134 19.7873 –
OCT 3292 19.7913 39,267
HRT-MRA 3335 19.7936 18,788
HRT-GPS 3350 19.7936 Dominateda
Current practice 3543 19.7943 282,447
60 GDx 3271 19.7932 –
OCT 3449 19.7969 48,375
HRT-MRA 3497 19.7990 23,231
HRT-GPS 3516 19.7990 Dominateda
Current practice 3746 19.7996 377,466
70 GDx 3393 19.7978 –
OCT 3593 19.8012 59,823
HRT-MRA 3647 19.8030 29,027
HRT-GPS 3668 19.8030 Dominateda
Current practice 3937 19.8036 495,605
80 GDx 3505 19.8015 –
OCT 3728 19.8045 73,741
HRT-MRA 3788 19.8061 36,177
HRT-GPS 3813 19.8061 Dominateda
Current practice 4119 19.8067 637,178
continued
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5 years) to 10% (once every 10 years), savings (at the expense of a QALY) decreased from £106,392 to
£71,187. This is driven by a reduction in costs of the current practice and, since glaucoma progresses
relatively slowly, there is only a small reduction in QALY for missed cases. Therefore, any reduction in total
QALYs is more than offset by a reduction in costs.
Regardless of the annual probability of having an eye test, HRT-GPS is always dominated as this strategy is
always more expensive and less effective than HRT-MRA. Moreover, when a higher proportion of the
cohort comes back every year, it is less clear which triage strategy should be adopted. The extreme case is
for the cohort to come back every year (100% annual probability), in which case adopting a triage strategy
with HRT-MRA would represent savings of £983,958, but moving from HRT-MRA to OCT and from OCT
to GDx would account for savings of £54,140 and £108,907, respectively, but at the expense of a QALY.
Therefore, at a willingness-to-pay threshold value of £30,000 per QALY, GDx-based triage should be
adopted. It should be noted that this is an extreme example.
Changes in the costs of the triage strategies
The costs of the triage strategies included in the base-case analysis were estimated on the basis of a
bottom-up approach to costing and were therefore micro-costed. Owing to the relatively large cost
differential between the triage strategies and current practice and that NHS secondary care providers charge
for a non-consultant-led outpatient appointment, the effects of introducing an NHS Reference Cost for a
non-consultant-led first outpatient appointment (£85) was explored.22 The results are presented in Table 51.
These data suggest that increasing the cost of the triage strategies by including a NHS Reference Cost
renders all strategies dominated by current practice. On the basis of this result, a threshold analysis was
performed to explore the maximum NHS Reference Cost which could be applied to the triage strategies for
them to become undominated compared with current practice. The additional cost was varied from £10 to
£85 in £3 intervals. The results are presented in Appendix 7 and suggest that, as the cost of the triage
strategies increases, the incremental cost per QALY of current practice decreases. Once the reference cost
of the triage strategies reaches £61, all triage strategies are dominated by current practice. The ICERs of
current practice relative to GDx or OCT are below the value typically considered to be cost-effective in the
UK48 and HRT-GPS is always dominated. Triage (with HRT-MRA) is cost-effective if the NHS Reference Cost
tariff lies below £22, given a willingness-to-pay threshold of £30,000 per QALY.
TABLE 50 Incremental cost-effectiveness ratios for the cohort of 40-year-old males by varying annual probabilities
of having a community optometrist eye test (continued )
Probability (%) Strategy Cost (£) QALYs ICER
90 GDx 3611 19.8044 –
OCT 3858 19.8071 90,141
HRT-MRA 3924 19.8086 44,594
HRT-GPS 3952 19.8086 Dominateda
Current practice 4297 19.8091 800,615
100 GDx 3713 19.8067 –
OCT 3983 19.8092 108,907
HRT-MRA 4057 19.8106 54,140
HRT-GPS 4088 19.8106 Dominateda
Current practice 4471 19.8110 983,958
a Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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Changes to the start age of the cohort
The base-case analysis included a cohort of men with an age of 40 years to be modelled for 50 years. The
impact of modelling older cohorts of men was explored by varying the start age from 40 to 70 years in
10-year intervals for the same 50-years time horizon. The results are shown in Table 52.
As the starting age of the cohort increases, the incremental cost per QALYs of all interventions increases.
Incrementally, as the cohort ages, both costs and QALYs decrease, but decreases in costs are outweighed
by decreases in QALYs. This can be explained by the fact that treating younger populations yields larger
health gains.
TABLE 51 Incremental cost-effectiveness ratios for an increase to the unit costs of the triage strategies
Intervention Cost (£) QALYs ICER
Current practice 3084 19.778 –
GDx 3217 19.7701 Dominateda
OCT 3339 19.7746 Dominateda
HRT-MRA 3372 19.7771 Dominateda
HRT-GPS 3381 19.7771 Dominateda
a Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
TABLE 52 Incremental cost-effectiveness ratios for changes in the age of the cohort at referral
Start age (years) Intervention Cost (£) QALYs ICER
40 GDx 2791 19.7701 0
OCT 2917 19.7746 27,904
HRT-MRA 2952 19.7771 13,896
HRT-GPS 2961 19.7771 Dominateda
Current practice 3084 19.7780 156,985
50 GDx 2390 17.2356 0
OCT 2503 17.2392 30,995
HRT-MRA 2535 17.2412 16,016
HRT-GPS 2544 17.2412 Dominateda
Current practice 2647 17.2419 165,616
60 GDx 1886 13.9949 0
OCT 1983 13.9975 36,940
HRT-MRA 2011 13.9989 20,152
HRT-GPS 2018 13.9989 Dominateda
Current practice 2098 13.9994 180,864
70 GDx 1318 10.3259 0
OCT 1395 10.3274 49,717
HRT-MRA 1419 10.3283 29,376
HRT-GPS 1423 10.3283 Dominateda
Current practice 1478 10.3285 211,668
a Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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Changes to the patients treated: not treating patients ‘at risk’
The base-case analysis was conducted on the basis that all glaucoma patients and those ‘at risk of glaucoma’
(including those with glaucoma suspect, OHT and PAC) would be monitored and treated depending on their
definitive diagnosis. Owing to the potential overload of hospital eye services, it was agreed there was a need
to explore the effects of a hypothetical hospital eye service where those patients diagnosed as ‘at risk of
glaucoma’ would be discharged from the service, thus potentially reducing the diagnostic, monitoring and/or
treatment costs. This analysis was conducted for all diagnostic strategies. The results are presented in Table 53.
Compared with base case, all strategies have lower expected costs and lower expected QALYs. This is
explained by the lower proportion of individuals that are under treatment. In addition, the ICERs for all
interventions have increased; in moving from current practice to HRT-MRA, HRT-MRA to OCT and OCT to
GDx, savings are £752,248, £83,590 and £68,362, respectively, but at the expense of a QALY.
The higher ICERs are a result of fewer people ‘at risk of glaucoma’ being referred to hospital eye services for
rediagnosis and further savings from the triage strategies are expected compared with base-case analysis. In
other words, there is not much benefit from referral to the clinician for the ‘at risk of glaucoma’ group, as
the decision would always be to discharge these patients and wait until conversion to glaucoma in order to
start treatment. Given the value of all ICERs, all the triage strategies except the dominated HRT-GPS can be
considered cost-effective given the typical thresholds used for decision-making in the UK.48
Changes to the sensitivity and specificity of the clinician
The base-case analysis assumed that clinicians were 100% sensitive and specific in their diagnosis of
patients. In this sensitivity analysis, the sensitivity and specificity of clinicians was varied between 0.85 and
1 incrementally for all cohorts to explore the impact for patients of not always being seen in hospital eye
services by a consultant ophthalmologist with glaucoma expertise, and thus having the possibility of
reduced diagnostic accuracy. In the triage strategies, the diagnostic performance of the diagnosing
clinician was not altered: for those referred (i.e. with a positive result of the triage testing) the clinician
diagnosis was assumed to be perfect. The results are presented in Tables 54 and 55.
As the sensitivity of the clinician decreases from 1 to 0.95, the incremental cost per QALY of moving from
HRT-MRA to current practice increases from £156,985 to £2,068,661. The incremental effect in terms of
QALYs lost decreases as fewer patients are being correctly diagnosed. Similarly, incremental costs decrease;
this is because fewer patients are seen by a clinician, which is only partially offset by cost increases as a
result of more people being referred back for diagnostic testing with more expensive treatments. The
incremental cost-effective ratio decreases and is very sensitive to the performance of the clinician as the
QALYs lost outweigh the cost gains. Once the sensitivity drops below 0.95, current practice along with
HRT-GPS becomes dominated by HRT-MRA, which is cheaper and either more or equally effective. This is
because the cost savings realised by not being seen by a clinician are outweighed by the higher sensitivity
of the alternative triage strategy (HRT-MRA). The ICERs of moving to any of the other triage strategies are
below the values that are deemed acceptable in the UK to be cost-effective (£30,000).48
TABLE 53 Incremental cost-effectiveness for treating glaucoma patients only and discharging those ‘at risk’
Intervention Cost (£) QALYs ICER
GDx 2673 19.7392 –
OCT 2794 19.741 68,362
HRT-MRA 2824 19.7414 83,590
HRT-GPS 2833 19.7414 Dominateda
Current practice 2954 19.7415 752,248
a Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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TABLE 54 Incremental cost-effectiveness ratios for changes in sensitivity of clinicians
Sensitivity Intervention Cost (£) QALYs ICER
0.85 GDx 2791 19.7701 –
OCT 2917 19.7746 27,904
HRT-MRA 2952 19.7771 13,896
HRT-GPS 2961 19.7771 Dominateda
Current practice 3025 19.7754 Dominateda
0.90 GDx 2791 19.7701 –
OCT 2917 19.7746 27,904
HRT-MRA 2952 19.7771 13,896
HRT-GPS 2961 19.7771 Dominateda
Current practice 3046 19.7763 Dominateda
0.95 GDx 2791 19.7701 –
OCT 2917 19.7746 27,904
HRT-MRA 2952 19.7771 13,896
HRT-GPS 2961 19.7771 Dominateda
Current practice 3066 19.7772 2,068,661
a Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
TABLE 55 Incremental cost-effectiveness ratios for changes in specificity of clinicians
Specificity Intervention Cost (£) QALYs ICER
0.85 GDx 3029 19.7706 –
OCT 3227 19.7752 42,496
HRT-MRA 3283 19.7778 22,333
HRT-GPS 3302 19.7778 1,028,309
Current practice 3542 19.7789 221,312
0.90 GDx 2952 19.7704 –
OCT 3126 19.7750 37,961
HRT-MRA 3176 19.7776 19,709
HRT-GPS 3191 19.7776 1,278,469
Current practice 3395 19.7786 201,885
0.95 GDx 2872 19.7703 –
OCT 3023 19.7748 33,106
HRT-MRA 3065 19.7773 16,902
HRT-GPS 3078 19.7774 2,027,006
Current practice 3243 19.7783 177,341
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As the specificity of the clinician decreases from 1 to 0.85, the incremental cost per QALY of moving
from current practice to another triage strategy increases from £156,985 to £221,312. The incremental
effect in terms of QALYs lost increases as more patients, although being incorrectly diagnosed, who would
go on eventually to develop glaucoma or be ‘at risk’ are already being monitored/treated. Incrementally,
costs are also increasing because more patients are being seen by a clinician and are subsequently
monitored/treated. The costs are sensitive to clinicians’ specificity, as the cost increases are outweighed by
the QALY gains. The values of ICERs for current practice and HRT-GPS are above the acceptable threshold
in the UK. That is, the savings, but with the loss of a QALY, of moving from current practice to HRT-GPS
and from this strategy to HRT-MRA exceed the willingness to pay for a QALY and, therefore, a movement
to HRT-MRA would be worthwhile.
Changes in the costs of the triage strategies and not treating patients ‘at risk’
A threshold analysis was conducted in order to explore the impact of increasing the costs of the triage
strategies and discharging those patients who are given a diagnosis of ‘at risk of glaucoma.’ Full results are
presented in Appendix 7.
Adding an NHS Reference Cost of £85 to the cost of the triage station has the impact of current practice
dominating all strategies. This prevails until the unit cost of triage station falls below £64, when both
current practice and GDx become undominated. Reducing the reference cost to around £46, GDx becomes
cost-effective compared with current practice. OCT also becomes undominated when the unit cost of the
triage strategy falls to £34. Adding a lower reference cost to the triage station makes the triage strategies
with lower expected cost worthwhile. This is reflected in the values of the ICERs that, compared with the
usual threshold value for cost-effectiveness in the UK,48 would render higher expected cost strategies to be
not cost-effective and, therefore, would make a triage with GDx worthwhile.
Changes to the diagnostic performance of the imaging technologies
The base-case analysis incorporated point estimates for the sensitivities and specificities of each of
the imaging technologies that were estimated from the GATE study. We explored the impact of changing
these to a best-case diagnostic scenario and a worst-case diagnostic scenario for each of the imaging
technologies (see Chapter 6) on the ICERs. These figures were based on the CIs of diagnostic performance
measures used in the base-case analysis and the results are presented in Table 56.
The results show that in all scenarios, current practice always has the highest undominated ICER, as it is
always more costly and less cost-effective than any of the triage strategies. Furthermore, the order of the
strategies, according to ascending cost, does not change, with GDx, even under a best-case scenario,
always having the lowest expected cost and the fewest expected QALYs.
When considering the performance of OCT in a best-case scenario, it does not form part of the efficiency
frontier and would never be considered as a triage strategy, as it is always dominated by other strategies. The
worst-case scenario for OCT does not affect the ICER, as OCT was not on the base-case efficiency frontier.
Compared with base-case analysis, when the best-case diagnostic scenarios are applied to HRT-MRA and
HRT-GPS technologies in turn, the particular triage technology either replaces the other as the dominant
option or reinforces its position as the dominant technology. The results of the sensitivity analysis
investigating the best-case scenarios show that the choice of strategies, in order of willingness to pay, is
sensitive to the relative performance of HRT-MRA and HRT-GPS. Given the assumptions in the model
about consultant performance, no strategy displaces it as the most effective treatment.
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TABLE 56 Incremental cost-effectiveness ratios for exploring triage performance best- and worst-case scenarios
Strategy Cost (£) QALYs ICER Strategy Cost (£) QALYs ICER
GDx best case GDx worst case
GDx 2778 19.7717 – GDx 2696 19.7683 –
OCT 2917 19.7746 Extendedly
dominateda
OCT 2917 19.7746 Extendedly
dominateda
HRT-MRA 2952 19.7771 31,863 HRT-MRA 2952 19.7771 28,988
HRT-GPS 2961 19.7771 Extendedly
dominateda
HRT-GPS 2961 19.7771 Extendedly
dominateda
Current practice 3084 19.778 156,985 Current practice 3084 19.778 156,985
OCT best case OCT worst case
GDx 2791 19.7701 – GDx 2791 19.7701 –
OCT 2928 19.7751 Extendedly
dominateda
OCT 2925 19.7746 Extendedly
dominateda
HRT-MRA 2952 19.7771 26,326 HRT-MRA 2952 19.7771 26,326
HRT-GPS 2961 19.7771 Extendedly
dominateda
HRT-GPS 2961 19.7771 Extendedly
dominateda
Current practice 3084 19.778 156,985 Current practice 3084 19.778 156,985
HRT-GPS best case HRT-GPS worst case
GDx 2791 19.7701 – GDx 2791 19.7701 –
OCT 2917 19.7746 Extendedly
dominateda
OCT 2917 19.7746 Extendedly
dominateda
HRT-MRA 2952 19.7771 26,326 HRT-GPS 2921 19.7755 Extendedly
dominateda
HRT-GPS 2965 19.7773 89,632 HRT-MRA 2952 19.7771 26,326
Current practice 3084 19.778 172,479 Current practice 3084 19.778 156,985
HRT-MRA best case HRT-MRA worst case
GDx 2791 19.7701 – GDx 2791 19.7701 –
OCT 2917 19.7746 Extendedly
dominateda
HRT-MRA 2905 19.7755 25,658
HRT-MRA 2955 19.7773 26,275 OCT 2917 19.7746 Dominatedb
HRT-GPS 2961 19.7771 Dominatedb HRT-GPS 2961 19.7771 34,269
Current practice 3084 19.778 186,408 Current practice 3084 19.778 145,579
a Extendedly dominated: a combination of a less costly and less effective intervention and a more costly and more
effective intervention would be more efficient.
b Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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When the worst-case diagnostic scenarios are applied to all the imaging technologies in turn, with the
exception of GDx and of OCT, which were dominated already, they all become dominated and are
not cost-effective. This can be explained by the lower cost of the GDx imaging technology. However,
HRT-MRA was always undominated, except in the worst-case diagnostic scenario, when it was replaced by
HRT-GPS. This can be explained by the similarities in the diagnostic performance and CIs of these two
imaging technologies. Identical to the base-case results, with the exception of reducing the diagnostic
ability of HRT-MRA (see Table 56), GDx, HRT-MRA and current practice are all dominant strategies and
have increasing ICERs relative to each other.
In summary, in terms of GDx and current practice having the lowest and highest ICERs, respectively, the
base-case results are not sensitive to changes in the diagnostic accuracy of the imaging technologies.
Similar to the base-case analysis, current practice is not deemed cost-effective in any scenario.48 However,
the results are sensitive to improvements in the diagnostic accuracy in all the imaging technologies. The
corresponding ICERs rise and the best-case triage strategy becomes cost-effective. When the diagnostic
accuracy of the imaging technologies is reduced, HRT-MRA remains the winning strategy. The exception to
this is the worst-case scenario for HRT-MRA where HRT-GPS becomes cost-effective. This can be explained
by the similarities in the diagnostic accuracy of these two technologies.
Changes to the prevalence of glaucoma and ‘at-risk’ groups in the
referred population
The base-case analysis assumed that the prevalence of disease in the referred population was as found for
the GATE study. We explored the impact of a more enriched referred population (with higher proportion
of glaucoma and ‘at-risk’ patients and a lower proportion of normal patients) if the existing triage system
was used alongside a referral refinement scheme to filter out normal cases before referral to secondary
care. The results are reported in Table 57 and show higher expected costs and lower expected QALYs for
all strategies than the base-case analysis. This was expected as the proportions of glaucoma and ‘at risk of
glaucoma’ individuals entering the model are higher than in the base-case analysis. In addition, and also
compared with base-case analysis, triage strategies are less appealing (e.g. ICER for current practice
compared with HRT-MRA of £156,985 for base case and £99,227 in Table 57); however, the ICER of
£99,227 is still above the usual cost-effectiveness threshold.
Changes to the quality of life for the ‘at-risk’ health state
The base-case analysis assumed a quality of life for the ‘at-risk’ health state equal to the mild glaucoma
health state (quality of life= 0.8371). We explored the impact of assuming that the ‘at-risk’ health state
would have a quality of life equal to the normal health state (quality of life= 1). As expected, Table 58
shows no changes in expected costs as well as higher values for expected QALYs for all strategies in the
model. Moreover, there is no major impact on cost-effectiveness results, with ICERs being lower but close to
the values observed for the base-case analysis. Hence, base-case results are robust to this sensitivity analysis.
TABLE 57 Incremental cost-effectiveness ratios of increasing the prevalence of glaucoma and ‘at-risk’ groups in the
referred population
Intervention Cost (£) QALYs ICER
GDx 3991 19.1070 –
OCT 4123 19.1131 Extendedly dominateda
HRT-MRA 4158 19.1163 18,152
HRT-GPS 4166 19.1163 Extendedly dominateda
Current practice 4266 19.1174 99,227
a Extendedly dominated: a combination of a less costly and less effective intervention and a more costly and more
effective intervention would be more efficient.
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Summary and discussion
This chapter reported the results of a cost–utility analysis of alternative composite triage strategies using
alternative diagnostic imaging technologies compared with current practice for patients referred to hospital
eye services for possible glaucoma.
The base-case results suggest that HRT-MRA is the most cost-effective strategy. Given that current practice
represents standard care in the UK, large savings in costs (£156,985) could be made, but at the expense
of a QALY. Furthermore, the ICER for current practice relative to HRT-MRA would exceed the value that is
deemed to be cost-effective in the UK.
Another potential benefit is the release of clinicians’ time, which could be used to deliver other interventions.
Moreover, the sensitivity analysis results show triage strategies to be a potential cost-effective use of
resources if the triage station cost does not reach £30 per triage visit. However, sensitivity analysis results
were inconclusive in signalling a unique cost-effective triage strategy. HRT-GPS was often dominated by
HRT-MRA, but the expected QALYs that these two strategies produce were almost identical, with the
difference in total expected costs at around £10, which is not surprising since the results were obtained
from the same imaging machine.
Furthermore, on a cost-effectiveness basis, GDx (or even OCT on a few occasions) could not be completely
ruled out. GDx is highly specific and in a resource-constrained health economy it could be an efficient use
of resources. It should be noted, however, that clinically, this strategy may not be acceptable to clinicians
and/or patients because of its poor diagnostic performance (with low sensitivity). Determining a minimum
level of diagnostic accuracy that is acceptable for clinical staff and patient was beyond the aims of this
study and could be the subject of further research.
The QALY outcomes of all strategies depend only on the sensitivities of the tests to identify glaucoma and
those at risk of glaucoma. The sensitivities of the different triage strategies for glaucoma are very close to
each other, with the exception of GDx, but there is a greater difference between the strategies in their
ability to identify people at risk of glaucoma. The consequences, in QALY terms, of missing a diagnosis of
glaucoma are greater than those that result from missing a diagnosis of being ‘at risk of glaucoma’. For
these reasons, the quality-of-life differences between triage strategies are small. The sensitivity of the triage
strategies also means that the QALY differences between them and the base-case scenario are small. This
was to a certain extent expected for a study in which triage strategies have similar diagnostic accuracies
and a slow progression of disease. For example, this difference in the base-case analysis between current
practice and HRT-MRA triage strategy was 0.0008 QALYs, representing less than 8 hours in full health.
This small difference might make easier to accept a triage strategy that would result in loss of QALYs in
exchange for potential savings.
TABLE 58 Incremental cost-effectiveness ratios of changing the quality of life for the ‘at-risk’ health state
Intervention Cost (£) QALYs ICER
GDx 2791 20.1788 –
OCT 2917 20.1836 Extendedly dominateda
HRT-MRA 2952 20.1864 21,107
HRT-GPS 2961 20.1864 Dominatedb
Current practice 3084 20.1873 142,873
a Extendedly dominated: a combination of a less costly and less effective intervention and a more costly and more
effective intervention would be more efficient.
b Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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Furthermore, the incremental cost-effectiveness of the triage strategies compared with current practice was
very sensitive to costs included in the model. Unnecessary outpatient visits and associated treatment costs
within current practice and, in particular, the costs of the actual triage strategies are model result drivers
for the expected costs as well as the resulting ICERs. The cost-effectiveness of any triage strategy is heavily
dependent on the unit cost of the triage station. As such, all these strategies were dominated by the
current practice under the plausible assumption that an NHS provider of care would charge, for the triage
station, an NHS Reference Cost tariff corresponding to an outpatient appointment. Indeed, current practice
becomes dominant when the cost of an outpatient appointment increases to £61 and above.
A key assumption used in the model was that clinicians are 100% accurate in their diagnostic ability.
Relaxing this assumption further increased the ICERs of current practice relative to other triage strategies
above a level that would be deemed to be cost-effective in the UK.48 Even under extreme scenarios, in
which the diagnostic accuracy of the triage strategies was reduced, current practice could not be deemed
the most cost-effective. Hence, in terms of diagnostic accuracy, no plausible scenarios rendered current
practice the most cost-effective. A probabilistic sensitivity analysis was therefore not warranted. Only
when the costs of the triage strategies increased with an NHS Reference Cost did current practice
become cost-effective.
The strengths of this research are that an economic model has been developed and analysed using good
modelling research practice.51,52 The cost-effectiveness of the different imaging technologies and their
subsequent care management pathways was assessed using a multistate Markov model. This modelling
approach is highly relevant, as glaucoma is a chronic condition, which progresses slowly over time,
allowing the model to reflect the timing of both diagnostic testing and disease progression following the
initial diagnostic strategy. Furthermore, we believe that this is the first economic evaluation of these
interventions to be conducted in this context.
There are limitations to this research. A key issue for the study is paucity of data regarding parameter
inputs used in the model. As stated in the introduction (see Chapter 1), there is a lack of evidence
regarding the diagnostic accuracy of imaging techniques in a triage setting and thus the parameter
estimates regarding this have been based on the GATE study alone and not from multiple studies.
Furthermore, the diagnostic accuracy of clinicians has been assumed to be perfect but explored in
sensitivity analysis.
Only very limited data on the costs of diagnosis and treatment were available and, although efforts were
made to identify the best data applicable to the UK, these were sparse. The model estimates would be
more robust if further data were to become available and as previously stated by Burr et al.,18
consideration should be given whether or not further primary research is needed. The model was very
sensitive to the costs of the triage strategies and as stated above, adding additional costs to their unit costs
renders triage not cost-effective compared with current practice.
The quality and usefulness of the economic model is dependent not only on the quality of the data, but
also on the way in which the data are used. The data requirements and the use of the data were
determined by the structure adopted for the model. The development of the economic model was, as
described in Chapter 6, based on discussions with a number of key stakeholders. It then underwent
a prolonged period of refinement during which the care pathways were critically examined and refined.
The model structure applies to a UK context and may not be relevant to other country settings, although
other strategies could be developed and readily added to the model.
As described in Chapter 6, the model structure was developed so that the assumptions made in the
base-case analysis could be explored in future work. For example, in the base-case analysis it was assumed
that the clinician would make a perfect diagnosis. The model structure has allowed for the possibility that
this will not be the case and that the clinician might possibly initiate treatment when it is not required
(a false positive) and fail to diagnose some cases of glaucoma (a false negative).
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The model is a simplification of the care pathways that may follow. For example, the model structure does
not include all possible health states that may be relevant in context, such as misdiagnosis of those at risk
of glaucoma as true positives. A second simplification made in the model was the relatively small number
of stages used to reflect the progression of this chronic condition. While this assumption may fail to
represent the subtleties of disease progression, it was believed the health states were sufficient in number
to reflect the relevant issues needed for this economic evaluation.
Estimates of the risk of progression between health states are based on data from one eye and do not
necessarily represent the definition of the health states in the model, which is based on binocular visual
field loss. The fellow eye may not have such advanced disease as the study eye and, therefore, the
quality-of-life loss might be overestimated. While this is a limitation of the study, the alternative of using
the better eye for the analysis would result in an underestimation of the risk of progressive binocular visual
field loss. Furthermore, there were insufficient data to determine whether or not some of the parameter
values varied between the stages of disease, for example the diagnostic performance of the diagnostic
strategies. The model was, however, structured in such a way that, should such data become available in
the future, the model could be readily adapted and the data incorporated.
A further simplification in the model structure was that, rather than modelling the full variety of treatments
available for glaucoma, it has been assumed that the effect of treatment can be represented by a single
relative effect size for treatment compared with no treatment. In addition, when interpreting the results of
the economic evaluation it should be borne in mind that the estimates of cost-effectiveness relate to
a male cohort. Sex-specific data were not available for any of the parameter estimates except for annual
all-cause mortality.
Finally, there is no clear decision rule or willingness-to-accept threshold value to interpret cost–utility
analysis results where savings are obtained at expense of QALY being lost. In this study, a similar threshold
value to the one often used as willingness-to-pay for a QALY gained was assumed (i.e. £30,000). Although
this is one value from many possible, in the great majority of the analyses the savings per QALY lost (ICERs)
were well above this threshold. In other words, the adopted interpretation would be consistent with higher
willingness-to-accept value should this become common practice.
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Chapter 8 Discussion
The GATE study was a large multicentre study designed to evaluate the performance of a triage testfor patients referred to hospital eye services with possible glaucoma. The triage test would include VA
and IOP measurements, and one of four imaging tests from three different instruments [the HRT-III
confocal scanning laser ophthalmoscope (HRT-GPS and HRT-MRA), GDx scanning laser polarimeter and a
SD-OCT (Spectralis®)]. There were two diagnostic evaluations: (1) an estimation of the ability of imaging
technologies to diagnose glaucoma at an eye level and (2) an assessment of the performance of a triage
test. All instruments are currently available in the NHS.
Regarding the diagnostic ability to detect and rule out glaucoma, all four imaging tests had some value;
HRT-MRA had the highest sensitivity but lower specificity than other tests. In contrast, GDx had the best
specificity but the lowest sensitivity. HRT-GPS results were similar to HRT-MRA results, as might be
expected given that their analysis is based on imaging the same structure (i.e. the optic disc). The sensitivity
of OCT was very similar in magnitude to its specificity. OCT gave the lowest percentage of low-quality
imaging results, and GDx the highest, according to the image quality classification provided in the device
software. Average time taken to conduct the tests was lowest for OCT. Patient preference tended to
favour OCT followed by GDx, although almost half of participants did not have a preference.
A number of sensitivity analyses were carried out to assess the robustness of the findings of the default
analysis. Varying the test definition of an abnormal imaging result by including the borderline category
had the expected impact of improving the detection of glaucoma, although at the expense of more
non-glaucoma cases being falsely classified as glaucoma. The impact of combining two imaging tests
improved detection of glaucoma, but the improvement was marginal and smaller than the loss of specificity.
Regarding the triage analysis, four composite triage tests – which each consisted of an imaging test, IOP
measurement and VA assessment – were compared with regard to their performance for determining who
should be referred to a clinician for further assessment or discharged. All four triage tests had value in terms
of ruling in and ruling out the need for referral to a clinician. The diagnostic performance of the triage tests
differed substantially. HRT-GPS with HRT-MRA consistently having the highest sensitivity across analyses but at
the cost of lower specificity than other tests. In contrast, GDx consistently had the best specificity though the
lowest sensitivity. OCT generally had similar levels of sensitivity and specificity. A number of sensitivity analyses
were carried out that confirmed the robustness of the findings of this default triage analysis.
The economic analysis suggested that a composite triage test, introduced into the care pathway for
patients referred from community with possible glaucoma, appears to be cost-effective compared with
current practice, in which all referred patients are seen by a clinician. Our findings are based on a relatively
inexpensive composite triage test (< £30) including an imaging technology, IOP and VA testing.
Triage using HRT-MRA was the most cost-effective strategy. Given that current practice in the model
represented standard care in the UK, large savings in costs (£156,985) could be made for each QALY
forgone. For the ICER, current practice, compared with HRT-MRA, would largely exceed the value that is
deemed to be cost-effective in the UK. With the exception of GDx, the diagnostic accuracy of all the triage
strategies and their unit costs are very similar. Using GDx in a triage test is the least costly and least effective
diagnostic strategy but it was still cost-effective compared with current practice for a number of analyses.
A variety of sensitivity analyses were conducted. The ICER of the triage strategies compared with current
practice was very sensitive to costs included in the model. With the exception of increasing, the costs of the
triage stations to NHS commissioners, within the uncertainty analysis, triage was always more cost-effective
than current practice. Furthermore, the present analysis is inconclusive on the decision about a particular
imaging test to be included in a triage station. Further research on acceptability of the alternative imaging
tests is warranted.
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There are emerging models of eye care in the community that try to reduce the number of false-positive
referrals to hospital eye services.53–55 Their effectiveness, efficiency and acceptability need to be evaluated
in primary research before implementing change. The GATE study provides robust data on how such
services might be reconfigured.
Strengths and limitations
A number of strengths can be highlighted. GATE was a large prospective paired diagnostic study and it
evaluated diagnostic tests in the desired setting. The benefit of the large sample size is reflected in the
precision with which the sensitivity and specificity were calculated, with differences between every pair of
tests identified for one if not both of sensitivity and specificity. McNemar’s test was used to compare the
sensitivity and specificity of the tests. Following the rationale of others in effectiveness studies, the paired
comparisons were not adjusted for multicomparisons. Even if such a correction had been applied, such
was the strength of evidence that there would still be evidence of differences in the diagnostic
performance of the different imaging tests.
The population enrolled in GATE consisted of subjects without a known history of disease, which would
reflect the potential clinical application of the triage test. Other reported studies evaluating the performance
of diagnostic technologies have used a population of patients already diagnosed with glaucoma, which has
a risk of selection bias. This study recruited patients before diagnosis, and the population tested had a broad
spectrum of disease at presentation, from early through to severe glaucoma, and included a large percentage
of healthy individuals. The healthy individuals in whom the test ‘specificity’ was determined were subjects
referred from primary care with a possible glaucoma-related finding (either risk factor or suspected sign).
Thus, the diagnostic performance reported here refers to a secondary care setting and may be different in an
unselected population.
An intentional aspect of the study’s design is the focus on both the diagnostic performance of imaging
tests for the identification of individuals with glaucoma and the performance as a triage test where
imaging tests would be used in conjunction with other routine measurements (IOP and VA). Both aspects
are important for understanding the potential value of the imaging tests. We have also evaluated other
important considerations for diagnostic technologies, such as interpretability, patient preference and time
taken to perform the test.
The reference standard was provided by different ophthalmologists with glaucoma expertise. The
ophthalmologists had been trained in the study protocols and agreed to a common set of criteria to define
glaucoma and normality. By using different ophthalmologists working at different units, the results of the
study are more likely to be generalisable than results from studies performed in a single unit. The participating
units are likely to be representative of the NHS practice, including two district general hospitals and
three academic units of different size: relatively small (Aberdeen), medium (Liverpool) and large (Moorfields).
The economic model was developed and analysed using good modelling research practice.51,52 The
cost-effectiveness of the different imaging technologies and their subsequent care management pathways
were assessed using a multistate Markov model. This modelling approach is highly relevant as glaucoma is
a chronic condition, which progresses slowly over time, allowing the model to reflect both the timing of
diagnostic testing and the disease progression following the initial diagnostic strategy.
Among the limitations, we recognise that diagnosing glaucoma during the very early stage of disease is
challenging, and ideally a longitudinal follow-up would provide the best possible reference standard. This
was proposed by Medeiros et al.34 who used optic nerve head progression on stereophotographic examination
as the criterion for glaucoma diagnosis, but we could not contemplate this possibility in GATE, as years of
follow-up would have been required. The reference standard was assumed to be perfect, although it is
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widely recognised that diagnosis of glaucoma is difficult in early disease, and uncertainty exists even
among specialists. While consensus was sought through structured training, some assessor differences may
have remained between the sites. Adding central corneal thickness information for patients referred for
high IOP could potentially add valuable information and help further refine the referral pathway of
such patients.
There was lack of evidence base regarding some parameter inputs used in the economic model. Only very
limited data on the costs of diagnosis and treatment were available and, although efforts were made to
identify the best data applicable to the UK, these were sparse. Data with respect to health utilities were
available, but it is unclear whether or not the EQ-5D is sensitive enough to detect clinically significant
changes in glaucoma. The model is a simplification of the care pathways that may follow, with a relatively
small number of stages used to reflect the progression of this chronic condition. Estimates of the risk of
progression between health states were based on data from one eye and do not necessarily represent the
definition of the heath states in the model, which is based on binocular visual field loss. A further
simplification in the model structure is that, rather than modelling the full variety of treatments available
for OAG, it has been assumed that the effect of treatment can be represented by a single relative effect
size for treatment compared with no treatment.
Uncertainties
l The diagnosis, natural history and risk of conversion to glaucoma of untreated or treated patients
classified as glaucoma suspects is unknown. It is likely this is a very heterogeneous group, as reflected
in the categories of glaucoma suspect defined in GATE.
l The natural history and risk of conversion to glaucoma of untreated or treated patients with OHT
undergoing standard care is unclear. Although there is evidence on the efficacy of treatment of
OHT from large randomised controlled trials, the generalisability of their findings to routine clinical care
in the NHS is ill defined.
l It is unclear how often people attend community optometrists for regular eye examinations. If they
have glaucoma that is missed by the triage, it is unknown how quickly it would be detected by the
optometrist and at what severity of disease. In our model we hypothesised that all those with a
false-negative diagnosis at the triage stage would return to hospital eye services within 3 years.
l The triage analysis used the IOP information provided by a consultant ophthalmologist. A triage system
would rely on IOP measurements taken by a technician or a nurse, and it is uncertain whether or not
such IOP measurements, possibly obtained with different tonometers, will be significantly different and
what impact this would have in the performance of the triage test. The diagnostic accuracy of clinicians
is uncertain. Glaucoma is diagnosed clinically, relying on the experience of the examiner, and it is likely
that the relative performance of the imaging technologies may be underestimated if the reference
standard comparator consists of experienced glaucoma experts, as were used in GATE. Glaucoma in
the NHS is diagnosed by a variety of health-care professionals, including optometrists, specialist nurses,
senior ophthalmologists with variable glaucoma expertise and trainees.
l There are other OCT instruments in the market with glaucoma diagnostic capabilities and the results of
this study using the Spectralis® device may not be fully applicable to other OCT technologies.
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Chapter 9 Conclusions
Implications for health care
Automated imaging technologies can be effective tests to aid in the diagnosis of glaucoma among
individuals referred from the community to hospital eye services with possible glaucoma. A model of care
incorporating a triage composite test for diagnosing patients referred from the community appears to be
cost-effective compared with current practice. Our findings are based on a relatively non-expensive
composite triage test (< £30) including an imaging technology, IOP and VA testing. The most efficient
strategy would include HRT-MRA imaging. However, a triage test would be associated with reduced
health, and the acceptability of this option among users and clinicians has not been evaluated.
Recommendations for research
l Acceptability to patients and health-care providers of implementing an efficient triage glaucoma
diagnostic system but with reduced health should be explored. A qualitative or mixed-methods study,
for example including a discrete choice experiment and also incorporating public perspectives, would
be suitable.
l Further data on the glaucoma disease progression under routine care, and specifically including
patients classified as having glaucoma suspect or OHT, on associated utility, on the cost of providing
health-care services and on sight loss are needed. A long-term longitudinal cohort study would be ideal
to address these issues.
l Further investigation of varying the thresholds for classification of the imaging tests beyond the
standard options presented in the software could be undertaken, as the standard classification may not
be the one best suited to the population referred from the community to hospital eye services. Further
analysis of GATE data or review of data from other relevant diagnostic studies would be able to answer
this question.
l The effectiveness of implementing a triage test incorporating imaging, an IOP measurement and VA
requires evaluation. A longitudinal diagnostic impact study is needed.
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Appendix 1 Information for patients
 
 
Evaluation of novel imaging techniques for the detection of Glaucoma. 
 
Dear  
 
Invitation to take part in a research study 
 
I am currently undertaking a national study to evaluate the performance of three new automated 
eye tests for the diagnosis of glaucoma in conjunction with The Health Services Research Unit, 
University of Aberdeen.  As you are coming to the eye out patients department for an 
appointment I would like to invite you to take part. 
 
I have enclosed an information sheet about the study which will help you decide whether or not 
you would like to participate and would be most grateful if you could take a few minutes to read 
through the information. 
 
If you agree to take part then you will be given three automated eye tests during your 
appointment which should take no longer than one hour to complete before being seen by the 
ophthalmologist as per a normal clinic appointment. 
 
Although your involvement is very important to us we would like to stress that you are under no 
obligation to participate.  We will be happy to discuss any aspect of the study with you at the 
clinic when we see you and if you have any questions about the study we will be pleased to 
answer them then.  
 
Yours sincerely, 
 
 
Augusto Azuara-Blanco 
Consultant Ophthalmologist.
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 Evaluation of novel imaging techniques for the detection of 
Glaucoma (GATE study). 
 
Information leaflet. 
 
You are being invited to take part in a research study.  Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take the time to 
read the following information carefully and discuss it with others if you wish.  Ask us anything 
that is not clear or if you would like more information.  Take time to decide whether you wish to 
take part. Thank you for reading this. 
 
What is the purpose of the Study? 
Glaucoma can reduce vision and quality of life but if diagnosed early it can be treated and 
reduction of vision prevented.  The main risk factor for a reduction in vision due to glaucoma is 
being diagnosed late and damage to the eyesight has already begun.  New promising diagnostic 
imaging tests are available and are easy to perform.  They use a laser to explore and analyse the 
structure of the optic nerve head and surrounding tissues in the back of the eye.  However, which 
test is the best to use is uncertain at present and this project will evaluate the performance of three 
new imaging tests.  If one of the tests proves to be accurate and easy to perform, it could be 
implemented in the community to reduce the risk of reduced vision from glaucoma. 
 
Why have I been chosen? 
As you are attending the eye out-patient clinic for an eye examination from an ophthalmologist 
we would like to invite you to take part. 
 
Do I have to take part? 
No. It is up to you to decide whether you take part. If you do decide to take part, you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part, you are still free to withdraw at any time and without giving a reason. 
GATE study patient information leaflet 
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What will happen if I take part? 
The study is carried out alongside your appointment in the local Eye Out-Patient Clinic. 
Depending on routine practice at your local clinic this may be one or two appointments. You will 
be given a visual fields test along with three imaging tests and finally a basic eye examination by 
an Ophthalmologist.  The addition of the imaging tests may extend your appointment time by 
approximately one hour. 
 
What do the imaging tests involve? 
There will be three imaging tests carried out by a research technician. The imaging tests are non-
invasive and do not usually require eye drops. During the test you will have to look at a fixation 
light for a short period whilst a series of images of the optic nerve head at the back of the eye are 
acquired. The imaging tests are rapid and take approximately 10 minutes to complete. In a small 
number of cases we may have to place some eye drops in your eyes to dilate your pupils.  This 
can make it easier to take the image.   
 
What are the possible disadvantages and risks of taking part in this study? 
Most people will not need their pupils dilated.  If we need to dilate your pupils it can sometimes 
cause some temporary blurring of vision and sensitivity to light.  This is, however, a routine 
procedure which would normally be performed as part of your eye examination 
 
Are there any benefits to taking part in the study? 
There will be no direct benefit to yourself in taking part in the study, however if any of the tests 
prove to be accurate and easy to perform, they could be implemented in the community. 
 
Will my taking part in this study be confidential? 
All information which is collected about you for the study will be kept strictly confidential.  
Information for all participants in the study will be kept for a minimum of ten years in line with 
current research governance arrangements and then destroyed.  Only researchers involved with 
the study will have access to your information 
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What happens to the results of the study? 
The results of the research will be published in relevant scientific journals and a report will be 
sent to the funder of the research, the NHS Health Technology Assessment programme.  We 
would also be happy to send you a short report when the study when the research is complete.  
You will not be identifiable in any publications from this research. 
 
How do I Complain? 
If you wish to complain or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal NHS complaints mechanisms 
are available to you. 
 
Who has reviewed the study? 
This study has been reviewed and approved by the North of Scotland Research Ethics 
Committee. 
 
Thank you very much for considering taking part in this research. 
 
Contact details for further information 
 
Central office:      Local contact details: 
GATE Study Office       
Health Services Research Unit     [Contact details]  
University of Aberdeen     [for local researchers] 
Health Sciences Building     [Affix sticker here] 
Foresterhill 
Aberdeen AB25 2ZD 
Tel: 01224 438196 
Fax: 01224 438165 
Email:gate@abdn.ac.uk
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
  
GATE study consent form 
 
 (Form to be on headed paper) 
 
Participant Study Number:  
 
CONSENT FORM 
 
 
Comparative study of new imaging technologies for the diagnosis of glaucoma: the GATE study 
 
 
       Please initial box 
 
 
1 I confirm that I have read and understand the information sheet dated ............................ 
 (version ............) for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
 
 
2 I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
 
3 I understand that relevant sections of my medical notes and data collected during the study, 
may be looked at by individuals from the University of Aberdeen, from regulatory 
authorities or from the NHS Trust/Health Board, where it is relevant to my taking part in 
this research.  I give permission for these individuals to have access to my records. 
 
 
  
4  I understand that my personal details collected during the study will be held in a secure 
central database, and may be subject to audit and monitoring by University of Aberdeen or 
NHS Trust/Health Board staff, without breaching data confidentiality 
 
 
5 I agree to take part in the above study.    
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________________________ ________________ ____________________ 
Name of Patient   Date Signature 
 
 
 
I confirm that I have explained to the person named above the nature and purpose of the GATE study and the 
procedures involved  
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
 
 
 
 
GATE study office, Health Services Research Unit, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD. 
Tel: 01224 438196, Fax 01224 438165, Email: gate@abdn.ac.uk 
 
Copies: Original to be returned to study office: 1 copy for patient; 1 copy to be filed with hospital notes 
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Appendix 2 GATE study case report forms
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Version 1 2 - 1 - 20-07-11
 
 
 
 
 
 
 
 
 
 
Participant Study No      
            
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Research Officer Data Collection Form 
 
 
 
 
 
 
 
 
       This study is funded by the NHS National Institute for Health Research 
 Health Technology Assessment Programme   
CONFIDENTIAL 
R
es
ea
rc
h 
O
ffi
ce
r D
at
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C
ol
le
ct
io
n 
Fo
rm
 
DOI: 10.3310/hta20080 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 8
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Azuara-Blanco et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
11
Research Officer Data Collection Form 
 
Participant Study number      
 
Date of Assessment D D / M M / Y Y Y Y 
 
 
CHI number (Scotland only) or 
NHS number           
 
Date of Birth D D / M M / Y Y Y Y 
 
Gender  Male  Female 
 
ETHNIC ORIGIN 
 
Please note the following are the main classification categories used by the Census 2001.  Please ask the patient how they 
would describe themselves. 
 
Black or Black British-Caribbean    
Black or Black British-African    
Other Black Background  Please specify  
    
Asian or Asian British-Indian    
Asian or Asian British-Pakistani    
Asian or Asian British-Bangladeshi    
Chinese     
Other Asian Background  Please specify  
Mixed – White and Black Caribbean    
Mixed – White and Black African    
Mixed – White and Asian    
    
White     -       British    
Other   Please specify  
 
Has patient been fully consented? Yes  
 
SECTION A - PATIENT DETAILS 
- -Version 1 2 2 20-07-
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Referral Eye (please tick only one) Right  Left  Both   
 
IOP on referral (mmHg) 
 
Method of assessment (please tick only one) 
 
Right 
  
Left 
 
 
 
NCT 
  
    
 
 
GAT 
  
    
 
 
Other 
  
Please specify  
 
Refraction 
 +/- Sphere +/- Cyl Axis 
Right eye     .   /     .   x      
 +/- Sphere +/- Cyl Axis 
Left eye     .   /     .   x  
 
Best corrected visual acuity (Snellen) 
Right eye            Left eye 
     
 
 
 
Visual fields (Humphrey 24.2)  
SITA standard or SITA fast.  Record reliability information defined by the Humphrey 
   
Right Eye: Reliable  Unreliable  Not done   
Fixation 
losses 
False pos 
errors (%) 
False neg 
errors (%) 
  
+/- 
 
   MD (dB) 
 
    PSD (dB) 
 
    VFI (%) 
 /                      
 
 
 
Left Eye: Reliable  Unreliable  Not done   
 
Fixation 
losses 
False pos 
errors (%) 
False neg 
errors (%) 
  
+/- 
 
   MD (dB) 
 
    PSD (dB) 
 
    VFI (%) 
 /                      
 
  
Printout of Visual Fields for research site file attached to CRF. Yes  
 
  
SECTION B – CLINICAL DATA 
Version 1 2 - 3 - 20-07-11
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Test order   
The order that tests should be performed is found on the study website clinic log for this study number.  
Please record the order in which the tests were performed (1=1st,2=2nd,3=3rd) 
 
   HRT     GDX     OCT  
HRT 
Start time (24hr clock) H H : M M   End time (24hr clock) H H : M M 
 
Were pupils dilated? Yes  No   
 
Right Eye: Completed  Not performed   Reason  
 
Left Eye: Completed  Not performed   Reason  
 
Raw data  Raw data       Hard copy  MRA right eye  
filename  saved to disk           report printed   MRA left eye  
    GPS  
GDX  
Start time (24hr clock) H H : M M   End time (24hr clock) H H : M M 
 
Were pupils dilated? Yes  No   
 
Right Eye: Completed  Not performed   Reason  
 
Left Eye: Completed  Not performed   Reason  
 
Raw data filename   Raw data saved to disk  Hard copy report printed    
OCT 
Start time (24hr clock) H H : M M   End time (24hr clock) H H : M M 
 
Were pupils dilated? Yes  No   
 
Right Eye: Completed  Not performed   Reason  
 
Left Eye: Completed  Not performed   Reason  
 
Raw data filename   Raw data saved to disk  Hard copy report printed    
   (RNFL basic report OU)  
 
Has participant completed the GATE Participant Preference questionnaire? Yes  No  
If No, why?    
 
SECTION C – IMAGING DATA 
Version 1 2 - 4 - 20-07-11
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
 
 
 
Participant Study No       
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
 
       Participant Preference Questionnaire 
 
 
 
 
 
 
 
 
This study is funded by the NHS National Institute for Health Research 
 Health Technology Assessment Programme 
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Version 1 1 31 01 11 Page 2
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant Study No 
            
           
Date of examination   /  /    
           
 Now that you have had all three tests can you please give an order of 
preference from 1 for the most preferred test, to 3 for the least.   
If you have no preference please tick the last box.  
 
  
 
Optical Coherence Tomography  
 
 
 
 
    
  
 
Scanning laser polarimetry –  
GDx-VCC 
 
 
 
 
 
    
  
 
Heidelberg Retinal Tomography 
 
 
 
 
    
  
  
I have no preference  
  
 
Please note you may not have had your tests in the order above and may not remember which 
test is which.  If you are unsure then ask the research nurse for help.  
Participant Preference Questionnaire 
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    Page 1 01-09-11   Version 1.3  
 
 
DO NOT LOOK AT IMAGING RESULTS  
BEFORE COMPLETING THIS FORM 
 
 
Participant Study number      
 
Date of Assessment D D / M M / Y Y Y Y 
 
Clinician Name (Capitals)  
IOP (mmHg)     
Today Right  Left  
  
DIAGNOSIS 
(tick only one category in each column) Right Left 
   R L 
Glaucoma     Severity of glaucoma Mild   
Disc suspect     Moderate   
VF suspect     Severe   
VF+disc suspect      
OHT (normal disc and field)        
PAC (normal disc and field)       
PAC suspect (normal disc and field)       
No glaucoma-related findings     
Undetermined 
(could not complete assessment) 
  Please specify reason   
 
For glaucoma and suspects:  R L 
Please tick mechanism Open angle   
Angle closure   
Other   
 
Co-morbidity – tick all that apply Right Left  
AMD    
Cataract    
Neurological   Please specify 
Other    
    
ACTION (please tick) 
Discharge?    Yes     No  
    
  If NO please complete – tick only one box in each column 
CLINICIAN CRF 
 Right Left Comments 
Treat    
Monitor only    
Repeat  assessment required    
CONFIDENTIAL 
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   Page 2 01-09-11   Version 1.3  
Clinical diagnosis definitions 
 
Glaucoma:  
Evidence of glaucomatous optic neuropathy* and a characteristic visual field loss**  
 
Glaucoma severity:  according to Humphrey SITA standard perimetry of a reliable VF ***:  
Mild: MD better than or equal to -6 dB;      
Moderate: MD between -6.01dB and -12 dB     
Severe: MD worse than or equal to -12.01 dB  
  
Mechanism:  
Open angle:  includes POAG, NTG,  
Angle closure:   includes evidence of glaucomatous optic neuropathy combined with a characteristic visual 
field loss, and a closed anterior chamber angle (appositionally or synechial) in at least 270°  
Other:  pigmentary glaucoma, pseudoexfoliation glaucoma or any other type of glaucoma  
 
Disc suspect:  appearance suggestive of glaucomatous optic neuropathy but may also represent a 
variation of normality, with normal visual fields (with or without high IOP).  
 
VF suspect:  visual field loss suggestive of glaucoma, but may also represent a variation of normality, with 
normal appearance of the optic disc (with or without high IOP) 
 
VF+disc suspect:  both the optic disc and visual field have some features that resemble glaucoma but 
may also represent a variation of normality (with or without high IOP) 
 
OHT:  when both the visual field and optic nerve appear normal in the presence of elevated pressure,  
> 21 mmHg 
 
PAC:  Closed anterior chamber angle (appositionally or synechial) in at least 270°, and at least one of the 
following two: IOP > 21 mmHg and/or presence of peripheral anterior synechiae.  Both visual field and optic 
nerve appear normal 
 
PAC suspect:  Closed anterior chamber angle (appositionally without any synechiae) in at least 270°, with 
IOP < 21 mmHg.  Both visual field and optic nerve appear normal 
 
The decision to monitor/treat will be defined in accordance with the NICE guidelines 
 
*  Evidence of optic nerve damage from any of the following:  Optic disc or retinal nerve fibre layer structural 
abnormalities.  Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior 
or superior poles.  Documented, progressive thinning of the neuroretinal rim with an associated increase in 
cupping of the optic disc.  Diffuse or localized abnormalities of the peripapillary retinal nerve fibre layer, 
especially at the inferior or superior poles.  Disc rim or peripapillary retinal nerve fibre layer haemorrhages. 
Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.  
 
**  Reliable visual field abnormality considered a valid representation of the subject's functional status. 
Visual field damage consistent with retinal nerve fibre layer damage (e.g., nasal step, arcuate field defect, or 
paracentral depression in clusters of test sites). Visual field loss in one hemifield that is different from the 
other hemifield, i.e., across the horizontal midline (in early/moderate cases). Absence of other known 
explanations.  
 
***A reliable visual fields is classified as: False positive error <15% and no evidence for learning effect or 
poor performance which could impact on MD value (clinical judgement).  In patients with unreliable visual 
field, the severity of glaucoma will be based upon clinical judgement.  
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Appendix 3 Example imaging report outputs from
the four imaging tests
Heidelburgh Retinal Tomography glaucoma probability score
(HRT-GPS)
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Heidelbergh Retinal Tomography Moorfields regression analysis
(HRP-MRA)
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Glaucoma diagnostics (GDx)
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Spectralis optical coherence topography (OCT)
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Appendix 4 Imaging standard operating
procedures for the GATE study
 
STANDARD OPERATING PROCEDURES (SOP) 
Image acquisition and storage 
 
GATE: Glaucoma Automated Test Evaluation 
 
Comparative study of new imaging technologies  
for the diagnosis of glaucoma (HTA Reference Number: 09/22/111) 
 
Sites: 
 
1. Aberdeen Royal Infirmary 
2. Hinchingbrooke Hospital 
3. Moorfields Eye Hospital 
4. St. Paul’s Eye Unit, Liverpool 
5. Bedford Hospital Trust 
 
 
 
Instruments: HRT-III, GDx-PRO, Spectralis-OCT 
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Contact lens wear 
There is currently no consensus as to whether a patient should be imaged with or 
without contact lenses.  If a patient presents wearing contact lenses please follow local 
best practice. 
 
Imaging Test order 
Imaging should be performed in the random order allocated for each participant in the 
study. This can be found on the clinic log entry for that patient study ID on the GATE 
website. 
 
Pupil dilation for imaging 
Images should routinely be performed without dilation prior to clinician assessment 
and prior to visual field measurements.  If pupil dilation is required to obtain an adequate 
quality HRT or OCT image then the GDx scan should be attempted prior to dilation (if 
not already performed).  If an adequate quality GDx image is still not obtained prior to 
dilation the GDx scan should be repeated after pupil dilation. Whenever possible the 
random allocated test order should be used. 
 
General indications for pupil dilation are media opacities and/or small pupils.  However, 
the scan should always be attempted first to determine whether images are acceptable 
or if dilation is necessary. 
 
Criteria for dilating the pupil are as follows: 
· Unable to ‘lock-on’ to the pupil and save a scan 
· Acceptability of best saved image is below requirements stated in SOP for that 
imaging technique 
 
Acceptability criteria for each imaging technique are clearly detailed in the text for each 
technique below. Once an acceptable image has been obtained no further images 
should be acquired. 
 
Acceptable quality criteria for imaging (summary) 
HRT Mean standard deviation ≤30,  
Image quality score: Good, Very Good, or Excellent 
GDx Q≥8 
OCT Q>15 
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Heidelberg Retina Tomograph (HRT-III) 
 
Acquiring the image 
Before imaging a subject on the HRT you should record their refraction (focimetry or 
auto-refraction. The focimetry/autorefraction is useful to guide the setting of the scan 
focus before image acquisition, but is not required to be input in the software. 
 
Patients should not be imaged with their contact lenses in. 
 
1. Ensure that IOP measurements (and other contact exams like gonioscopy) are 
done after HRT imaging. 
2. Explain examination (method, time and requirements) to the patient. 
3. Disinfect chin- and forehead supporting-stand. 
4. Check optics for dirt or smudges, clean if required, with lint/oil-free lens paper 
moistened with a drop or two of photography quality lens cleaner. 
5. Enter new patient details:  
 
a)  Click on the new patient icon on the HEYEX tool bar to enter the subject’s 
details and the operator initials.  Enter the corneal curvature as an average of 
the two axes (i.e. 7.6 x 7.8 = 7.7) and enter the refractive error. 
 
The patient details need to be recorded as follows: 
o Last Name: ‘GATE’ 
o First Name: <site> e.g. ‘Aberdeen’ 
o Title: leave blank 
o Date of birth: enter patient date of birth 
o Sex: enter patient gender 
o Patient ID: enter < Participant study number> 
o Ancestry: enter the patient’s ethnicity 
6. Ensure that the table and the headrest are at the correct height for the subject.  
Adjust the chinrest height so that the patient’s eyes are at the same level as the 
red canthus marks on the headrest posts. When the subject’s details are entered 
the laser will activate and image acquisition can begin. As a starting point the 
focussing dial at the front of the HRT should be set to the subject’s refraction.   
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7. Check that the subject is comfortable, and the scanning head is correctly aligned 
using the black adjustment handles on the HRT.  The imaging distance between 
the HRT objective lens and the cornea is 1.5 cm; this can be judged by focussing 
the scanning beam on the iris (moving the scanning head towards or away from 
the eye). When the laser beam is focussed (sharp outline) on the iris, move the 
scanner sideways so the beam enters the pupil.  All of the red light emitted from 
the HRT should be going straight into the pupil with little or none visible on the 
iris. 
8. If cylinder correction exceeds ±0.75 diopter, place supplemental cylinder lens in 
front of the objective (image acquisition) lens.  Note that the HRT will display a 
flashing alert on the refractive error correction dialog box if cylinder correction is 
recommended:  
a. click on the check box to display the recommended cylinder lens strength to 
be used.  The lens should be oriented according to the axis provided by the 
autorefractometer.  
b. orientation of the cylinder may be adjusted manually during imaging in order 
to achieve the highest image quality on the screen (see point 9) 
9. The HRT has an internal fixation point, a yellowy/green light which, when fixated 
by subject, should bring the optic disk into view on the screen.  Once the scan is 
activated, the fixation point will appear on the subject’s left for the right eye and 
on their right for the left eye (i.e. always towards the nose).  Explain the fixation 
target (green light outside the red “carpet”).  Once the subject is fixating, check 
the alignment of the laser in the pupil and make small adjustments to the 
focusing to optimise the image quality. The operator may also manually adjust 
the cylinder lens axis, if present, to achieve the best image quality. 
a. Images that are dark, have vignetting of the image corners or are 
grainy can be improved by dilation.  If a good quality image 
cannot be obtained and dilation is required, delay the image 
acquisition until after clinical assessment as described in the flow 
chart in the GATE study procedures manual.   
b. In some cases where the internal fixation light cannot be seen by 
the patient, the external fixation device must be used.  To use 
this, the opposite eye fixates on the green light which is manually 
positioned by the operator to display the optic nerve head in the 
centre of the screen. 
10. Instruct the subject to blink as much as possible before you attempt to acquire a 
scan to avoid imaging a “dry eye” (drying of the corneal surface). The scan 
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duration is approx 6-8 seconds, during which time the subject should not blink 
and must maintain fixation. When ready, an image is acquired by pressing either 
the foot pedal or the grey button on the rear of the scan head. 
11. Optimise image quality if necessary (artificial tears, elevate upper eyelids, re-
adjust camera).  
a. Detector sensitivity should be as low as possible (<80) 
b. The image quality bar should be green for a good quality 
image and above 70% 
12. The screen will display the progress of the scan; the HRT will take at least three scans of 
the optic nerve in one session.   
a. Monitor the progress of the scan to ensure that the subject’s position and 
fixation is constant.   
b. The image series may be reviewed as a movie immediately after 
acquisition. HRT software can compensate for some movement but any 
scans containing large eye movements or blinks will have to be discarded 
and repeated.  
c. If you are satisfied with the scan select “save”. Repeat to acquire another 
scan if image quality is not adequate. 
d. Move the machine over to image the fellow eye, the HRT software will 
recognise which eye you are scanning. 
 
Checking image quality 
Images acquired using the HRT III software allow the user to check the quality of the image by 
clicking on the QC icon in the right hand corner of the image: 
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a. Ensure that all elements are ticked.  The overall quality score is given as one of 
Very Poor, Poor, Acceptable, Good, Very Good, Excellent.  Ensure the overall 
quality score is Good or higher. 
b. Check the standard deviation value displayed at the top of the topography.  A 
value of 30 or below is considered good image quality.  
c. Repeat the image acquisition if required to obtain a good image quality. 
 
d. If an acceptable image cannot be obtained after repeated attempts then 
the image acquisition should be attempted again after pupil dilation 
(please refer to study procedures document flow chart to ensure the 
order of clinical/imaging tests and visual field testing is correct) 
 
Computing the topography 
1. Once both eyes have been imaged, the topographies need to be computed.   
a. Exit from of the acquisition mode by clicking the “X” in the right hand corner of the 
acquisition window and you will be prompted to process the scans that have just 
been taken.  When the scans are processed double click on the image to bring up 
the resulting topographical data in the examination results window   
 
Drawing a contour line 
1. Using the left mouse button select at least 3 points on the optic nerve rim to 
create a contour line and reposition to ensure the optic nerve rim is 
accurately located.  Use the 3D viewer button to review your selection if 
required. 
2. When you have located the optic nerve rim select ‘Contour’ then ‘Accept 
Contour’  
3. The contour and segment lines will appear. 
 
HRT Report Printout: 
Three printouts are required for the HRT scan,  
1. Moorfields Regression Analysis (MRA) of right eye, 
2. MRA of left eye and  
3. GPS report 
  
A hardcopy of each report should be filed in the study file for each participant.   
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An electronic copy of each report in JPEG format should also be saved to a memory 
stick and uploaded to the GATE study website.   
 
The naming convention for filenames of any saved reports should be followed: 
· MRA Right eye report:  ‘GATE<studyID>MRAright.jpg’ 
· MRA Left eye report:  ‘GATE<studyID>MRAleft.jpg’ 
· GPS report:   ‘GATE<studyID>GPS.jpg’ 
 
Printing a Moorfields Regression Analysis(MRA) Report  
· Click the Moorfields classification tab 
· Select ’Print’ 
· Select ‘Examination report’ 
· Ensure the ‘Moorfields report’ is selected in the reports window 
· Select ‘preview’ 
· The Moorfields report for that eye will appear 
· Select ‘Save as’ 
· Enter the filename as ‘GATE<studyID>MRAright.jpg’ for right eye (or 
GATE<studyID>MRAleft.jpg for left eye) 
· Select ‘Save’ to save the jpeg of the report 
· Select ‘print’ to print a hardcopy report for the file 
· Select other eye from Heidelberg Eye explorer window 
· Repeat from start to print/save report from the other eye. 
 
Printing a GPS report 
· To print report select ‘GPS classification’ tab 
· Select ‘Print’ 
· Select ‘Examination report’ 
To save as a jpeg file to upload to the GATE website 
· Ensure GPS report is highlighted in the report window 
· If more than one image is stored for the other eye, select the corresponding eye 
image for the GPS report 
· Select Preview 
· The GPS report will appear on the print preview screen 
· Select ‘Save as’ 
· Enter the filename as ‘GATE<studyID>GPS.jpg’ 
· Select save to save the jpeg of the report 
To print a hardcopy report 
· Select ‘Print’ 
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HRT Data Export: 
HRT imaging data should be exported on the same day every week. Export all the 
images since the last export. 
 
1) From the main database screen select the patient you wish to export. 
2) When the patient details appear on the right hand side of the screen double click 
the patient name. 
3) Right click on the exam you wish to export and select the export option. 
4) Select yes to export the 3D image series.  Selecting this option could result in a 
prompt to retrieve the raw image data for that exam. 
5) Select a folder to export using the browse option. 
6) The file will export and appear as an *.E2E file in the selected export folder. 
7) Save with filename ‘GATE<studyID>rawHRTOS.e2e’ for left eye, and 
‘GATE<studyID>rawHRTOD.e2e for right eye 
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GDx ECC/GDx Pro 
 
Acquiring the image 
 
1. Patients should not be imaged wearing their contact lenses.  Ensure that IOP 
measurements and other contact exams like gonioscopy are performed after 
GDx imaging 
 
2. With the GDx VCC and peripherals properly connected, the Access card 
inserted and the optics unlocked turn the machine on using the power switch 
on the side. 
 
3. Disinfect face rest. 
 
4. When the warm-up test is complete, the logo screen will be displayed. Select 
“new patient”. 
 
5. The patient details need to be recorded as follows: 
o Patient ID - Use <GATE Participant study number> 
o Last name – ‘GATE’ 
o First name – <site>e.g. Aberdeen 
o Middle name – leave blank 
o DOB – enter patient date of birth 
o Doctor –use any identifier usually used or leave blank 
 
Press √ button to continue. 
6. Input ancestry and gender information as prompted. Press √ button to 
continue. 
7. Check patient information for accuracy. If changes are needed press edit. 
8. Select “full exam”. 
9. Refraction input is needed for focusing purposes. Select Refraction.  Press the 
auto-refraction button.  
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10. Position the subject in front of the GDx with the face placed comfortably 
against the face rest. For optimal positioning, ask the patient to place their 
brow bones on top of the upper rest “like wearing a mask”.  Ask the subject to 
gaze at the blinking fixation target in the red field– located to the left hand side 
for the right eye and vice versa. The exam begins with the right eye as the 
default position. 
 
11.  
· Move the joystick , by pulling forwards and backwards, to vertically align 
the white focus dot on the horizontal red line  
 
· Centre the pupil in the target by moving the joystick up/down/ left/right and 
ensure that the 2 white dots are located in the bottom 2 quadrants of the target 
 
· Once aligned, ask the patient not to blink and press the image 
acquisition button on top of the joystick to scan the eye 
· Once the refraction data is displayed on the top lhs select image 
acquisition button again to acquire refraction data from the other eye 
· Click image acquisition button a 3rd time to display the ‘modify ellipse – 
measuring cornea’ screen 
12.  Following a cornea measurement, the “Modify Ellipse – Measuring Cornea” 
screen appears. The macular ellipse should be centred directly over the macula 
“bowtie”-pattern.  
13. To change the macular ellipse position, use the arrow buttons. Do not change the 
size of the macular ellipse. 
14. If the macula “bowtie” is not well defined, press the “Irregular Pattern” button to 
use an alternative cornea calculation based on the macula area within the dotted 
square which does not require macular ellipse placement (press the “Macular 
Ellipse” button to re-enable the macular ellipse placement options).  
15. Press √ button to go to the “Modify Ellipse – Measuring Cornea” screen for the 
next eye. Optimise the placement of the cornea measurement ellipse in the same 
manner as for the first eye. Press √ button again when complete. 
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16. When ellipse modification is completed, the system displays the “Image Check-
Measuring cornea” screen. The scan quality score should be 8 and above. If 
the scan quality is less than 8 then retake the image for that eye.  
17. If image quality is acceptable then select “Accept”. The acquisition screen will now 
appear. If after repeating the GDx scan the image quality is still not acceptable then the 
image acquisition should be attempted again after pupil dilation (please refer to GATE 
study procedures flow chart to ensure the order of clinical/imaging tests is correct) 
18. Move the joystick to vertically align the white focus dot on the horizontal red line 
and centre the pupil in the reticule. Once aligned, press the image acquisition 
button on top of the joystick to scan the eye. After the first image is captured the 
system will automatically move to the other eye. 
19. Repeat step 18 for the left eye. 
20.  At the “Image Check” screen verify that the ellipses for both eyes are the correct 
size, shape and centred on the Optic Nerve Head (ONH). You can both change 
the ellipse diameter and shape using the arrow keys. (Note: While it is helpful to 
align the ellipse with the ONH margin, accurate centration is more important than 
perfect ellipse size). 
 
21. When ellipse modification is completed, verify that the scans quality scores are 8 
or above. If quality is less than 8, re-scan the patient.  Proper ONH placement can 
influence image quality scores. Verify that placement is correct before deciding to 
retake an image.  
22. If image quality is acceptable then select “Accept”. 
If not acceptable then the image acquisition should be attempted again after the 
clinician has dilated pupils for their routine clinical assessment (please refer to GATE 
study procedures flow chart to ensure the order of clinical/imaging tests is correct) 
23. Press “print” or “save only” button. 
DOI: 10.3310/hta20080 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 8
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Azuara-Blanco et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
145
GDx Printout 
 
A printout of the GDx ECC report is required for the study file.  Ensure that ECC is reported in 
the middle text box (white).  
 
A hardcopy of each report should be filed in the study file for each participant.   
 
A scanned electronic copy of each report in JPEG format should be uploaded to the GATE 
study website.   
The naming convention for filenames of any saved reports should be followed: 
· GDx ECC report:  ‘GATE<studyID>GDX.jpg’ 
 
After printing out the report you should select ‘Save’ to save the file for this patient 
 
GDx Data Export 
 
Data export is done on a floppy disk.   
1. Select “existing patient”. 
2. Enter the patient ID number in the “Patient ID”. 
3. Press the “review” button 
4. Use “Previous” and “Next” buttons to move through the list 
5. Then using the “Select/Deselect” button highlight the chosen exam 
6. Repeat  2 and 3 to select more then one exam 
7. Press “review” button and then “export” button 
8. Choose ‘Export raw data’ 
9. You will be presented with a folder: My Computer.  Press the tab key to get into 
the folder. 
10. Using the arrow keys highlight the Floppy A Folder.  Then press enter. 
11. Name the folder (although the software will automatically save the data with 
Patient name and ID). 
12. Press “√” button or the “enter” key. 
13. You will be presented with the message: “Exporting Data” and when finished with 
the message “Export complete”. 
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Optical Coherence Tomography Using: Heidelberg Spectralis OCT 
 
Patients should not wear contact lenses   
 
Acquiring the image 
 
1. Explain examination (method and requirements) to the patient 
2.  Ensure that IOP measurements (and other contact exams like gonioscopy) are done after 
OCT imaging 
3. Disinfect chin-and forehead-supporting stand 
4. Check optics for dirt or smudges, clean if required/with lint/oil free lens paper moistened with 
a drop or two of photography quality lens cleaner 
5. Ensure that the table and headrest are the correct height for the subject.   Adjust the 
chinrest height so that the patient’s eyes are at the same level as the red canthus 
marks on the headrest posts. 
 
5. Create a new patient record by clicking on the New Patient button. 
 
In the Patient File window you should enter the following patient details 
o Patient ID - Use < Participant study number> 
o Patient Name (Surname= ‘GATE’, Forename=<site> e.g. ‘Aberdeen’) 
o DOB – enter patient date of birth 
o Enter Gender and Ethnicity information 
 
Examination Data Window 
 
The Examination Data dialog opens before each exam, but can also be opened at any 
later stage using the Examination button in the patient file. 
The respective Device Type for the examination must be selected from the dropdown 
menu; all other data is optional. 
 
1. Select Spectralis OCT 
2. Enter operator initials 
3. Enter Study name as GATE 
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Eye Data Window 
This window enables the entry of the eye parameters for both eyes. Please Note: Do NOT 
enter any data into this window. 
1. Wait for the Laser On/Off button on the Control Panel to turn from Red to Yellow.   
2. Press the Yellow On/Off button on the Control Panel to activate the Laser/OCT. Make 
sure that the OCT button is selected.  (Note - On the Control Panel, Inactive/unselected 
buttons are Red; Active/Selected buttons are Blue). 
3. Select the IR + OCT button.  
4. Make sure that the Volume button is selected. 
6. Field button should be at 30 degrees. 
7. IR Intensity button will default to 100% but should be adjusted for patient            media, 
typically 50%  75%. 
8. Always activate the ART Mean function when performing an OCT-Scan 
9. Select RNFL preset on the monitor screen  
10. Ensure HR for high resolution imaging is selected (not HS – high speed) 
11. The OCT has a blue internal fixation point which when fixated by the subject should 
bring the optic disc into view on the screen  
a) slowly bring the camera towards the patient’s eye,  
b) encourage the patient to blink just before a scan, since maintaining a good tear 
film is important for OCT image quality. In cases where the patient suffers from 
dry eye, or when the cornea cannot be kept moist enough by blinking alone, 
artificial tears may be used. 
c) Using the joystick (up, down, right or left) move the camera to the center of the 
pupil and adjust the distance between the objective and the examined eye to 
approx. 14 mm between the front edge of the objective and the cornea.   
d) Use the OCT Acquisition Window on the monitor to align the camera with the 
Optic disc Image on the left side of the window. 
e) Fine tune brightness and sharpness of the image using the focus knob. The 
 optimum camera position is reached when no dark corners and overexposed 
areas are visible. 
11.  The bar above the OCT image will appear red if the OCT image touches the upper 
border. Move the camera further away from the patient if the OCT image is shown 
inverted. If the OCT image is tilted in a horizontal direction, move the camera slightly 
left/right (if capturing a horizontal scan) or up/down (if capturing a vertical scan). (Note 
in patients with moderate myopia, the scan can be tilted). 
 
12 . The blue Quality bar in the lower part of the image indicates the signal strength. The 
quality score range is 0 (no image) to 40 (excellent quality). Acceptable quality is 
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>15. If the score is 15 or less, the quality bar turns red.   If an acceptable quality image 
cannot be obtained, imaging should be repeated after pupil dilation (see flowchart in 
study procedures manual to determine test order) 
13. To achieve optimum image quality, position the OCT image in the upper half of the 
Acquisition window. Using the joystick, move the camera slightly up/down and 
sideways until the optic disc and OCT image appear brightest and most evenly 
illuminated. 
 
14.  To acquire images, press the foot switch, the Acquire button on the control panel or the 
 central button on the joystick. After acquiring images, save them using the Save   
 images option in the top left corner of the Acquisition window. To end the acquisition 
 session, exit the Acquisition window. The camera will automatically turn off. 
 
 
OCT RNFL Basic Report OU Printout 
 
· A hardcopy RNFL Basic Report OU should be filed in the study file for each participant.   
· Add an image from each eye to the lightbox  
· Select both images in the lightbox then select Print from the context menu 
· The ‘print spectralis report’ window will appear 
· Select the RNFL Basic Report option  
· Select Preview 
· Select Save to save a JPEG format then select Print to printout a hardcopy 
· An electronic copy of each report in JPEG format should also be saved to a memory stick 
and uploaded to the GATE study website.  The naming convention for filenames of any 
saved reports should be followed: OCT report:  ‘GATE<studyID>OCT.jpg’ 
 
OCT Data Export 
 
OCT imagining data should be exported on the same day every week. Export all the images 
since the last export. 
 
1) From the main database screen select the patient you wish to export 
2) To export images and other data in an examination as an E2E file, select the desired 
thumbnail image(s) from the Patient File window, and select the item Export ► asE2E 
from the Context Menu in the Patient File. 
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3) Save with filename ‘GATE<studyID>rawHRTOS.e2e’ for left eye, and 
‘GATE<studyID>rawHRTOD.e2e for right eye 
4) The Batch ► Export E2E feature in the Database window enables export of         
multiple patient records at once. 
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Appendix 5 Further assessment of threshold
effects under diagnosis analysis using individual
parameters from the imaging tests
As for default analysis, abnormal imaging test results were those classified as ‘outside normal limits’and the corresponding reference standard definition of disease was a diagnosis of glaucoma of
the worse eye. Only participants with an imaging test output with an overall classification which met the
manufacturer quality cut-off point were included in the analysis.
The HRT-MRA parameters for which a ROC curve was produced and the AUC calculated were the global,
temporal, temporal superior, temporal inferior, nasal, nasal superior and nasal inferior areas. For HRT-GPS
and OCT, the probabilities and the RNFL thickness values were used for the same segments of the eye. For
GDx, the TSNIT parameters (NFI, TSNIT average, superior average, inferior average, TSNIT SD were used).
The corresponding ROC curves are shown in Figures 28–31 with the corresponding AUC with 95% CIs in
Table 59. From visually assessment it can be seen that the OCT and GDx curves differed the most between
parameters with the HRT tests, MRA and particularly GPS showing less variation in the curve shape
between parameter. The point estimates for the AUC differed by only 0.02 for GPS, compared with GDx
for 0.1 and 0.13 for OCT.
HRT-MRA ROC curve (area)
Global (0.78)
Temporal (0.72)
Temporal superior (0.79)
Temporal inferior (0.78)
Nasal (0.70)
Nasal superior (0.73)
Nasal inferior (0.75)
Worthless test
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FIGURE 28 Receiver operating characteristic curve for HRT-MRA parameters.
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HRT-GPS ROC curve (area)
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FIGURE 29 Receiver operating characteristic curve for HRT-GPS parameters.
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FIGURE 30 Receiver operating characteristic curve for GDx parameters.
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FIGURE 31 Receiver operating characteristic curve for OCT parameters.
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TABLE 59 Area under the ROC curve using imaging test parameters for a diagnosis of glaucoma in the worse eye
Test Parameter Value 95% CI
HRT-MRA Global area 0.78 0.73 to 0.82
Temporal area 0.72 0.67 to 0.76
Temporal superior area 0.78 0.74 to 0.83
Temporal inferior area 0.79 0.74 to 0.83
Nasal 0.70 0.65 to 0.75
Nasal superior area 0.75 0.71 to 0.80
Nasal inferior area 0.73 0.69 to 0.78
HRT-GPS Global probability 0.80 0.77 to 0.84
Temporal probability 0.81 0.77 to 0.85
Temporal superior probability 0.80 0.76 to 0.84
Temporal inferior probability 0.80 0.76 to 0.83
Nasal probability 0.81 0.77 to 0.85
Nasal superior probability 0.80 0.76 to 0.84
Nasal inferior probability 0.79 0.76 to 0.83
GDx NFI 0.78 0.74 to 0.83
TSNIT average 0.73 0.69 to 0.78
TSNIT SD 0.74 0.69 to 0.78
Superior average 0.73 0.68 to 0.78
Inferior average 0.73 0.68 to 0.78
OCT Global thickness 0.83 0.79 to 0.87
Temporal thickness 0.68 0.63 to 0.73
Temporal superior thickness 0.79 0.75 to 0.83
Temporal inferior thickness 0.82 0.78 to 0.86
Nasal thickness 0.72 0.68 to 0.77
Nasal superior thickness 0.72 0.68 to 0.77
Nasal inferior thickness 0.74 0.70 to 0.79
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Appendix 6 Additional triage analysis to inform
the health economic model
Overview
An additional set of two statistical analyses (see Triage sensitivity analyses 9 and 10) were carried out to
specifically inform the economic modelling for GATE. These were set up to mirror the model structure
in terms of population (i.e. with the simplification of ignoring the presence of non-glaucoma-related
comorbidities). The first additional analysis used a reference standard definition of disease of glaucoma,
glaucoma suspect, OHT and PAC; the second analysis used diagnosis of glaucoma alone as the reference
standard (Table 60). The test was a composite, as previously described in Chapters 2 and 5,
of the imaging test result, IOP and VA measurements (referred to throughout this appendix by the
name of imaging test used within the composite test, e.g. HRT-MRA, HRT-GPS, GDx or OCT). Where a
classification was not provided by the imaging test, the patient was defined as a ‘for referral’. For the first
analysis, borderline imaging results were also classified as ‘for referral’, whereas for the second analysis
they were classified ‘not for referral’. Triage sensitivity analyses 9 and 10 represent the analyses used to
populate the diagnostic accuracy results of the base case and the sensitivity analysis scenarios, respectively
(see Chapter 6 for further details). Subgroup sensitivity and specificity values were calculated for each
diagnosis separately (e.g. glaucoma, ‘at risk of glaucoma’ and neither groups) breaking down the
performances of the triage test to provide estimates for the economic model. ‘At risk of glaucoma’ was
defined as being suspected of any type of glaucoma, or having OHT or PAC.
TABLE 60 Additional analyses carried out to inform the health economic model
Analysis
Reference standard
definition of disease
Test ‘for referral’
definition
Handling of ‘no
result’ categories
Figure
number
Table
number
Triage sensitivity
analysis 9
Glaucoma, OHT, PAC
and glaucoma suspect
Imaging (outside normal
limits or borderline) or
IOP > 21mmHg or VA
6/12 or poorer
A–D for referral 32 61
E excluded
Triage sensitivity
analysis 10
Glaucoma Imaging (outside
normal limits)
A–D for referral 33 62
E excluded
No result categories: A, test performed and imaging report produced but quality is lower than manufacturer quality cut-off
point; B, test performed and imaging report produced but no overall classification generated by machine; C, test performed
but there was a clear imaging artefact on the report; D, test attempted but no imaging could be acquired from the
patient’s eyes – no report generated; E, missing imaging output (because of study-related or data-collection issues).
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Diagnostic performance of the triage tests
The diagnostic accuracy results of the two analyses are given in the following two sections.
Triage sensitivity analysis 9
The flow of study participants according to triage sensitivity analysis 9 is shown in Figure 32 with
corresponding numbers of referral, not for referral and no results cases by triage test. The diagnostic
performance for the four tests is given in Table 61. The results showed a trade-off between the detection
Reference standard definition: glaucoma OR glaucoma suspect
OR OHT or PAC
For referral: imaging (outside normal limits or
borderline) or IOP > 21 mmHg or VA  6/12 or poorer)
Handling of no result categories: A–D for referral
     E excluded 
For referral
IOP + VA + MRA (HRT), n = 788
IOP + VA + GPS (HRT), n = 805
IOP + VA + GDx, n = 624
IOP + VA + OCT, n = 741
Not for referral
IOP + VA + MRA (HRT), n = 125
IOP + VA + GPS (HRT), n = 124
IOP + VA + GDx, n = 305
IOP + VA + OCT, n = 192
No result
IOP + VA + MRA (HRT), n = 30
IOP + VA + GPS (HRT), n = 14
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
No reference standard
MRA, n = 8
GPS, n = 7
GDx, n = 6
OCT, n = 7
No reference standard
MRA, n = 2
GPS, n = 3
GDx, n = 5
OCT, n = 4
No reference standard
MRA, n = 1
GPS, n = 1
GDx, n = 0
OCT, n = 0
Reference standard
IOP + VA + MRA (HRT), n = 29
IOP + VA + GPS (HRT), n = 13
IOP + VA + GDx, n = 14
IOP + VA + OCT, n = 10
Reference standard
IOP + VA + MRA (HRT), n = 780
IOP + VA + GPS (HRT), n = 789
IOP + VA + GDx, n = 618
IOP + VA + OCT, n = 734
Reference standard
IOP + VA + MRA (HRT), n = 123
IOP + VA + GPS (HRT), n = 121
IOP + VA + GDx, n = 300
IOP + VA + OCT, n = 188
Not discharged
IOP + VA + MRA (HRT),
 n = 517
IOP + VA + GPS (HRT),
 n = 524
IOP + VA + GDx,
 n = 433
IOP + VA + OCT,
 n = 486
Not discharged
IOP + VA + MRA (HRT),
n = 13
IOP + VA + GPS (HRT),
n = 14
IOP + VA + GDx,
n = 106
IOP + VA + OCT,
n = 53
Discharged
IOP + VA + MRA (HRT),
n = 260
IOP + VA + GPS (HRT),
n = 271
IOP + VA + GDx,
n = 183
IOP + VA + OCT,
n = 245
Not discharged
IOP + VA + MRA (HRT),
n = 16
IOP + VA + GPS (HRT),
n = 8
IOP + VA + GDx,
n = 7
IOP + VA + OCT,
n = 7
Discharged
IOP + VA + MRA (HRT),
n = 110
IOP + VA + GPS (HRT),
n = 106
IOP + VA + GDx,
n = 192
IOP + VA + OCT,
n = 134
Discharged
IOP + VA + MRA (HRT),
n = 12
IOP + VA + GPS (HRT),
n = 5
IOP + VA + GDx,
n = 7
IOP + VA + OCT,
n = 3
Inconclusive
reference standard
MRA, n = 3
GPS, n = 3
GDx, n = 2
OCT, n = 3
Inconclusive
reference standard
MRA, n = 1
GPS, n = 0
GDx, n = 0
OCT, n = 0
Inconclusive
reference standard
MRA, n = 0
GPS, n = 1
GDx, n = 2
OCT, n = 1
Eligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 32 Flow diagram: triage sensitivity analysis 9.
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of patients who need to be referred and the discharge of those who do not need to be referred: HRT-MRA
had the highest sensitivity (HRT-GPS was only very slightly lower) but also the second lowest specificity
(HRT-GPS had the lowest), GDx had the lowest sensitivity but the highest specificity and OCT provided
intermediate results. Likelihood ratios (and 95% CI) showed evidence of being able to both rule in and rule
out the presence of glaucoma for all four triage tests (CIs did not contain 1.0). DORs ranged from 4.29 for
GDx to 16.83 for HRT-MRA.
From this analysis, the sensitivity for participants with glaucoma was calculated as 99%, 99%, 88% and
97% for HRT-MRA, HRT-GPS, GDx and OCT, respectively; similarly the sensitivity for participants ‘at risk of
glaucoma’ was calculated as 97%, 97%, 77% and 87%, respectively, and the specificity for participants
classified as normal (not glaucoma or ‘at risk of glaucoma’) was 30%, 28%, 51% and 35% for HRT-MRA,
HRT-GPS, GDx and OCT, respectively.
TABLE 61 Triage sensitivity analysis 9
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 97.5 95.8 to 98.7
Specificity (%) 29.7 25.1 to 34.7
Positive likelihood ratio 1.39 1.30 to 1.49
Negative likelihood ratio 0.08 0.05 to 0.14
DOR 16.83 9.29 to 30.47
HRT-GPS Sensitivity (%) 97.4 95.7 to 98.6
Specificity (%) 28.1 23.6 to 32.9
Positive likelihood ratio 1.35 1.27 to 1.45
Negative likelihood ratio 0.09 0.05 to 0.16
DOR 14.64 8.23 to 26.05
GDx Sensitivity (%) 80.3 76.7 to 83.6
Specificity (%) 51.2 46.0 to 56.4
Positive likelihood ratio 1.65 1.47 to 1.84
Negative likelihood ratio 0.38 0.32 to 0.47
DOR 4.29 3.2 to 5.75
OCT Sensitivity (%) 90.2 87.3 to 92.5
Specificity (%) 35.4 30.5 to 40.4
Positive likelihood ratio 1.39 1.29 to 1.51
Negative likelihood ratio 0.38 0.21 to 0.37
DOR 5.02 3.52 to 7.14
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Triage sensitivity analysis 10
The flow of study participants according to triage sensitivity analysis 10 is shown in Figure 33, with
corresponding numbers of referral, not for referral and no results cases by triage test. The diagnostic
performance for the four tests is given in Table 62. The results generally showed a trade-off between the
detection of patients who need to be referred and the discharge of those who do not need to be referred:
HRT-MRA had the highest sensitivity (HRT-GPS was only very slightly lower) but also the second lowest
specificity (HRT-GPS had the lowest), GDx had the lowest sensitivity but the highest specificity and OCT
provided intermediate results. Likelihood ratios (and 95% CI) showed evidence of being able to both rule
in and rule out the presence of glaucoma for all four triage tests (CIs did not contain 1.0). DORs ranged
from 5.11 for GDx to 12.83 for HRT-MRA.
Abnormal result
MRA (HRT), n = 531
GPS (HRT), n = 518
GDx, n = 202
OCT, n = 381
Normal result
MRA (HRT), n = 382
GPS (HRT), n = 411
GDx, n = 727
OCT, n = 552
No result
MRA (HRT), n = 30
GPS (HRT), n = 14
GDx, n = 14
OCT, n = 10
No reference standard
MRA (HRT), n = 6
GPS (HRT), n = 5
GDx, n = 4
OCT, n = 5
No reference standard
MRA (HRT), n = 4
GPS (HRT), n = 5
GDx, n = 7
OCT, n = 6
No reference standard
MRA (HRT), n = 1
GPS (HRT), n = 1
GDx, n = 0
OCT, n = 0
Reference standard
MRA (HRT), n = 29
GPS (HRT), n = 13
GDx, n = 14
OCT, n = 10
Reference standard
MRA (HRT), n = 525
GPS (HRT), n = 513
GDx, n = 198
OCT, n = 376
Reference standard
MRA (HRT), n = 378
GPS (HRT), n = 406
GDx, n = 720
OCT, n = 546
Inconclusive
reference standard
MRA (HRT), n = 3
GPS (HRT), n = 2
GDx, n = 1
OCT, n = 3
Inconclusive
reference standard
MRA (HRT), n = 0
GPS (HRT), n = 2
GDx, n = 3
OCT, n = 1
Inconclusive
reference standard
MRA (HRT), n = 1
GPS (HRT), n = 0
GDx, n = 0
OCT, n = 0
Glaucoma present
MRA (HRT), n = 145
GPS (HRT), n = 138
GDx, n = 77
OCT, n = 128
Glaucoma present
MRA (HRT), n = 11
GPS (HRT), n = 17
GDx, n = 80
OCT, n = 26
Glaucoma absent
MRA (HRT), n = 377
GPS (HRT), n = 373
GDx, n = 120
OCT, n = 245
Glaucoma present
MRA (HRT), n = 2
GPS (HRT), n = 3
GDx, n = 1
OCT, n = 4
Glaucoma absent
MRA (HRT), n = 367
GPS (HRT), n = 387
GDx, n = 637
OCT, n = 519
Glaucoma absent
MRA (HRT), n = 26
GPS (HRT), n = 10
GDx, n = 13
OCT, n = 6
Reference standard definition: glaucoma
For referral: imaging (outside normal limits or borderline)
Handling of no result categories: A–D for referral
                E excludedEligible patients
(n = 2088)
Not consented
(n = 1122)
Excluded (n = 11)
• Ineligible, n = 10
• Withdrawn, n = 1
Consented
(n = 966)
Available for index test
(n = 955)
Completed composite index test (imaging + IOP + VA)
(n = 943)
Imaging not performed
for all four index tests
(n = 12)
FIGURE 33 Flow diagram: triage analysis sensitivity 10.
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From this analysis, the sensitivity for participants with glaucoma was 93%, 89%, 49% and 83% for
HRT-MRA, HRT-GPS, GDx and OCT, respectively; the sensitivity for participants ‘at risk of glaucoma’
was calculated as 61%, 59%, 17% and 36%, respectively; and the specificity for participants in the
normal health state (without glaucoma or ‘at risk of glaucoma’) was calculated as 60%, 61%, 85% and
72%, respectively.
TABLE 62 Triage sensitivity analysis 10
Test Diagnostic parameter Value 95% CI
HRT-MRA Sensitivity (%) 92.9 87.7 to 96.4
Specificity (%) 49.3 45.7 to 53.0
Positive likelihood ratio 1.83 1.69 to 21.99
Negative likelihood ratio 0.14 0.08 to 0.25
DOR 12.83 6.84 to 24.08
HRT-GPS Sensitivity (%) 89.0 83.0 to 93.5
Specificity (%) 50.9 47.3 to 54.5
Positive likelihood ratio 1.81 1.66 to 1.99
Negative likelihood ratio 0.22 0.14 to 0.30
DOR 8.42 4.99 to 14.88
GDx Sensitivity (%) 49.0 41.0 to 57.1
Specificity (%) 84.1 81.3 to 86.7
Positive likelihood ratio 3.09 2.46 to 3.89
Negative likelihood ratio 0.61 0.52 to 0.71
DOR 5.11 3.53 to 7.39
OCT Sensitivity (%) 83.1 76.2 to 88.7
Specificity (%) 67.9 64.5 to 71.2
Positive likelihood ratio 2.59 2.29 to 2.94
Negative likelihood ratio 0.25 0.17 to 0.35
DOR 10.43 6.66 to 16.33
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Appendix 7 Cost-effectiveness supplementary
tables
TABLE 63 Incremental cost-effectiveness for the base case with different NHS Reference Costs applied to the
triage strategies
NHS Reference Cost (£) Intervention Cost (£) QALYs ICER
10 GDx 2841 19.7701 –
OCT 2967 19.7746 27,812
HRT-MRA 3001 19.7771 13,807
HRT-GPS 3011 19.7771 Dominateda
Current practice 3084 19.7780 98,231
13 GDx 2856 19.7701 –
OCT 2982 19.7746 27,784
HRT-MRA 3016 19.7771 13,780
HRT-GPS 3026 19.7771 Dominateda
Current practice 3084 19.7780 80,605
16 GDx 2872 19.7701 –
OCT 2996 19.7746 27,757
HRT-MRA 3031 19.7771 13,754
HRT-GPS 3040 19.7771 Dominateda
Current practice 3084 19.7780 62,979
19 GDx 2887 19.7701 –
OCT 3011 19.7746 27,729
HRT-MRA 3046 19.7771 13,727
HRT-GPS 3055 19.7771 Dominateda
Current practice 3084 19.7780 45,353
22 GDx 2902 19.7701 –
OCT 3026 19.7746 27,701
HRT-MRA 3060 19.7771 13,700
HRT-GPS 3070 19.7771 Dominateda
Current practice 3084 19.7780 27,727
25 GDx 2917 19.7701 –
OCT 3041 19.7746 27,673
HRT-MRA 3075 19.7771 13,673
Current practice 3084 19.7780 10,101
HRT-GPS 3085 19.7771 Dominateda
continued
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TABLE 63 Incremental cost-effectiveness for the base case with different NHS Reference Costs applied to the
triage strategies (continued )
NHS Reference Cost (£) Intervention Cost (£) QALYs ICER
28 GDx 2932 19.7701 –
OCT 3056 19.7746 27,646
Current practice 3084 19.7780 8313
HRT-MRA 3090 19.7771 Dominateda
HRT-GPS 3100 19.7771 Dominateda
31 GDx 2947 19.7701 –
OCT 3071 19.7746 27,618
Current practice 3084 19.7780 3853
HRT-MRA 3105 19.7771 Dominateda
HRT-GPS 3115 19.7771 Dominateda
34 GDx 2962 19.7701 –
Current practice 3084 19.7780 15,579
OCT 3086 19.7746 Dominateda
HRT-MRA 3120 19.7771 Dominateda
HRT-GPS 3129 19.7771 Dominateda
37 GDx 2977 19.7701 –
Current practice 3084 19.7780 13,663
OCT 3101 19.7746 Dominateda
HRT-MRA 3135 19.7771 Dominateda
HRT-GPS 3144 19.7771 Dominateda
40 GDx 2992 19.7701 –
Current practice 3084 19.7780 11,747
OCT 3116 19.7746 Dominateda
HRT-MRA 3149 19.7771 Dominateda
HRT-GPS 3159 19.7771 Dominateda
43 GDx 3007 19.7701 –
Current practice 3084 19.7780 9831
OCT 3130 19.7746 Dominateda
HRT-MRA 3164 19.7771 Dominateda
HRT-GPS 3174 19.7771 Dominateda
46 GDx 3022 19.7701 –
Current practice 3084 19.7780 7315
OCT 3145 19.7746 Dominateda
HRT-MRA 3179 19.7771 Dominateda
HRT-GPS 3189 19.7771 Dominateda
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TABLE 63 Incremental cost-effectiveness for the base case with different NHS Reference Costs applied to the
triage strategies (continued )
NHS Reference Cost (£) Intervention Cost (£) QALYs ICER
49 GDx 3037 19.7701 –
Current practice 3084 19.7780 5999
OCT 3160 19.7746 Dominateda
HRT-MRA 3194 19.7771 Dominateda
HRT-GPS 3204 19.7771 Dominateda
52 GDx 3052 19.7701 –
Current practice 3084 19.7780 4083
OCT 3175 19.7746 Dominateda
HRT-MRA 3209 19.7771 Dominateda
HRT-GPS 3218 19.7771 Dominateda
55 GDx 3067 19.7701 –
Current practice 3084 19.7780 2168
OCT 3190 19.7746 Dominateda
HRT-MRA 3224 19.7771 Dominateda
HRT-GPS 3233 19.7771 Dominateda
58 GDx 3082 19.7701 –
Current practice 3084 19.7780 252
OCT 3205 19.7746 Dominateda
HRT-MRA 3238 19.7771 Dominateda
HRT-GPS 3248 19.7771 Dominateda
61 Current practice 3084 19.7780 –
GDx 3097 19.7701 Dominateda
OCT 3220 19.7746 Dominateda
HRT-MRA 3253 19.7771 Dominateda
HRT-GPS 3263 19.7771 Dominateda
64 Current practice 3084 19.7780 –
GDx 3112 19.7701 Dominateda
OCT 3235 19.7746 Dominateda
HRT-MRA 3268 19.7771 Dominateda
HRT-GPS 3278 19.7771 Dominateda
67 Current practice 3084 19.7780 –
GDx 3127 19.7701 Dominateda
OCT 3250 19.7746 Dominateda
HRT-MRA 3283 19.7771 Dominateda
HRT-GPS 3292 19.7771 Dominateda
continued
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TABLE 63 Incremental cost-effectiveness for the base case with different NHS Reference Costs applied to the
triage strategies (continued )
NHS Reference Cost (£) Intervention Cost (£) QALYs ICER
70 Current practice 3084 19.7780 –
GDx 3142 19.7701 Dominateda
OCT 3265 19.7746 Dominateda
HRT-MRA 3298 19.7771 Dominateda
HRT-GPS 3307 19.7771 Dominateda
73 Current practice 3084 19.7780 –
GDx 3157 19.7701 Dominateda
OCT 3279 19.7746 Dominateda
HRT-MRA 3313 19.7771 Dominateda
HRT-GPS 3322 19.7771 Dominateda
76 Current practice 3084 19.7780 –
GDx 3172 19.7701 Dominateda
OCT 3294 19.7746 Dominateda
HRT-MRA 3327 19.7771 Dominateda
HRT-GPS 3337 19.7771 Dominateda
79 Current practice 3084 19.7780 –
GDx 3187 19.7701 Dominateda
OCT 3309 19.7746 Dominateda
HRT-MRA 3342 19.7771 Dominateda
HRT-GPS 3352 19.7771 Dominateda
82 Current practice 3084 19.7780 –
GDx 3202 19.7701 Dominateda
OCT 3324 19.7746 Dominateda
HRT-MRA 3357 19.7771 Dominateda
HRT-GPS 3367 19.7771 Dominateda
85 Current practice 3084 19.7780 –
GDx 3217 19.7701 Dominateda
OCT 3339 19.7746 Dominateda
HRT-MRA 3372 19.7771 Dominateda
HRT-GPS 3381 19.7771 Dominateda
a Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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TABLE 64 Incremental cost-effectiveness ratios of increasing costs of triage strategies and not treating patients
diagnosed as ‘at risk’
Increasing cost of triage strategy (£) Intervention Cost (£) QALYs ICER
+ 10 GDx 2719 19.7393 –
OCT 2840 19.7410 68,260
HRT-MRA 2869 19.7414 83,488
HRT-GPS 2879 19.7414 Dominateda
Current practice 2954 19.7415 488,759
+ 13 GDx 2733 19.7393 –
OCT 2853 19.7410 68,229
HRT-MRA 2883 19.7414 83,457
HRT-GPS 2893 19.7414 Dominateda
Current practice 2954 19.7415 409,713
+ 16 GDx 2747 19.7393 –
OCT 2867 19.7410 68,198
HRT-MRA 2897 19.7414 83,426
HRT-GPS 2906 19.7414 Dominateda
Current practice 2954 19.7415 330,667
+ 19 GDx 2761 19.7393 –
OCT 2881 19.7410 68,167
HRT-MRA 2910 19.7414 83,396
HRT-GPS 2920 19.7414 Dominateda
Current practice 2954 19.7415 251,620
+ 22 GDx 2775 19.7393 –
OCT 2895 19.7410 68,137
HRT-MRA 2924 19.7414 83,365
HRT-GPS 2934 19.7414 Dominateda
Current practice 2954 19.7415 172,574
+ 25 GDx 2788 19.7393 –
OCT 2908 19.7410 68,106
HRT-MRA 2938 19.7414 83,335
HRT-GPS 2947 19.7414 Dominateda
Current practice 2954 19.7415 93,527
+ 28 GDx 2802 19.7393 –
OCT 2922 19.7410 68,075
HRT-MRA 2952 19.7414 83,304
Current practice 2954 19.7415 14,481
HRT-GPS 2961 19.7414 Dominateda
continued
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TABLE 64 Incremental cost-effectiveness ratios of increasing costs of triage strategies and not treating patients
diagnosed as ‘at risk’ (continued )
Increasing cost of triage strategy (£) Intervention Cost (£) QALYs ICER
+ 31 GDx 2816 19.7393 –
OCT 2936 19.7410 68,044
Current practice 2954 19.7415 34,813
HRT-MRA 2965 19.7414 Dominateda
HRT-GPS 2975 19.7414 Dominateda
+ 34 GDx 2830 19.7393 –
OCT 2949 19.7410 68,014
Current practice 2954 19.7415 8882
HRT-MRA 2979 19.7414 Dominateda
HRT-GPS 2989 19.7414 Dominateda
+ 37 GDx 2843 19.7393 –
Current practice 2954 19.7415 48,341
OCT 2963 19.7410 Dominateda
HRT-MRA 2993 19.7414 Dominateda
HRT-GPS 3002 19.7414 Dominateda
+ 40 GDx 2857 19.7393 0
Current practice 2954 19.7415 42,328
OCT 2977 19.7410 Dominateda
HRT-MRA 3006 19.7414 Dominateda
HRT-GPS 3016 19.7414 Dominateda
+ 43 GDx 2871 19.7393 –
Current practice 2954 19.7415 36,314
OCT 2991 19.7410 Dominateda
HRT-MRA 3020 19.7414 Dominateda
HRT-GPS 3030 19.7414 Dominateda
+ 46 GDx 2885 19.7393 –
Current practice 2954 19.7415 30,300
OCT 3004 19.7410 Dominateda
HRT-MRA 3034 19.7414 Dominateda
HRT-GPS 3043 19.7414 Dominateda
+ 49 GDx 2898 19.7393 –
Current practice 2954 19.7415 24,287
OCT 3018 19.7410 Dominateda
HRT-MRA 3048 19.7414 Dominateda
HRT-GPS 3057 19.7414 Dominateda
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TABLE 64 Incremental cost-effectiveness ratios of increasing costs of triage strategies and not treating patients
diagnosed as ‘at risk’ (continued )
Increasing cost of triage strategy (£) Intervention Cost (£) QALYs ICER
+ 52 GDx 2912 19.7393 –
Current practice 2954 19.7415 18,273
OCT 3032 19.7410 Dominateda
HRT-MRA 3061 19.7414 Dominateda
HRT-GPS 3071 19.7414 Dominateda
+ 55 GDx 2926 19.7393 –
Current practice 2954 19.7415 12,260
OCT 3045 19.7410 Dominateda
HRT-MRA 3075 19.7414 Dominateda
HRT-GPS 3084 19.7414 Dominateda
+ 58 GDx 2940 19.7393 –
Current practice 2954 19.7415 6246
OCT 3059 19.7410 Dominateda
HRT-MRA 3089 19.7414 Dominateda
HRT-GPS 3098 19.7414 Dominateda
+ 61 GDx 2954 19.7393 –
Current practice 2954 19.7415 233
OCT 3073 19.7410 Dominateda
HRT-MRA 3102 19.7414 Dominateda
HRT-GPS 3112 19.7414 Dominateda
+ 64 Current practice 2954 19.7415 –
GDx 2967 19.7393 Dominateda
OCT 3087 19.7410 Dominateda
HRT-MRA 3116 19.7414 Dominateda
HRT-GPS 3126 19.7414 Dominateda
+ 67 Current practice 2954 19.7415 –
GDx 2981 19.7393 Dominateda
OCT 3100 19.7410 Dominateda
HRT-MRA 3130 19.7414 Dominateda
HRT-GPS 3139 19.7414 Dominateda
a Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.
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